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ABSTRACT 
 
Background 
Recent evidence implicates human cytomegalovirus (HCMV), immune activation and 
inflammation as risk factors for tuberculosis (TB) disease. Evidence also points towards the 
underappreciated importance of humoral immunity in protection against TB.  
 
Methods 
This PhD thesis uses stored serum samples from an established rural Ugandan cohort to 
investigate associations between HCMV, inflammation and TB. Firstly, HCMV epidemiology is 
investigated, and levels of mycobacterial antibodies are characterised in a cross-sectional 
study design including over 2,000 individuals. Secondly, a nested case-control study design was 
employed to explore longitudinal relationships prior to TB diagnosis in 343 matched samples.  
 
Results 
This work has characterised the HCMV seropositivity in this population and found that 95% of 
individuals are infected by age 5. Mycobacteria-specific antibody levels increased in all 
individuals until a plateau was reached at approximately age 20. HIV positivity and high HCMV 
IgG levels were independently associated with decreased levels of mycobacterial antibodies. 
 
HCMV IgG levels, but not other chronic herpes infections EBV and HSV, are associated with 
increased risk of TB up to 14 years prior to TB diagnosis. HCMV IgG levels, but not EBV or HSV, 
are positively correlated with the inflammatory serum marker IP10.  
Increased antibody avidity against the mycobacterial antigen mixture, PPD, showed a 
directional trend towards decreased risk of TB at early time points prior to TB diagnosis. 
 
Conclusions 
Data presented in this thesis confirm that HCMV burden is high in this rural Ugandan 
population. Anti-mycobacterial antibody levels increase with age, suggestive of cumulative 
exposure to either antigenically related non-tuberculous mycobacteria (NTM) or to M.tb itself.  
This body of work provides more evidence that HCMV infection is associated with TB disease 
risk. As opposed to a simple binary seropositive measurement, I have found that risk of TB 
disease is associated with magnitude of HCMV IgG response.  
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In summary, the data presented in this thesis:  
1. Characterise HCMV infection in this large rural Ugandan cohort 
2. Provide data on anti-mycobacterial antibody levels by age 
3. Add to the evidence that HCMV infection is a risk factor for TB disease, and highlights 
the link between TB disease risk and magnitude of HCMV IgG level 
4. Suggest that, in studies of TB risk, the wider immune environment (specifically 
inflammatory markers) should be investigated 
5. Suggest that measures of antibody quality, not just quantity, should be investigated in 
the search for immune correlates of TB disease risk.  
  
 4 
 
ACKNOWLEDGEMENTS 
 
Heartfelt thanks go to my PhD supervisors Helen Fletcher and Rob Newton. Thank you for 
taking me on as your PhD student and giving me the space to pursue a host of extra-curricular 
opportunities during my project. Special thanks to Rob for hosting me in Uganda and feeding 
me Nile Special and tilapia.  
 
Stephen Nash. My stats guru. Thank you for dealing with my Stata Face and calming me down 
when coding seemed too much. It has been a privilege to work with you. 
 
Angela Nalwoga at UVRI, Entebbe. Thank you for being on my ELISA dream team. Carolynne 
Stanley for being incredibly long-suffering and answering all my lab questions and for giving 
me tips for running ELISAs in Uganda. John Raynes for being a constant source of answers for 
ELISA technical death traps. The Fletcher team; thank you for the chats and gossip. Thank you 
also to Suresh Malikaarjun, Graham Bothamley and Paul Fine for scientific discussions.  
 
A huge thank you to the MRC Entebbe team at UVRI and all participants of the GPC. Without 
you all, this project would not have been possible.  
 
Thanks go to my family. The Spankdales. My Mum and Dad; Chris and Kathy, and Dum and 
Mad; Laura and Bob.  
 
Finally. Will. In that still and settled place, there’s no one there but you. You’re where I breathe 
my oxygen, you’re where I see my view. And when the world seems full of noise, my heart 
knows what to do. It finds that still and settled place and dances there with you.  
 
  
  
 5 
LIST OF FIGURES 
 
Number Title Page 
1-1 The mycobacterial cell wall 11 
1-2 TB disease progression 12 
1-3 Spectrum of TB infection ranges from sterilising immunity to high 
bacterial load and clinical disease 
14 
1-4 Estimated TB incidence for countries with at least 100,000 incident 
cases 2016 
15 
1-5 Desired decline in global TB incidence rates to reach the 2035 targets 17 
1-6 Structure of the TB granuloma 24 
2-1 Sampling for cross sectional and case control study designs 75 
2-2 Matrix of antibody responses of randomly selected samples for MGIA 77 
2-3 Standard curve for IgG and test sera titrations 87 
2-4 96 well plate layout of sodium thiocyanate avidity assay. 90 
2-5 MGIA methodology 94 
3-1 Percent HCMV seropositive by age group (years). 104 
3-2A Mean HCMV IgG OD levels in HIV negative, HCMV seropositive 
individuals by age group (years) and sex 
105 
3-2B Mean HCMV IgG OD levels in HIV positive, HCMV seropositive 
individuals by age group (years) and sex 
105 
3-2C Mean HCMV IgG OD levels (among HCMV seropositive) in HIV positive 
and negative individuals by age group (years) and sex 
105 
3-3 Number of active TB cases by HCMV IgG tertile 107 
4-1 Median adjusted mycobacterial antibody OD by age group 126 
4-2A Median OD levels for TT IgG by sex and age group 127 
4-2B Median total IgG (g/L) by age group 127 
4-3 Adjusted mean OD change associated with HCMV tertile comparing to 
medium HCMV tertile as baseline. 
129 
5-1 Correlations of IP10 and IFN-γ with HCMV, EBV and HSV IgG 153 
5-2 Odds of TB disease with different levels of HCMV IgG 156 
5-3 Graphical representation of odds ratios associated with univariate 
conditional logistic regression 
159 
6-1 Log CFU of serum from BCG vaccinated and unvaccinated individuals 172 
6-2 Log CFU of serum from TB cases and serum from individuals without 
active TB disease 
173 
6-3 Log CFU for all antibody level groups 176 
 
 6 
LIST OF TABLES 
 
Number Title Page 
1-1 Examples of the array of Mycobacterial antigens used to study 
antibody responses in human TB cases 
30 
2-1 Study participant characteristics (cross sectional study) 71 
2-2 Study participant characteristics (nested case control study) 74 
2-3 TB case sample numbers and time before TB diagnosis 71 
2-4 IgG standard curve titration 85 
3-1  General Population Cohort characteristics of individuals included in 
this study 
100 
3-2 Unadjusted and fully adjusted mean differences in HCMV IgG OD 106 
3-3 Unadjusted and fully adjusted mean differences in HCMV IgG OD for 
HIV negative individuals only 
108 
3-4 Unadjusted and fully adjusted mean differences in HCMV IgG OD for 
HIV positive individuals only 
109 
4-1 Study participant characteristics of evaluable individuals 125 
4-2 Fully adjusted mean differences in mycobacterial antibodies 130 
4-3 Fully adjusted mean differences in TT OD and total IgG 132 
5-1 Number of TB case samples and matched controls for time periods 
prior to, and at point of TB diagnosis 
148 
5-2 Odds of TB disease by chronic herpes virus IgG level 155 
5-3 Odds of TB disease in a univariate conditional logistic regression 
model including age, sex, HIV status and HCMV tertile 
157 
5-4 Changes in serum IFNα2 levels and PPD IgG avidity at different time 
points prior to TB disease 
158 
6-1 Correlations between mycobacterial growth inhibition and levels of 
exposures 
174 
 
  
 7 
LIST OF APPENDICES 
 
Number Title Page 
1 Ethical Approval Uganda Virus Research Institute 194 
2a Ethical Approval LSHTM 2015 195 
2b Ethical Approval LSHTM 2016 196 
3 ELISA worksheets 197 
4 Total IgG calculations 202 
5 NaSCN calculations 204 
6 Stockdale, Nash, Nalwoga, Painter, Asiki, Fletcher, Newton.  
Human cytomegalovirus epidemiology and relationship to 
cardiovascular and tuberculosis disease risk factors in a rural 
Ugandan cohort. PLOS one (2018) 
205 
7 Stockdale, Nash, Nalwoga, Gibson, Painter, Raynes, Asiki, Fletcher, 
Newton. HIV, HCMV and mycobacterial antibody levels: across-
sectional study in a rural Ugandan cohort. Tropical Medicine and 
International Health (2018) 
 
221 
 
 8 
GLOSSARY 
 
Ag85A Antigen 85A 
Ag85B Antigen 85B 
APC Antigen presenting cell 
BCG Bacille Calmette-Guérin vaccine 
CFP10 10-kDa culture filtrate protein of M.tb 
CFU Colony-forming units 
CRP C-reactive protein 
CVD Cardiovascular disease 
DC Dendritic cell 
EBV Epstein Barr virus 
ESAT6 6-kDa early secreted antigenic target of M.tb 
HCMV Human Cytomegalovirus 
HIC High-income country 
HIV Human Immunodeficiency virus 
HSV Herpes simplex virus 
IFN-γ Interferon gamma 
Ig Immunoglobulin 
IGRA Interferon- γ release assay 
IL Interleukin 
LAM Lipoarabinomannan 
LMIC Low- and middle-income country 
LLOQ Lower limit of quantitation  
LTBI Latent TB infection 
M.tb Mycobacterium tuberculosis 
MHC Major histocompatibility complex 
MDR-TB Multidrug resistant TB 
MGIA Mycobacterial Growth Inhibition Assay 
MSMD Mendelian susceptibility to mycobacterial infections  
MVA Modified Vaccinia Ankara  
NHP Non-human primate 
NK Natural killer cell 
NTM Non-tuberculous mycobacteria 
OD Optical density 
PBMC Peripheral blood mononucleocytes 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline with Tween 
PPD Purified protein derivative 
RD1 Region of differentiation 
SCID Severe Combined Immunodeficiency  
TB Tuberculosis 
TNF-α Tumor necrosis factor alpha 
TST Tuberculin skin test 
TTP Time to positivity 
WHO World Health Organisation 
XDR-TB Extensively drug resistant TB 
 
 9 
 
CHAPTER 1: INTRODUCTION 
 
In this first chapter, I will introduce Tuberculosis disease and its etiological agent 
Mycobacterium tuberculosis (M.tb), as well as provide an overview on current diagnostics, 
treatment and vaccines. A brief overview of the immune response to M.tb will separate the 
cell-mediated and humoral immune responses and detail immune correlates.  
Next I will discuss Human Cytomegalovirus (HCMV) and provide an overview of its important 
role in immune activation and senescence before detailing the specific project aims and 
objectives which encompass these two pathogens.  
 
1.1 Tuberculosis 
1.1.1 Mycobacterium tuberculosis – the pathogen 
Tuberculosis (TB) in humans is caused by the bacteria Mycobacterium tuberculosis (M.tb). First 
identified as a pathogen in 1882 by Robert Koch, M.tb is part of the acid-fast genus 
Mycobacterium, characterised by the mycolic acid-containing, nearly impermeable cell walls. 
M.tb is very slow growing (generation time of 20-24 hours [1]) and is able to remain dormant 
within an individual for decades before reactivating into active tuberculosis. 
The genus Mycobacterium also comprises M. leprae, the etiological agent of leprosy, M. bovis, 
which causes disease in cattle, as well as approximately 120 atypical or Non-Tuberculous 
Mycobacteria (NTM), which are soil-dwelling saprophytes [2]. It has been found that around a 
third of these NTMs are capable of causing localized disease in the lungs, lymph glands, skin, 
wounds or bone, some can cause disseminated disease in immune-compromised individuals 
[3,4].  
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Tubercular deformities found in individuals with TB in the bone who died more than 4,000 
years ago suggests that the disease was common in Europe and the Middle East. Recent 
genomic analyses indicate that TB probably emerged 70,000 years ago and accompanied 
human migration around the world [5].  
The complete genome sequence of M.tb was published in 1998 and comprises around 4,000 
genes, many of which are involved in production of enzymes involved in fatty acid metabolism 
[6]. This large genetic investment in lipid synthesis and breakdown has given rise to novel 
biosynthetic pathways to generate cell-wall components contributing to the highly 
hydrophobic cell envelope; the major constituents being peptidoglycan, arabinogalactan and 
mycolic acids [7] (Figure 1-1).  
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Figure 1-1 The mycobacterial cell wall. Taken from Kieser & Rubin, Nature Reviews 
Microbiology (2014) [8] 
 
 
The lipid-rich cell wall acts as a barrier to drugs, making treatment difficult [9]. M.tb is able to 
withstand harsh intracellular conditions by virtue of the DosR regulon; a set of approximately 
48 co-regulated genes induced by hypoxia which facilitate entry to a latent state characterised 
by very low metabolic turnover [10]. 
 
1.1.2 TB Disease 
Upon exposure to M.tb bacilli, it is estimated that 70% of individuals remain uninfected (Figure 
1-2). Of the 30% that do become infected, over 90% of individuals are able to contain the 
bacilli by forming a physical barrier known as the granuloma [11] which leads to latent 
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infection. While the majority of individuals exposed to M.tb do not develop TB disease, HIV 
and other forms of immunosuppression increase the likelihood of developing disease, increase 
the severity of symptoms, and decrease the time to progression [1,12]. 
 
Figure 1-2: TB disease progression. More than 90% of infected individuals enter a clinically 
asymptomatic latent state. Taken from Shaler et al, Clinical and Developmental Immunology 
(2012) [11] 
 
 
TB is spread by symptomatic individuals with pulmonary TB when M.tb bacteria are expelled in 
droplets during coughing fits. TB can be pulmonary (affecting the lungs) or extra-pulmonary 
(affecting a range of other organs such as pleura, lymph nodes, skin, joints, bones or meninges; 
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causing TB meningitis). The World Health Organisation (WHO) estimates that extra-pulmonary 
TB represents 15% of all TB cases [13] however this is likely an underestimation given the 
difficulties in diagnosis [14].  
Active TB disease may follow soon after initial infection, resulting in what is termed “primary” 
disease, or many years later due to reactivation of latent infection. For latently infected 
individuals, lifetime risk of developing clinical TB disease is estimated at 5-10% [15]; among 
those co-infected with HIV, this increases to a 10% annual risk [16]. 
The existence of a spectrum of TB disease has long been noted and is based on differences in 
clinical outcome, pathology of disease and immunological responses [17]. It is thought that a 
quarter of the world’s population is infected with TB and yet show no clinical symptoms [18]. 
This figure equates to 1.7 billion individuals who are latently infected with M.tb and are at risk 
of developing active disease, and thus transmitting TB to others.  
Notifications of disease due to the approximately 120 NTM have increased since the early 
1980’s, coinciding with the AIDS epidemic. Some NTM infections in HIV positive individuals are 
clinically indistinguishable from M.tb, and some cause a higher proportion of disseminated 
disease which is harder to diagnose [19]. In general, NTM are inherently resistant to standard 
TB chemotherapy.  
It is thought that exposure to NTMs may contribute to variability of effectiveness of the only 
licensed TB vaccine, BCG [20].  
 
1.1.2.1 Latent TB Infection 
Latent infection is thought to comprise a continuous spectrum from containment of M.tb 
bacilli with priming of a T-cell response, to clinical disease with symptom severity positively 
correlated with bacterial load (Figure 1-3) [21,22]. Targeting of preventative treatment to 
latently infected individuals most at risk of developing active TB disease would be an effective 
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way to stop transmission, however latent phenotypes are not readily elucidated by current 
diagnostic techniques [23].  
 
Figure 1-3: Spectrum of TB infection ranges from sterilising immunity to high bacterial load and 
clinical disease. Taken from Pai et al, Nat Rev Dis Prim. 2, 1-23 (2016). [21] 
 
1.2 TB epidemiology 
TB is the leading cause of death from a single infectious agent, currently ranking above 
HIV/AIDS. In 2016, an estimated 10.4 million people were ill with active TB disease, of whom 
6.3 million (61%) were newly diagnosed in that year. There were an estimated 1.34 million TB 
deaths in 2016; 85% of these occurred in the WHO African and South-East Asian regions 
(Figure 1-4) [13]. Without treatment, the 10-year case fatality rate for HIV negative sputum 
smear positive primary TB is 70% [24].  
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Figure 1-4: Estimated TB incidence for countries with at least 100,000 incident cases 2016. 
Taken from WHO Global TB Report 2017 [13] 
 
 
 
According to WHO, in 2016 90% of the 10.4 million reported cases were adults and 65% were 
male. Five countries accounted for 56% of the global total; India, Indonesia, China, the 
Philippines and Pakistan, with India, Indonesia and China having the largest number of incident 
cases [13]. Although TB is a notifiable disease, in areas with poor access to healthcare and no 
active case-finding, these numbers are likely an underestimate of the true burden.  
With respect to age distribution, a large observational study which enrolled over 82,000 
tuberculin skin test (TST) positive children in Puerto Rico between 1949-1951 and followed 
them for 8-20 years [25], found a distinct age distribution of disease which was confirmed in a 
systematic review of studies from the pre-chemotherapy era [26]: a peak in the first 1–4 years 
of life, followed by a trough until early puberty, rising to a second peak around the age of 20 
years. 
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High incidence in the very young is important since risk of developing active TB disease 
increases with younger age at which initial infection occurs [25]. Diagnosis in this group is 
often problematic due to the low bacterial count found in TB infection in children [27] 
resulting in under-reporting and delays to treatment initiation.  
 
In many countries, TB case notification is twice as high for men as it is for women and this is 
not thought to be completely accounted for by differences in health seeking behaviour [28]. 
Indeed a recent TB household risk study in Germany revealed active TB was more prominent in 
men [29], and an animal study showed a preponderance of male mice in accelerated disease 
progression upon aerosol M.tb challenge [30].  
 
1.2.1 End TB Strategy 
In 2013, the WHO published a roadmap of how to meet the goal of ending the global TB 
epidemic [31].  The target was a 95% reduction of deaths due to TB by 2035. The three pillars 
of this strategy consist of integrated, patient-centred TB care and prevention, bold policies 
(including universal health coverage and social protection), and intensified research and 
innovation. Specifically, the document focusses on research to deliver better diagnostics, safer 
and more effective treatment for both active and latent TB and effective pre- and post-
exposure vaccines.  
 
Models suggest that in order to meet these goals, the TB field needs to optimise current tools 
but also it will require the introduction of a new vaccine, new drugs and treatment regimes, as 
well as a new point-of-care diagnostic (Fig 1-5). 
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Fig 1-5: Desired decline in global TB incidence rates to reach the 2035 targets (taken from End 
TB strategy) [32] 
 
 
1.2.2 Diagnosis  
Developed more than 100 years ago, the most common way to diagnose contagious TB is the 
cheap and simple sputum smear microscopy in which bacteria are visualised under a 
microscope from sputum samples. This is a relatively insensitive technique, firstly requiring 
that a sputum sample be produced (which is not straightforward in children), and necessitates 
at least 5,000 bacilli per millilitre of sputum (which is problematic in HIV-infected individuals 
due to reduced cavitation and transfer of bacilli into respiratory secretions). Sensitivity is 
reduced in patients with extra-pulmonary TB and this technique is further limited by its 
inability to distinguish between viable and non-viable TB, as well as between TB and NTM 
[33,34].  
 
Although longer, more complex and expensive, culture methods allow for distinction between 
viable and non-viable bacteria, as well as between TB and NTM.  Culture diagnosis can detect 
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cases prior to becoming infectious and hence often increases the number of cases identified by 
up to 50% compared with sputum smear microscopy [33]. Further culture in the presence of 
anti-TB drugs can determine drug sensitivity and resistance. 
 
Genotypic methods such as the Xpert MTB/RIF are fast, high throughput and are useful in 
populations with a high incidence of HIV. The Xpert MTB/RIF is a cartridge based nucleic acid 
amplification assay which detects TB and Rifampicin resistance directly in sputum in 2 hours. 
Although more expensive than sputum smear and culture, the enhanced sensitivity of Xpert 
MTB/RIF contributes to its cost effectiveness, especially in HIV infected individuals [35].  
 
The Tuberculin Skin Test (TST or Mantoux test) has been used for more than a century as an 
initial screening test for both latent and active TB. A cellular immune response to antigens 
present in an M.tb extract, tuberculin (collectively known as protein purified derivative - PPD), 
causes a hard induration at the point of subcutaneous injection. A positive result is indicative 
of an increased risk of developing TB, or currently having TB [36]. Despite its widespread use, 
false positives in BCG-vaccinated individuals are common [37]. 
 
Interferon Gamma Release assays (IGRA) such as QuantiFERON Gold and T-SPOT.TB are used 
to detect latent TB and function on the basis of ex vivo blood lymphocyte Interferon Gamma 
(IFN-γ) release after stimulation with PPD. Although unable to differentiate between active 
and latent TB, IGRAs have higher sensitivity than TST in BCG vaccinated populations [38] and 
do not rely on production of sputum. 
 
An ideal diagnostic would be a cheap, fast and low-tech assay using an easily-accessible 
biological sample. Although still in development, a ‘dipstick’ assay measuring the M.tb cell wall 
 19 
 
lipopolysaccharide, lipoarabinomannan (LAM), has promise as a new diagnostic in HIV positive 
individuals [39] and an alternative skin test using antigens ESAT6 and CFP10 has shown good 
diagnostic efficacy in a field-friendly format [40]. 
 
The lack of a specific and sensitive diagnostic to differentiate stages of active and latent 
infection has hampered the advancement of knowledge into TB epidemiology as well as drug 
and vaccine development. 
 
1.2.3 Treatment  
First-line therapeutics for TB include isoniazid, rifampicin, pyrazinamide, ethambutol and 
streptomycin.  All are associated with hepatotoxicity and related side effects, and were 
developed in the early twentieth century.  The World Health Organisation (WHO) recommends 
a 6 month regimen for treatment of drug sensitive TB: consisting of 2 months of isoniazid, 
rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin 
[41].  
Injectable agents such as kanamycin, amikacin, capreomycin, along with the fluoroquinolones 
levofloxacin, moxifloxacin, ofloxacin, and other bacteriostatic drugs are termed “Second-line” 
therapeutics and are used in drug resistant cases of TB [42].  
Multidrug resistant (MDR) TB is defined as resistance to isoniazid and rifampicin.  Extensively 
drug-resistant (XDR)-TB is resistant to at least one fluoroquinolone and one injectable second-
line anti-TB drug in addition to isoniazid and rifampicin. Of the 6.3 million new cases of TB in 
2016, over half a million of those are thought to be MDR-TB strain, with up to 30% of new TB 
cases being MDR-TB in former Soviet Union hot-spots [13].  
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Recommendations for treatment of MDR-TB are not straightforward, and depend on the 
capacity of the country to carry out drug resistance testing, as well as the availability of 
second-line therapeutics, but the minimum treatment duration is eight months [43]. The 
estimated direct cost of treating MDR-TB is eight times, and XDR-TB 25-35 times higher than 
treating drug-sensitive TB [44]. The potentially devastating indirect costs to patients include 
travel to clinics and loss of productivity.  
 
In summary, TB treatment regimens are long, expensive and cause side-effects which have 
ramifications on compliance. Development and roll-out of an efficacious vaccine would greatly 
aid the battle against drug resistance.  
 
1.2.4 TB Vaccines 
There exists only one licensed TB vaccine: Bacille Calmette-Guérin (BCG) is a live attenuated 
strain of bovine tuberculosis introduced in 1921 [45]. Although efficacious in protecting 
children and infants from disseminated TB and tuberculous meningitis, it has shown varied 
protection in adults against the most transmissible pulmonary form [20,46]. The large variation 
(0-80%) in protection elicited by BCG is thought to be multifactorial, with age at which BCG is 
given and previous exposure to mycobacteria (either M.tb or NTM, which has been linked to 
distance from the equator) being implicated [20]. 
 
A large trial of BCG involving approximately 50,000 people in the UK gave a protective efficacy 
against pulmonary disease risk ratio (RR) estimation of 0.22 (CI 95% 0.16-0.31) during the first 
five years of the study [47] (BCG vaccinated individuals were 78% less likely to be diagnosed 
with TB compared to unvaccinated individuals). The final 15 years of the 20 year study period 
however coincided with a general decrease in prevalence and incidence of TB in the UK and so 
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the predicted benefit of BCG was deemed to be decreased as well [48]. Conversely, the 
Chingleput study in India found an absence of any clinical benefit in over 200,000 individuals, 
with an RR of 1.05 (CI 95% 0.88-1.25) [49].  
 
A recent systematic review of all published BCG efficacy trials found that BCG was protective 
against pulmonary TB. Greater protection was seen when BCG was given earlier in life, and 
when given to individuals with no TST evidence of prior exposure to mycobacteria [20]. 
Protection against meningeal and miliary TB was greater than pulmonary TB, and again, was 
greater when given to younger infants with lower risk of prior mycobacterial exposure. The 
protective effect against pulmonary TB was seen to change with latitude: protection was 
absent or low in trials conducted near the equator, and higher in those conducted more than 
40° distant [20].  
Proposed explanations for the association of variable BCG efficacy with latitude include host 
genetics, nutritional status and vitamin D availability, however it is now thought that the fact 
that NTMs are more prevalent closer to the equator may be the main driver behind the effect 
seen [50].  It is thought that exposure to NTM or M.tb itself, prior to BCG vaccination could 
lessen its efficacy [20]. 
 
Evidently there is a need to develop more efficacious vaccine candidates. Ideally, a vaccine 
would protect against both infection with M.tb in exposed persons and the development of 
disease in those who have already been infected. As of 2017 there were 12 vaccine candidates 
in clinical trials. The pipeline consists of products designed to replace BCG (prime vaccines), 
improve upon BCG (prime-boost vaccines), or shorten TB chemotherapy (immunotherapeutic 
vaccines). Some are being developed as prophylactic vaccines in very young infants prior to 
exposure to M.tb and some as therapeutic vaccines in previously exposed individuals [51]. 
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There have been very few large-scale efficacy studies of developmental TB vaccines. Results of 
a Phase 2b trial with a fusion protein plus adjuvant (M72 AS01E) are expected in 2018 and the 
results of a pre-proof of concept prevention of infection study were published in July 2018 for 
the subunit vaccine H4:IC31 [52]. Another was a virally vectored prime-boost vaccine based on 
Modified Vaccinia Ankara (MVA) subunit vaccine, MVA85A [53]. The vaccine contains the gene 
for highly immunogenic Antigen 85A (Ag85A), a protein secreted by M.tb, as well as other 
mycobacteria, which is involved in maintenance of cell wall integrity through mycolic acid 
transfer. The vaccine was not found to confer any additional protection above BCG in infants 
(n=1399 MVA85A, n=1398 placebo). The lack of efficacy was not predicted by either mouse 
nor non-human-primate (NHP) animal studies [54] and, in the absence of a reliable correlate or 
biomarker of protection from, or risk of, disease, large and expensive clinical trials are the only 
way to test clinical efficacy (see section on ‘Immune Correlates and Biomarkers’ below).  
BCG is the only vaccine thought to function primarily through induction of a T-cell response 
[55], whereas all licensed vaccines against other pathogens rely upon induction of antibodies 
to exert a protective effect [56]. The divergence of immunology from vaccinology in the 
infancy of both fields of research has led to the empiric development of effective vaccines with 
little understanding of the underlying immune mechanisms. Given the failure to develop 
successful vaccines against global diseases such as HIV and TB, there is increasing cooperation 
to dissect protective immunological pathways [57]. 
 
1.3 Immune response to TB  
When M.tb bacilli are spread by aerosolised droplets and inhaled into the airways of a new 
host, the initial host response is characterised by an influx of phagocytic cells including 
resident alveolar macrophages, lung dendritic cells (DCs) and neutrophils [58]. M.tb bacilli are 
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taken up by a variety of cell types including DCs, macrophages, neutrophils, monocytes and 
epithelial type II pneumocytes [59]. Infected DCs migrate to the local draining lymph node 8-12 
days after infection where they activate antigen-specific T-cells and drive differentiation 
towards an inflammatory Th1 phenotype [60].  
M.tb has evolved a variety of immune evasion strategies including; induction of macrophage 
production of the immune regulatory cytokine IL-10 which prevents phagosome maturation 
and phagolysosomal fusion [60]; ESAT-6 directed sequestration of host beta-2-microglobulin 
resulting in the down-regulation of macrophage antigen presentation through MHC Class-I 
[61]; lipoarabinomannan (LAM) signalling through alveolar macrophage mannose receptor to 
reduce the cellular secretion of pro-inflammatory cytokines TNF-α and IL-β and chemokines 
MCP-1 and IP-10, thereby impairing recruitment of innate immune cells to the lungs [62,63], 
and delaying migration of antigen presenting cells (APC) to the draining lymph node, resulting 
in subsequent delays in T-cell priming [11].  
The delayed onset of the adaptive immune response to M.tb allows the migration of infected 
cells into tissues and their aggregation into granulomas with accompanying bacterial 
proliferation, before activation of mycobacterial-specific T-cells [64,65]. The granuloma is a 
general term to describe an organized aggregate of mature macrophages that arises in 
response to a persistent stimulus. In TB, the granuloma consists of a dynamic array of cell 
types attempting to segregate intra- and extra-cellular bacteria from the host (Figure 1-6) [66].  
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Figure 1-6: Structure of the TB granuloma. Taken from Ramakrishnan, Nature Reviews 
Immunology, 2012 [66].  
 
 
The large number of TB cases around the world is evidence that the sequestration of bacteria 
in these complex aggregates often fails. Observational studies in humans, and research in 
mice, evidence the importance of the inflammatory cytokine IFN- in granuloma formation and 
maintenance. IFN--deficient mice are unable to develop granulomas [67] and humans with 
Mendelian susceptibility to mycobacterial infections (MSMD) were found to have variants in 
genes involved in IFN- signalling pathways [67].  
 
 In addition, the bacteria themselves have evolved ways of manipulating the ability of the host 
to produce IFN-: the early secreted proteins ESAT-6 and CFP-10, which form two of the gene 
products of a 9.5-kb section of M.tb DNA called Region of Deletion 1 (RD1), by virtue of the 
fact that they are deleted in BCG and NTM, are involved in virulence and pathogenesis of M.tb 
infection [68]. ESAT-6 contributes to virulence by inhibiting T-cell IFN- production [69]. 
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While granulomas are a host defence mechanism to ‘wall off’ invading M.tb, the necessary 
inflammatory response needed to contain infection can also cause immunopathology in the 
form of necrosis. Infection with M.tb can elicit macrophage death in two ways: apoptosis 
whereby the cell retains an intact plasma membrane and bacteria are destroyed, or necrosis, 
where cell lysis allows bacteria to spread and infect other cells [60]. The type of cell death that 
results after initial infection is thought to depend on pathogen and host factors (the more 
virulent strains induce more necrotic cell death). Ultimately, TB morbidity and mortality is 
thought to result from an aberrant and excessive host immune response that is both 
pathologic in consequence yet ineffective in containing the pathogen [70]. 
 
Being a disease associated with high human morbidity and mortality, and with poor treatment 
options, TB human challenge models are considered unethical. Much of our knowledge of the 
immunology of tuberculosis infection has come from observational studies in humans and 
experimental animal studies, with the most important species being the mouse. While the 
mouse model has been crucial in demonstrating the protective role of CD4+ T-cells, IFN-γ, and 
TNF-α, there are limits to the use of genetically inbred laboratory mouse studies to any human 
pathology, and the same is seen in TB [71]. The currently used mouse strains are particularly 
poor models for M.tb lung granuloma formation and so many groups prefer to use guinea pig 
or non-human primate (NHP) alternatives.  
 
1.3.1 Cell mediated responses 
T-cell immunity is critical for protection against TB. The HIV epidemic in humans has 
highlighted the crucial role of CD4 T-cells: the preferential depletion of M.tb-specific CD4+ T 
cells is thought to contribute to the susceptibility of HIV positive people to TB disease [72]. 
 26 
 
Indeed, an increased 1.43 (95% CI 1.16–1.88) fold risk of TB incidence has been associated with 
every 100 cells per mm3 decrease in CD4 cell count [73]. In a TB challenge mouse model, CD4+ 
T-cell, or MHC-II deficient mice, were unable to control mycobacterial growth. CD8+ T-cells are 
also thought to be important in protection against TB disease through the production of IFN-γ 
which in turn plays a role in the activation of macrophages. However CD8+ T-cells cannot 
compensate for the lack of CD4+ T cells in a CD4+ deficient model [74].   
 
IFN-γ is a mediator of macrophage activation and resistance to intracellular pathogens. As 
previously mentioned,  its importance in TB was highlighted by recognition of mutations in 
IFN-γ receptors of highly susceptible individuals, as well as the presence of IFN-γ specific auto-
antibodies acting to block induction of IFN-γ inducible genes [75,76]. The important role of 
Tumour Necrosis Factor α (TNF- α) in human TB control was illustrated in 2001 when 70 
reports of reactivation of active TB in subjects with latent TB were filed after receiving the anti-
TNF monoclonal antibody, Infliximab, for rheumatoid arthritis or Crohn’s disease [77]. TNF-/- 
knockout and mice depleted of TNF by treatment with anti-TNF antibodies resulted in fatal TB 
infection in previously resistant strains [78,79]. 
 
Although human observational studies and mouse models have shown that Th1 responses 
such as CD4+ T cells, IFN- γ and TNF- are all important in progression of M.tb infection [80–
82], these factors do not explain the large heterogeneity in clinical outcomes.  More likely is 
that disease outcome is dependent on many host, pathogen and environmental interactions 
[60].  
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1.3.2 Humoral responses 
In the late nineteenth century, early immunological theory separated out defence against 
intracellular, and extracellular pathogens, and so ensued the concept that they are moderated 
by cell-mediated, and humoral (comprising B-cells and antibody) immune responses 
respectively [83,84]. With the overwhelming evidence for the importance of cell-mediated 
immunity in TB, and the inconsistent results of passive serum transfer in the late nineteenth 
century [85], the role of humoral immunity in TB has been largely overlooked despite evidence 
of its critical role in many other intracellular pathogens (reviewed in [86]). 
Data showing a lack of association between frequency and amplitude of classical Th1 cytokine 
responses [87], and release of IFN- [53] with protection against TB disease in South African 
infants following BCG have cast doubt over the theory that a cell-mediated response is the 
only important factor in protective responses against M.tb [88].  
 
For the purposes of this introduction, B-cells and their soluble secreted product, antibody, will 
be considered separately in the next section. 
 
1.3.2.1 B-cells 
B-cell activation is necessary for their maturation into plasmablasts, which produce high 
affinity pathogen-specific antibodies, as well as maturation into memory B cells which are 
crucial for immunologic memory. Whereas T-cells can only recognise processed (normally 
protein) antigens, as a professional APC, B-cells are able to interact with antigen in the native 
form [89] which may be particularly important in TB considering the high lipid component in 
M.tb cell wall.  Their interaction with CD4 T-cells in peripheral lymphoid tissue structures, 
called germinal centres, activate antigen-specific T-cells and, under the right conditions, the T-
cells provide activatory signals to the B-cells [90]. Reports suggesting modulatory roles for B-
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cells in TB [91,92], along with evidence that B cells themselves are a source of IFN-γ [93] thus 
promoting a Th1 response, have renewed interest in investigation of B-cells in TB [94]. 
 
This renewed interest in B-cells in TB coincided with the discovery of B-cell aggregates within 
the granuloma, which were reminiscent of germinal centre follicle-like structures, in the lungs 
of TB patients [95]. The finding that T-cells could be found in these B-cell clusters [96] and that 
the aggregates contained germinal centre-type markers [97] gave rise to the hypothesis that 
this could be a site of antigen presentation and B-cell maturation similar to a germinal centre 
[98]. Further evidence of the potential importance of B-cells came from; exacerbated lung 
pathology and disruption of granuloma architecture in B-cell deficient mice [97], the detection 
of both activated B-cells and mycobacteria-specific antibody-producing plasmablasts within 
the granuloma of TB-infected NHPs [99], and that humans with active pulmonary TB disease 
have lower circulating B-cell counts than uninfected individuals [100].  
 
1.3.2.2 Antibodies 
Investigations conducted in the late 1800’s using sera from various animals to induce 
protection in different animals (sometimes of different species), unsurprisingly showed highly 
variable results [85]. However, despite our improved understanding that the M.tb bacillus is 
not limited to an intracellular niche [66], and so therefore accessible to humoral responses, 
along with the discovery that antibody mode of action is not limited to extra-cellular locations 
[101], the TB field has been slow to investigate the role of antibodies in disease progression.  
 
Antibodies have mainly been investigated for their use in TB diagnosis. An accurate serological 
test that could provide rapid diagnosis of TB and in a suitable format (e.g. point-of-care) would 
be particularly useful both as a replacement for laboratory-based tests and for extending TB 
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diagnosis to lower levels of health services, especially those without on-site laboratories. 
Unfortunately, almost all the antibody-based assays are limited by sensitivity, especially in 
smear-negative TB patients (reviewed in [102,103]). Based upon a systematic review of the 
diagnostic accuracy of commercial tests for 67 pulmonary TB and 25 extrapulmonary TB 
studies [104], in 2011, the WHO “strongly recommended that these tests not be used for the 
diagnosis of pulmonary and extra-pulmonary TB” [105].  
 
While it has been repeatedly observed that although single-antigen-based assays never 
achieve satisfactory sensitivity and specificity, more recently, measurement of a combination 
of antibodies has been investigated for potentially better assay performance with equally 
disappointing results [106]. Antibody responses to a panel of 10 extracellular and 
immunodominant M.tb proteins failed to show a consistent pattern of antigen reactivity 
among confirmed TB cases [107], and more recently, a high throughput multiplex assay 
containing 119 M.tb antigens, found no predictive value based on differences between IgG 
responses from children with active TB and ‘unlikely’ TB [108].  
 
While antibodies may not have been the diagnostic panacea people had hoped, it is important 
to note the heterogeneity of diagnostic methodologies to which antibody-based assays have 
been compared. The methodology used to diagnose TB in many studies has changed over time 
depending on technological advances. Indeed, studies use an array of measures to distinguish 
various groups: occupational exposure [109,110], sputum smear microscopy [111], culture 
positivity [112,113], persistent cough [114], x-ray [107], response to anti-TB treatment [115], 
TST reactivity (also referred to as PPD skin test) [111,116], IGRA using cell-mediated responses 
to ESAT-6 and CFP-10 antigens [116], some studies do not detail method of diagnosis, only 
using “WHO TB diagnosis” group which comprises Confirmed, Probable or Suspected [117]. 
Along with the heterogeneity of TB diagnostic methods used, many studies are not 
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comparable to one another due to the use of different antigen mixtures from different strains 
of Mycobacteria, and at different stages of growth (see Table 1-1) 
 
Table 1-1 – Examples of the array of Mycobacterial antigens used to study antibody responses 
in human TB cases 
MIXTURES (different methods for extraction, 
different strains of M.tb, at different stages of 
growth [118]) 
INDIVIDUAL ANTIGENS 
PPD [119–121] 38kDa [107,115,122] called TB72 in [109] 
CFP [123,124] Alanine dehydrogenase [115] 
TBGL [125] Rv2626c [115] 
Mtb whole cell lysate [123] 16kDa [115] 
Ag85 complex [123] Ferrodoxin A [115] 
Cell-free protein extract [122] ESAT6 [107,115,116] 
NTM Sonicates [112,126] 14kDa [107] called TB68 in [109] 
Mtb sonicate [117,124] MPT63 [107] 
BCG extract [121] 19kDa [107] called TB23 in [109] 
H37Rv extract/sonicate [112,121] MPT64 [107] 
H37Ra sonicate [112] MPT51 [107] 
Precipitated mucopolysaccharides of NTM 
[112] 
MTC28 [107] 
 Ag85B [107] 
 KatG [107] 
 CFP10 [116] 
 LAM [109,117,122,124,126,127] 
 65kDa HSP [126] 
 70kDa HSP [126] 
 32kDa (also known as Ag85A) [113]  
 DAT [111] 
 PGL-Tb1 [111] 
(NTM - non-tuberculous mycobacteria, HSP – Heat Shock Protein, DAT - diacyl-trehalose, CFP – 
Culture Filtrate Protein, TBGL – anti-tuberculous glycolipid antigen, MTC – M.tb complex, LAM 
– lipoarabinomannan, PGL – phenolglycolipid antigen) 
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Human antibody reactivity to M.tb is highly variable; comprehensive systems biology 
investigation of the M.tb proteome showed that sera from suspected TB cases recognized at 
least one of a panel of 484 proteins (representing only 10% of the total M.tb proteome) 
regardless of TB disease state [114]. Active TB was associated with reactivity to only 13 
proteins, all of which are extracellular, and the authors concluded that human antibody 
reactivity to M.tb antigens is likely determined by the metabolic state of the pathogen [114]. 
Many who work in the TB field are skeptical of the role of antibodies in TB because of the lack 
of a clear phenotype associated with magnitude of antibody response, however epidemiologic 
studies have shown a decrease in anti-LAM antibodies during reported peak TB incidence of 
disseminated TB in children [117], as well as in HIV positive TB patients [128] suggesting a 
possible protective role for anti-LAM antibodies. Antibody against the secreted 38-kDa antigen 
best correlated with advanced, multibacillary disease, while the antibody against the cell-
associated 16-kDa antigen (α-crystallin) is detected preferentially in asymptomatic, infected 
individuals [109,115,129,130].  
 
More recently, mechanistic studies have uncovered a more nuanced role for antibodies; 
enhanced phagocytosis of mycobacteria in the presence of post BCG-vaccination serum [131] 
and the observation that, despite overlapping antibody titres against M.tb antigens in 
uninfected, latently infected and individuals with active TB disease, active TB patients had 
lower avidity antibodies against surface antigens compared to uninfected controls [132]. It has 
been shown that pre-treatment of virulent M.tb bacilli with immune sera prior to infection 
inhibits the blockade of phagolysosomal fusion which, during normal TB infection allows the 
bacilli to evade host killing [133]. In immunotherapeutic vaccine studies, it has been shown 
that passive transfer of serum from vaccinated mice to Severe Combined Immunodeficiency 
(SCID) mice resulted in significant reduction of lung colony forming units (CFU) and reduced 
abscess formation. Authors concluded that antibodies might be used in conjunction with drug 
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therapy to treat tuberculosis [134,135]. A study carried out in Mexican Indians found that 
positive Ag85A antibody responses prior to initiation of anti-TB treatment was associated with 
less advanced disease and with subsequent responsiveness to chemotherapy in TB patients 
[136]. Following a developmental TB vaccine (MVA85A) which was not found to confer 
additional protection above BCG in a Phase 2b infant efficacy trial [53], a secondary study was 
initiated which aimed to identify correlates of protection based on pre- and post-vaccination 
stored cells and sera for cases and controls. Exploratory analysis suggested that Ag85A-specific 
antibodies were associated with reduced TB disease risk (estimated odds ratio 0.62 per 1 log10 
unit increase, p = 0.019) up to three years prior to diagnosis [137]. The majority of studies 
measure an immunoglobulin (Ig) G response however IgA may also be able to discriminate 
between M.tb infected and non-infected subjects [138–140]. A study investigating the 
qualitative differences in mycobacteria-specific antibodies in active TB patients found a 
difference in the sugar residues on immunoglobulin molecules [141]. These studies point 
towards the need for measurement of responses against standardised antigens and, in 
addition to measures of antibody quantity, investigate other aspects of antibody quality. 
 
In summary, early studies investigating the role of antibodies in TB were hampered by lack of 
standardisation of methods and reagents. More recent studies have moved on from measuring 
amount of antibody to attempting to measure functionality of antibody. Results from these 
studies show that while antibodies may not be sufficient for protection against TB, they may 
well be necessary, and definitely warrant further research.  
 
Next, I will discuss the need for accurate read-outs of disease progression, treatment efficacy 
and vaccine-induced protection. I will then introduce the current methods used to investigate 
these correlates or biomarkers. 
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1.3.3 Immune Correlates and Biomarkers 
In order to achieve the ambitious goals set by the ‘End TB Strategy’ [32], there is a critical need 
to identify early changes indicative of risk progression to, or protection from, active TB disease. 
These changes, termed correlates or biomarkers, should be measurable in an easily accessibly 
biologic sample and would direct treatment and provide read-outs from vaccine development 
studies. In many cases, multiple biomarkers are needed to identify a meaningful 
“biosignature”. Given the difficulties in interpretation of animal models in TB research, it will 
be important to use such biosignatures as surrogate markers for the protective efficacy of 
vaccines, as correlates of protection. 
A common immunological parameter measured in TB vaccine programmes is the cytokine 
profile of T-cells, knowing that a Th1 response is important to risk of disease - specifically IFN-γ 
release from T-cells stimulated ex-vivo with mycobacterial antigens. However caution is 
needed when interpreting these results as a 2010 study of 29 unprotected and two groups of 
55 protected infants which measured mycobacteria-specific T cell frequency and cytokine 
profile, found no correlation of IFN- γ, TNF- α, IL-2, and IL-17 production from CD4+, 8+ or γδ T-
cells [87]. Tighter TB disease definitions in a more recent study did however find that BCG 
specific IFN- γ release was associated with lower risk of TB disease [142]. The immune 
components already identified as playing a role in protection or risk of disease might not be 
the only useful correlates of protection against disease.  
 
An ideal TB biosignature should be reproducible in a diverse patient population, should 
differentiate between active and latent TB, it should return to normal levels during successful 
treatment, and predict vaccine efficacy thereby providing endpoints for clinical trials [143]. 
Factors likely to affect biomarkers include patient factors (age, ethnicity, environmental 
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exposure to NTM, co-infections and immune status), pathogen factors (infecting strain, route 
of infection, site of disease and stage of disease), and sample factors (type of sample taken, 
sampling handling and time between collection and analysis) [144]. 
 
1.3.3.1 Gene Expression Signatures 
Technological advances in methodologies such as gene expression analysis have allowed for 
measurement of global gene expression in TB cases. An analysis of eight global gene 
expression studies [145–152] was conducted comparing whole blood or PBMC signatures from 
individuals with active TB over time during treatment and with healthy infected controls, 
uninfected controls, as well as other inflammatory diseases [144]. In this study, the authors 
note the limitation of peripheral blood sampling and the likely differences between peripheral 
blood and site of disease. Nevertheless, the prominent activated myeloid cell signature seen in 
the circulation is noted to be probably due to the magnitude of the inflammatory response at 
site of infection [144]. The 409 genes identified as being associated with TB disease were 
overwhelmingly associated with patterns of inflammation, interferon signalling pathways and 
myeloid lineage cell activation, however these patterns were also found in other, non-TB, 
inflammatory conditions. Upregulation of T- and B-cell receptor signalling, as well as antibody 
Fc receptor signalling, again implicates humoral immunity in TB disease. In 2016, a large 
prospective cohort study identified a 16-gene signature of risk of TB progression in South 
African progressors (n=46) and matched controls (n=107), which was validated in separate 
South African and Gambian cohort [153]. This whole blood RNA signature may be useful in 
identifying individuals at risk and targeting interventions to prevent active TB disease.   
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1.3.3.2 Mycobacterial Growth Inhibition  
An alternative to gene expression signatures is to measure an individual’s ability to inhibit 
growth of Mycobacteria ex vivo in an assay known as the Mycobacterial Growth Inhibition 
Assay (MGIA) [154,155]. These assays measure the summative ability of all cell types in either 
whole blood or peripheral blood mononucleocytes (PBMCs) to control growth and so the exact 
immune mechanism does not need to be identified.  This assay has been used to compare 
growth of mycobacteria following BCG [156] and MVA85A [157] vaccination in humans. 
Although the assay requires optimisation, it has promise.  
 
1.3.3.3 Other Biomarkers 
In addition to their investigation as diagnostics, mycobacteria-specific antibodies have been 
investigated as biomarkers for treatment success. As opposed to the simplistic measurement 
of antibody level only, a study in UK adults measuring fluctuations during TB treatment found 
an initial increase in antibody levels with a subsequent decrease, a broadening of epitope 
recognition, and found no changes in antibody affinity in successfully treated individuals [158]. 
Differences were seen between patients with drug resistant M.tb and individuals who went on 
to relapse. A study in Ugandan active TB patients and uninfected or latently infected controls 
found differing ratios of B-cell phenotype. Healthy controls had higher plasmablasts compared 
to memory B-cells whereas active TB patients had higher memory B-cells compared to 
plasmablasts [159]. Unfortunately this study did not include patients with other inflammatory 
conditions which may have caused the shift in B-cell phenotype irrespective of TB status, 
especially since the same group previously found measurable levels of mycobacteria-specific 
memory B-cells in uninfected individuals both with and without BCG vaccination [160].  
In 2016, a correlates of protection study which followed infants for up to three years before 
development of active TB disease (n=50) and matched controls who did not develop disease 
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(n=136), found risk to be associated with increased frequency of CD4 T-cells with an activated 
phenotype, and reduced risk with frequency of BCG-specific IFN-γ-secreting T-cells and IgG 
against Ag85A [142].  
 
In summary, research into immune correlates is progressing with some important findings in 
recent years. It is increasingly unlikely that a single biomarker will be identified as a correlate 
of risk of disease progression or a marker of vaccine-induced protection however the 
combination of many markers into a biosignature may prove to be a useful tool. 
 
1.3.3.4 Immune Activation and TB 
As previously discussed, a major finding from a 2016 TB immune correlates study was that risk 
of TB disease was associated with pre-vaccination (D0) increased frequency of activated CD4+ 
T-cells (OR=1.12, 95% CI=1.04–1.2, P=0.002) and CD8+ T-cells (OR 1.02, 95% CI=1.00-1.04, 
P=0.056), n= 50 (cases), n= 136 (controls) measured up to three years prior to development of 
active TB disease in BCG vaccinated South African infants. This finding of increased risk of 
active TB disease with an activated immune phenotype was independently verified in M.tb 
infected adolescents (OR=1.387, 95% CI=1.068–1.801, P=0.014, n=30 (cases) n= 59 (controls) 
[142]. In this study the authors also included measurement of Human Cytomegalovirus 
(HCMV) infection (measured by T-cell IGRA) and found that magnitude of T-cell response to 
HCMV was correlated with T cell activation.  
As will be discussed in the following section, HCMV is a known driver of significant immune 
activation [161–163], immunosenescence [164–166] and associated with increased overall 
mortality [167] with outcomes seemingly having a dose-response relationship with magnitude 
of HCMV antibody level [168].  
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There is increasing evidence of a detrimental role of general immune activation on health 
outcomes. This has been investigated extensively in HIV, with immune activation being 
associated with increased overall mortality, cardiovascular disease (CVD), neurocognitive 
impairment, osteoporosis and frailty [169–175]. It has been found that immune activation is 
more predictive of survival than plasma virus burden [176], with effects of HIV-induced 
immune activation evident despite antiretroviral (ARV) treatment [177]. The harmful effects of 
immune activation appear to be compounded when an individual is infected with both HCMV 
and HIV, with the compound effect seen even due to HIV exposure and in the absence of 
actual infection [178]. Immune activation has also been investigated in the context of live 
attenuated yellow fever vaccine where vaccinated individuals from Switzerland and Uganda 
were compared [179]. Baseline levels of pro-inflammatory monocytes and exhausted NK cells 
were higher in the Ugandan volunteers and were associated with impaired cellular and 
humoral responses to vaccination [179]. Both latent and active TB are themselves a source of 
immune activation and in areas of high TB/HIV co-endemicity, latent TB-associated T-cell 
activation may contribute to HIV disease progression and exacerbate the HIV epidemic [180–
182]. Levels of serum activation markers have been linked to risk of TB drug toxicity in HIV/TB 
co-infected individuals [183]. 
 
The excess risk of active TB disease in HIV infected individuals is well known, however the 
relationship between HCMV and TB is very much less well researched. This PhD thesis will 
investigate the association of HCMV infection with markers of inflammation, and try to 
determine the impact of these on TB risk.  
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1.4 Human Cytomegalovirus 
Human Cytomegalovirus (HCMV), also known as human herpesvirus-5 (HHV-5), is a member of 
the β-herpesviridae subfamily which is widely distributed in human populations. HCMV 
transmission occurs through person-to-person contact. It can be transmitted transplacentally 
to neonates or through breast milk of an infected and shedding mother, by intimate contact 
and by transplantation from (or sharing syringes with) an infected individual [184]. It has been 
shown that young children shed HCMV virus in saliva and urine at high levels which may add to 
transmission between infants and adult care-givers [185]. Congenital HCMV infection is the 
leading cause of permanent hearing and neurological impairment as well as vision loss in 
infants worldwide [186]. Maternal primary infection or reactivation, especially during the first 
trimester, is particularly associated with adverse neonatal outcomes [187]. The incidence of 
congenital HCMV infection is estimated at between 0.7 and 5% of all births in low and middle 
income countries (LMICs) [188].  
 
In LMICs, such as Uganda, prevalence of HCMV infection is high, with 95% of individuals 
infected by age five [189]. In the United Kingdom, 15% of 1-4 year olds, 30% of 20-29 year olds, 
and approximately 80% of the population is infected by age 65 [190]. Much of the research on 
the clinical importance of HCMV has been conducted in HICs, where HIV-associated HCMV 
retinitis [191], congenital HCMV disease [192] and transplantation [193] are all important 
manifestations of disease. Despite generally higher seroprevalence, less is known about the 
clinical importance of HCMV in LMICs. It is a common cause of pneumonia and meningitis in 
immune-suppressed hospitalised patients, and autopsy studies in Africa frequently find HCMV 
in the absence of overt HCMV disease [194]. An anticipated decrease in HCMV-associated 
clinical issues with increased roll-out of antiretroviral drugs in sub-Saharan Africa has 
disappointingly not materialized [195]. Detection of HCMV in blood correlates with 
progression to other AIDS-defining illnesses and death, even in the era of ART [196], and there 
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may be a benefit to empiric systemic treatment with anti-HCMV drugs such as ganciclovir 
[191]. 
 
In immunocompetent adults, HCMV infection rarely causes disease; however, once infected, 
the virus remains latent in a wide range of cell types including lymphocytes, myeloid lineage 
cells as well as smooth muscle cells and endothelial cells which line blood vessels [197]. 
Monocytes are a key host cell of HCMV during latency [198,199]. While monocytes are not 
permissive to viral replication, HCMV infection can drive cell differentiation to macrophages 
[200] which do support the full lifecycle of HCMV.  
 
HCMV/HIV co-infection is common and HCMV infection is an important cause of severe non-
AIDS events, including death, in HIV-infected individuals [201,202]. Epidemiological studies in 
high income countries (HICs) have found associations between HCMV infection and increased 
risk of mortality in older people [168,203]. Further studies have implicated chronic HCMV 
Infection as a risk factor for cardiovascular disease (CVD);  a recent meta-analysis of studies 
conducted in HICs, estimated a 22% increased relative risk of CVD with exposure to HCMV 
[204]. In a UK setting, HCMV infection was associated with the development of arteriosclerosis 
[205] and an increase in blood pressure among older individuals [206].   
 
In this thesis, the use of HCMV IgG measurement as a proxy for HCMV virus exposure is an 
assumption [202,207,208]. Evidence does, however, exist to suggest that this is not the case 
and viral shedding is not associated with antibody levels [209]. It is well known that HCMV 
infection, and shedding is associated with lower socioeconomic status [210–212] however, it 
has also been postulated that genetic predisposition, or other factors such as stress, could 
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induce an excessive inflammatory profile which may be associated with increased production 
of HCMV-specific antibody [210].  
 
1.4.1 Impact of HCMV on the immune system 
The immune response to HCMV infection is one of the largest ever documented [162,213]. As 
already mentioned, HCMV infection is linked to long-term health outcomes. These include CVD 
[167,206], cancers [214,215] and a range of cognitive disorders such as Alzheimer’s [216,217]. 
A study of 105 twin pairs which measured over 200 cellular and serum characteristics found 
that most of the differences in immune parameters were due to non-heritable factors.  The 
authors found that discordant HCMV infection status in monozygotic twins was found to be 
associated with differences in 58% of all parameters tested [207].  
 
Latency in HCMV is not a silent process. Accumulating evidence suggests that the virus itself 
directs significant activity towards the maintenance of this state, and the expression of viral 
proteins occurs during non-replicative latency [218–220]. Some of these proteins are involved 
in manipulation of cellular immune recognition machinery, while others alter the cellular 
environment, contributing to an immune-suppressive environment (reviewed in [221]. 
Maintenance of HCMV in a latent state appears to be a very resource-intensive activity for the 
host immune system. Characterisation of the HCMV-specific T-cell population revealed that up 
to 30% of circulating CD4 and CD8 memory compartments are dedicated to the restraint of 
viral replication in HCMV seropositive individuals [222]. This phenomenon, termed ‘memory 
inflation’ depletes the available pool of naïve T-cells by pulling them into differentiated HCMV-
specific memory phenotypes [165]. HCMV-associated activation of T-cells is linked to 
permanent high expression of IFN-γ and other Th1 cytokines to induce a chronic pro-
inflammatory state associated with immune activation and senescence [213] and has been 
found to correlate to acute-phase response proteins such as CRP [162,223]. HCMV infection 
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has also been linked to the differentiation of Natural Killer (NK) cells [224,225], (an important 
cell type in early responses to infections, reviewed in [226]) impairing their ability to respond 
to cytokine stimulation in post-vaccination responses [227,228].  
 
The relationship between HCMV and vaccine responses is not straightforward. Influenza 
vaccine is given to at risk groups and the elderly in many countries. HCMV has been 
investigated as a possible reason for the variable protection seen. One US study showed up-
regulation of immune responses to influenza vaccine in HCMV positive younger people but 
down-regulation in HCMV positive older people [229], another showed higher anti-influenza 
serum responses in HCMV negative younger individuals and no difference in older people 
[230]. A study in the Netherlands found HCMV to have no impact on the poor responsiveness 
seen in elderly recipients of influenza vaccine [231] and in Poland, non-responsiveness was 
linked to a HMCV-induced pro-inflammatory environment [232]. It is interesting to note that 
the above studies use HCMV serostatus as a measure of infection status. It has been 
postulated that extent of exposure (reactivation and re-infection) to HCMV, as measured by 
HCMV-specific IgG titre, may be a better way to gauge correlation with HCMV infection 
[168,233]. Indeed, mouse studies have indicated a dose response to the initial inoculum, with 
compromised ability to clear heterologous viral infections with high initial exposure [234,235].  
 
HCMV utilises its 225 genes to manipulate the immune system in many ways [236]. Initially, 
HCMV evades host immune responses via phosphorylation of the major immediate-early gene 
product UL122, thereby preventing its proteasomal degradation and presentation on the 
surface of infected host cells [237]. Other virally encoded proteins essential in HCMV immune 
evasion include; US6 which blocks peptide presentation, reducing CD8 T-cell recognition 
[238,239]; US2 which causes degradation of HLA-DR-α and DM-α, two essential proteins in the 
MHC class II antigen presentation pathway, thereby blocking CD4 T-cell presentation of viral 
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antigens [240]; UL111A; a homologue to the Th2 cytokine IL-10 which restricts differentiation 
of myeloid progenitors into dendritic cells [241]; and UL148 which inhibits CD58, an adhesion 
molecule critical in co-stimulation of effector cells [242]  Notorious for down-modulating MHC 
Class-I, all herpes viruses, but HCMV specifically, rely upon Natural Killer (NK) cells (which lack 
the normal complement of MHC-I display) in the absence of cytotoxic T lymphocytic CD8 
responses. This is evidenced by individuals with NK cell deficiencies [243]. HCMV infection 
impacts the maturation and differentiation of NK cells [244] however Investigation into HCMV 
interaction with NK cells is not well characterised. It is known that HCMV dedicates many 
genes to facilitate NK cell evasion [245], and an evolutionary expansion of HCMV-encoded 
NKG2D ligands (molecules which regulate NK cell function) likely conferred a genetic 
advantage [246,247]. 
 
1.4.1.1 HCMV and TB 
The impact of HCMV infection on the immune-system is far-reaching and there is evidence to 
suggest that immune control mechanisms important in defence against M.tb are subverted in 
HCMV infection. Epidemiological studies have shown a possible link between HCMV and TB, 
however these studies investigated the impact of TB upon HCMV antibody levels, not the 
impact of HCMV upon TB; a study in Nigeria found significantly more HCMV seropositive 
people among TB patients compared to non-TB hospitalised patients, with those TB patients 
having higher titres of anti-HCMV antibodies [248].  Elevated levels of HCMV antibodies were 
found in plasma from patients with pulmonary NTM disease [249]. A study in Russian children 
and adolescents found that pulmonary TB patients were three times more likely to be HCMV 
infected compared to non-TB controls [250]. A strong cellular response against either HCMV or 
Epstein Barr virus (EBV) predicted a favourable anti-TB therapy in hospitalised TB patients in 
Tanzania [251] however these HCMV responses were likely an indicator of general immune 
fitness  and therefore may have been an independent predictor of survival.  
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1.5 Aims and Research Objectives  
There remain many gaps in our knowledge as to the reasons for some individuals’ ability to 
control infection with M.tb while others develop active disease. Given recent evidence, there 
has been renewed interest in the role of humoral immunity, specifically mycobacteria-specific 
antibodies, in TB disease. The evidence implicating immune activation in predicting onset of TB 
disease has also sparked interest from the TB community as a possible component of a 
biosignature of risk. The knowledge that HIV is a major risk factor for TB and that both diseases 
induce a co-aggravating environment of immune activation and cellular differentiation points 
towards the potential importance of other co-infections acting through a similar route. Not 
only has HCMV been shown to be a major driver of immune differentiation and activation, the 
route by which HCMV achieves this appear to be independent of, and in addition to, that seen 
in HIV [178].  
 
The central hypothesis of this thesis is that infection with HCMV will be associated with risk of 
TB disease and affect a putative protective antibody immune response to TB. The overall aim 
therefore of this PhD project is to investigate the effect of HCMV on TB risk and mycobacteria-
specific antibody responses. 
In order to achieve this, the main research objectives are to:  
1. Characterise HCMV serostatus in a rural Ugandan cohort (Chapter 3) 
2. Measure mycobacteria-specific antibody levels and link these to demographic 
information and co-infection with HIV and HCMV (Chapter 4) 
3. Identify associations between level of HCMV sero-reactivity (and other herpes viruses) 
and markers of inflammation (Chapter 5) 
4. Investigate links between HCMV infection, measures of antibody quality and TB 
disease risk (Chapter 5) 
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CHAPTER 2: MATERIALS, METHODS AND METHOD DEVELOPMENT 
2.1        Study Area and Design 
The General Population Cohort (GPC) is a population-based open cohort study, set up in 1989 by 
the Medical Research Council (MRC) UK in collaboration with the Uganda Virus Research Institute 
(UVRI). Initially established to examine trends in HIV prevalence and incidence, the GPC is located 
in Kyamulibwa sub-county of Kalungu district, rural south-western Uganda [1].  The cohort now 
comprises a cluster of 25 neighbouring villages with approximately 20,000 residents (52% aged 
≥13 years) from three major ethnic groups; the majority (75%) being from the Baganda tribe, the 
main tribal group in the region. The study population is recruited by an annual house-to-house 
census. To be eligible for the census, an individual must have spent or be planning to spend at 
least 3 months in a household within the study area. 
Since 2010 research questions have been expanded to include communicable and non-
communicable diseases. Long-term epidemiological studies provide evidence for health policy and 
public health programmes in Uganda and other countries in sub-Saharan Africa. The specific 
questions asked and the biological samples taken depend on research themes and resources. 
Blood samples are taken biannually and transported to MRC/UVRI laboratories in Entebbe where a 
portion of the venous blood sample is analysed immediately for HIV and other parameters 
depending on the GPC round protocol. Remaining serum samples are stored at –80C in a biobank 
in Entebbe. Most samples used in this PhD were taken from 2011 where vaccination status 
information was collected, and individuals over the age of 12 years were also investigated for 
cardiovascular risk factors. Based on a unique identifier, serum samples were linked to 
demographic information, HIV status and any other information that was collected as part of the 
annual census.  
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2.2       Sampling 
A total of 2,162 individuals without TB were selected at random, having been stratified by age and 
sex. Infants under 5 years of age were oversampled in anticipation of high age-dependent HCMV 
seropositivity based on evidence from other sub-Saharan countries [2]. A target sample size of 
approximately 100 individuals per year of age from under 1 year to 5 years, and 200 individuals 
per either 5 or 10 year age groups thereafter. The sex ratio was approximately equal within each 
age group.  
The age structure of sampling for this study was determined based on Ugandan demographics: 
49% of Ugandans are under 14 years of age, 21% are between 15-24 years of age, 28% between 25 
and 64 years of age and only 2% over 65. The sampling here was similar to the Ugandan 
demographic with 45% under 14 years, 18% 15-24, 32% 25-64 and 5% over 65 years of age. 
Samples from TB cases were specifically oversampled and were taken from a range of GPC rounds 
between 1999 and 2014.  Active pulmonary TB was diagnosed through positive sputum smear 
microscopy after passive case detection. Study participant characteristics are summarized in Table 
2-1. 
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TABLE 2-1: Study participant characteristics (cross sectional study) 
Non-TB individuals* (n=2,162) TB case individuals (n=27) 
Age, years (mean, 
range) 
22.5 (0.08-100.75) Age, years (mean, 
range) 
36.0 (13.08-56.50) 
Sex, percent female 
(number/total) 
50% (1,080/2,162) Sex, percent female 
(number/total) 
63% (17/27) 
HIV prevalence, 
percentage 
(number/total), 
number missing 
4.3% (93/2122), 40 
unknown HIV status 
HIV prevalence, 
percentage 
(number/total) 
33.3% (9/27) 
BCG vaccinated, 
percentage 
(number/total), 
number missing 
64.7% (1,371/1,927), 
192 unknown BCG 
status 
BCG vaccinated, 
percentage 
(number/total), 
number missing 
0% (0/3), 24 unknown 
BCG status 
* Non-TB individuals here were not investigated for active or latent TB.  
 
2.2.1 Power calculation 
Based on data from a Phase 2b South African infants vaccine study [3], an increase of 
approximately 0.5 Optical Density units (OD) in Ag85A IgG was observed in the median response in 
the control vs case infants. These data indicate that a change of 0.5 OD may be biologically 
meaningful in terms of protection against TB disease. Using power calculations for a type 1 error 
(alpha) of 0.05, power of 0.80, with an effect size of 0.5 OD, we would require 64 individuals per 
comparison group. However, using an estimate from a case control study is likely to result in 
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differences larger than we would find in the general population. Higher variability is likely to 
adversely affect the power of the study. Based on an increase in the variance estimate of 20%, the 
resulting effect size of 0.4 OD would require 100 individuals per group. Since we have a minimum 
of 100 individuals per comparison group, we are confident that this number will enable us to see 
differences between groups with 0.4 OD effect size. If individuals are given BCG at birth, we 
anticipate antibody levels to be rising and remain high up to approximately 5 years (when we 
know BCG to be effective) and then decline into adolescence and adulthood (where we see most 
disease). We therefore included approximately 100 children from each age group <1, 1, 2, 3, 4, 5 
years (total 600), 200 children aged 6-10, 11-15 and 16-20 (total 600), and 800 people aged 21 
years and over. As long as the effect size is equal or greater than 0.4 OD, we expect to have 
reasonable power to see a change in antibody optical OD between age groups. 
 
2.2.2 TB case samples 
Twenty seven individuals with active TB were identified, and all available stored samples were 
retrieved. These samples were taken at various times prior to, and up to 3 months after, diagnosis. 
Between 1 and 4 stored serum samples per TB case were identified and retrieved from the 
biobank of stored samples at time points before, and up to 3 months after TB diagnosis. 
All non-TB individual samples and all samples from TB cases were tested for HCMV IgG, 
mycobacterial antibodies, tetanus toxoid IgG and total IgG. A subset of samples was then selected 
as a nested ‘case-control’ sub study for further testing (detailed in Chapter 5). The nested case-
control study included 52 samples from 26 of the 27 active TB cases and included matched 
controls from the GPC (see Chapter 5 for details on sampling).  
For the purposes of analysis for Chapters 3 and 4, only one sample per TB case (the sample taken 
closest to TB diagnosis) was used for cross-sectional analyses of HCMV seropositivity, 
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mycobacterial and TT antibody and total IgG levels. For Chapter 5, all available samples taken from 
active TB cases was used.  
 
2.2.3 Sampling of matched controls  
Samples from non-TB individuals were selected to be part of a nested case-control sub study 
(Chapter 5) for further testing. Samples from the 2,162 individuals without active TB were 
matched to 52 samples from 26 TB cases based on age, sex and HIV status at the point of 
sampling. Between 4 and 6 control individuals were matched per TB case sample (a maximum of 
one sample per control. Total number of control individuals – 300). Characteristics of the 
individuals selected for the nested case-control study are summarized in Table 2-2 below. 
Table 2-2: Study participant characteristics (nested case control study – Chapter 5)) 
 
Non TB Control 
individuals 
TB Case individuals Total 
Number of individuals 300 26 326 
Mean age (range) yrs 34.5 (2.8-56.5) 36.3 (13.1-56.5) 34.8 (2.8-56.5) 
Number female (%) 183 (61%) 15 (58%) 198 (61%) 
Number HIV positive (%) 80 (27%) 8 (30%) 88 (27%) 
 
Random sampling without replacement was used based on sex and HIV firstly, and then age was 
matched as closely as possible. Age at which sample was taken was matched within one year for 
HIV negative samples however increased variation was seen in HIV positive samples due to a 
smaller initial pool of HIV positive individuals within the 2,162 sample of non-TB individuals. In 
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total, 352 samples were included in the nested case-control sub study. We categorized the TB case 
samples into three time point groupings based on numbers of samples available and time before 
TB diagnosis: between 14 and 5 years prior to TB diagnosis, between 5 and 1 year prior to TB 
diagnosis, and between 1 year prior and 3 months after TB diagnosis. Because of the ubiquity of 
HCMV infection, HCMV seronegative samples were excluded (n=9, all nine were control individuals 
with a mean age of 37 years (26.9-50.8 years), two of these nine were HIV positive, see Chapter 5). 
Table 2-3 details sample numbers included in the case-control sub study.  
 
Table 2-3: TB case sample numbers and time before TB diagnosis 
Time before/after TB diagnosis Non TB Control samples TB Case samples Total 
14-5 yrs before 99 17 116 
5-1 yr before 94 16 110 
1 yr before - 3 months after 107 19 126 
Total 300 52 352 
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Figure 2-1 – Sampling for cross sectional (blue) and case control (green) study designs. One TB case 
individual became HIV positive during sampling and so was excluded from the case control study.  
 
2.2.4 Sampling for MGIA assay 
Ex-vivo mycobacterial growth inhibition assay (MGIA) was used to determine effect of serum from 
the GPC Ugandan cohort. MGIA is used to assess effect of immune cells upon growth of BCG over 
a 4-day culture period before cells are lysed and bacteria transferred to a tube where bacterial 
growth is quantified based on a fluorescent quench curve (see methods below). Normally the 4-
day culture period uses Fetal Bovine Serum (FBS) as the source of serum. This experiment instead 
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used human serum from GPC serum samples characterised with respect to their anti-
mycobacterial and HCMV antibody content. Controls included FBS, pooled human serum (AB 
serum) and IgG-depleted AB serum.  
Serum samples from the GPC were chosen with respect to their content of certain antibodies 
hypothesised to be important in TB disease (Ag85A, LAM or HCMV). HIV negative GPC donor 
serum from individuals over the age of 15 years was randomly selected based on antibody levels. 
Four samples per group in the upper or lower 20% of antibody levels were chosen.  
To ensure that high and low responders for one antibody were controlled for other antibodies, a 
matrix was constructed (Figure 2-2). This ensured that, for example, all 4 samples that were high 
Ag85A IgG responders, were not all HCMV IgG high responders. Thirty-two samples were chosen, 
16 of which had low Ag85A IgG, 16 had high Ag85A IgG. Each of these 2 groups had 8 low LAM IgG 
responders and 8 high LAM responders. Within the 8 low or 8high LAM IgG responders, 4 had low 
HCMV IgG and 4 had high HCMV IgG.  
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Figure 2-2: Matrix of antibody responses of randomly selected samples for MGIA (sample numbers 
in parenthesis) 
  
 
 
2.3 Ethics  
Written consent for the use of clinical records and biological samples for research purposes was 
obtained from all GPC participants following Uganda National Council of Science and Technology 
guidelines. 
Ethical approval for the use of GPC samples for this study was obtained from The UVRI Research 
and Ethics Committee and from the Uganda Council for Science and Technology (APPENDIX 1), in 
addition to the London School of Hygiene & Tropical Medicine (LSHTM), London, UK (APPENDIX 
2a). Initially reagents were shipped to UVRI, Entebbe, Uganda and assays were conducted at UVRI 
laboratories. Subsequently samples were shipped to LSHTM and stored at -80°C until used.  
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Ethical approval for collection and use of samples from LSHTM volunteers was obtained 
(APPENDIX 2b). 
 
2.4 Preparation of ELISA standards  
Serum from BCG-vaccinated UK donors was tested for IgG to PPD and the highest and lowest 
responders were pooled to create a stock of standards for use in anti-mycobacterial ELISAs.  
 
2.5 Enzyme-linked immunosorbent assays (ELISAs) 
ELISAs were performed to determine Human Cytomegalovirus (HCMV), Epstein Barr Virus (EBV) 
and Human Simplex Virus (HSV)1/2 serostatus of GPC donors, to quantify the levels of anti-
mycobacterial antibodies against PPD, LAM, Ag85A and ESAT6/CFP10, and to measure IgG levels 
against tetanus toxoid in all GPC donors.  
ELISA was also used in combination with a standard curve to quantify total IgG levels, and to 
measure antibody avidity of PPD IgG antibodies. 
 
Methods pertaining to each assay are detailed below. 
 
2.5.1 Human Cytomegalovirus (HCMV) ELISA 
Serum samples were tested for antibodies against HCMV using a standard commercially available 
ELISA (IBL International, Germany). Testing was conducted at UVRI in Entebbe. Briefly, serum 
samples were thawed and diluted as per kit instructions to 1:100 in sample diluent. One hundred 
microliters of diluted serum and controls in duplicate were dispensed into a 96-well plate coated 
 79 
with HCMV antigen. Plates were covered and incubated for 1hr at 37°C and then washed before 
100μL of anti-IgG conjugate was added and the plate covered and incubated again for 30 minutes 
at room temperature. After another washing step, 100μL of tetra-methyl-benzidine (TMB) 
substrate solution was added and the plate incubated for 15 minutes in the dark at room 
temperature before 100μL of 0.2M sulphuric acid solution was added to stop the reaction. Plates 
were read at 450/620nm within 30 minutes.  
Individuals were considered to be seropositive if the IgG OD measurement of plate controls fell 
within the kit specifications and the mean of duplicate measurements was above the calculated 
cut off.  
 
2.5.2 Epstein-Barr virus (EBV) ELISA 
EBV is the etiological agent of infectious mononucleosis. A subset of serum samples was tested for 
IgG against Epstein-Barr virus nuclear antigen 1 (EBNA-1) using a commercial kit (Euroimmun, 
Germany). Testing was conducted at LSHTM, UK. As per kit protocol, all reagents were brought to 
room temperature and 100µL of calibrator samples, positive and negative controls along with 
1:100 diluted test samples were aliquotted into appropriate wells to extrapolate fully quantitative 
measurements. Samples were incubated for 30 minutes at room temperature before plates were 
washed 3 times. One hundred microliters of HRP-conjugated anti-human IgG was then added to 
each well and the plates incubated for another 30 minutes at room temperature. Following 
another 3 washes, 100µL of chromogen substrate was added, the plates incubated for 15 minutes 
at room temperature in the dark and 100µL of stop solution added. Plates were read at 450nm 
within 30 minutes of the addition of the stop solution.  
The resulting measurement (in relative units (RU)) was calculated based on a standard curve from 
the calibration sera and, based on kit cut-offs, samples were reported as positive or negative.  
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2.5.3 Herpes Simplex Virus (HSV) 1/2 ELISA 
This commercial kit (Euroimmun, Germany) uses a mixture of HSV1 and HSV2 full antigens to 
detect IgG specific to both subtypes.  Testing was conducted at LSHTM, UK. As per kit protocol, all 
reagents were brought to room temperature and 100µL of calibrator samples, positive and 
negative controls, along with 1:100 diluted test samples were aliquotted into appropriate wells in 
order to extrapolate fully quantitative measurements. Samples were incubated for 30 minutes at 
room temperature before plates were washed 3 times. One hundred microliters of HRP-
conjugated anti-human IgG was then added to each well and the plates incubated for another 30 
minutes at room temperature. Following another 3 washes, 100µL of chromogen substrate was 
added, the plates incubated for 15 minutes at room temperature in the dark and 100µL of stop 
solution added. Plates were read at 450nm within 30 minutes of the addition of the stop solution. 
The resulting measurement (in relative units (RU)) was calculated based on a standard curve from 
the calibration sera and, based on kit cut-offs, samples were reported as positive or negative.  
 
2.5.4 Mycobacterial ELISA method development  
Ag85A IgG ELISA methodology was transferred from Aeras (MD, USA) and method development 
was conducted on other mycobacterial antigens used in this study to determine the appropriate 
concentration of coating antigen and detection antibody. Serum titrations were performed to 
determine the best dilution of serum for the assays.  
Due to the small volume of sera from Ugandan GPC donors, method development was conducted 
using sera from UK volunteers and confirmed in randomly selected GPC samples. In addition, the 
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use of half volume ELISA plates was investigated to reduce the volume of serum needed to run the 
assays. 
A serum dilution of 1:100 was determined to give the largest range of OD readings of the 
spectrophotometer for all antigens. Dilutions of 1:500 for the IgG secondary antibody, and 
1:10,000 for the IgM secondary antibody were used. Half volume ELISA plates (Fisher Scientific) 
gave similar results as full volume and so half volume plates were used for all ELISAs in this project.  
Concentrations of coating antibodies are detailed in the mycobacterial ELISA section below. 
Coating antibodies were not fully titrated but based upon a concentration that gave good 
differentiation in serum titration experiments.  
ELISA worksheets were used for all experiments. Times and dates of experiments and addition of 
reagents, as well as incubation times were noted to ensure ELISA plates run on different dates 
were comparable. An example of a worksheet can be found in APPENDIX 3. 
 
2.5.5 Mycobacterial ELISA 
Antibody content was measured using an ELISA. Testing was conducted at UVRI in Entebbe, 
Uganda (Ag85A IgG and PPD IgG) and LSHTM, London, UK (CFP10/ESAT6 IgG, Ag85A IgM and LAM 
IgG). Half volume ELISA plates (Fisher Scientific) were coated overnight at 4°C with 50µL sodium 
carbonate buffer containing 1.5µg/mL recombinant Ag85A protein (Aeras, USA), 1.5µg/mL PPD 
(Lot 051815KA, Aeras, USA), 0.5µg/mL LAM (NR-14848; BEI Resources, VA, USA), 0.25ug/mL each 
CFP10 (NR-49425; BEI Resources, VA, USA) and ESAT6 (NR-14868; BEI Resources, VA, USA). Plates 
and reagents were brought to room temperature and the plate washed 3 times with PBS, 5% 
Tween20 (v/v) (PBST). The plate was blocked for 1 hour at room temperature with 100µL blocking 
buffer (PBS, 5% milk (w/v)). Serum was diluted 1:100 with PBS, 5% milk (w/v) and 50µL of each 
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sample in duplicate was added to the appropriate wells in the ELISA plate. High and low PPD 
responder control samples were prepared at the same dilution as the test samples, and controls 
and plate blanks (consisting of assay diluent alone with no serum) were added in triplicate. The 
plate was sealed and incubated for 2 hours at room temperature. Plates were then washed five 
times with PBST and 50µL of an appropriately diluted horseradish-peroxidase (HRP)-conjugated 
secondary antibody in PBST-5% milk: for measurement of IgG; 1:500 dilution of goat anti-human 
IgG-conjugated to HRP (04-10-20; KPL, Gaithersburg, MD, USA), for measurement of IgM; 1:10,000 
dilution of goat anti-human IgM-conjugated to HRP (ab97205; Abcam) was added to each well for 
one hour at room temperature. The plate was washed seven times with PBST and 50µL 
tetramethylbenzidine (TMB, BD BioSciences, San Jose, CA, USA) was added to each well. The plate 
was incubated for 15 minutes in the dark before the reaction was stopped by adding 50uL of 2M 
Sulphuric Acid (Sigma, St. Louis, MO, USA) to each well. Absorbance was measured using a 
microplate reader at 450nm within 30 minutes to obtain optical density (OD), a surrogate marker 
of antibody titre when the assay is conducted on the linear part of the curve. 
Mean blank values (wells coated with antigen and secondary conjugated antibody but no serum) 
were subtracted from all OD readings. Geometric means were used in order to reduce the effect 
of skewed distribution as has been recommended in immunoepidemiological studies [5].  
 
2.5.6 Tetanus toxoid ELISA 
IgG specific to TT was measured at LSHTM, UK by ELISA. Half volume ELISA plates (Fisher Scientific) 
were coated overnight at 4°C with 50µL sodium carbonate buffer containing 0.5µg/mL Tetanus 
Toxoid (02/232, NIBSC, Potters Bar, UK). Plates and reagents were brought to room temperature 
and the plate washed 3 times with PBS, 5% Tween20 (v/v) (PBST). The plate was blocked for 1 hour 
at room temperature with 100µL blocking buffer (PBS, 5% milk (w/v)). Test sera were diluted 1:100 
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with PBS, 5% milk (w/v) and 50µL of each sample in duplicate was added to the appropriate wells 
in the ELISA plate. Control serum (from vaccinated UK donor pooled sera) was also diluted 1:100. 
Controls and plate blanks consisting of assay diluent alone with no serum were added in triplicate. 
The plate was sealed and incubated for 2 hours at room temperature. It was then washed five 
times with PBST and 50µL of goat anti-human IgG- conjugated to HRP (04-10-20; KPL, 
Gaithersburg, MD, USA) diluted 1:500 in PBST-5% milk was added to each well for one hour at 
room temperature. The plate was washed seven times with PBST and 50µL tetramethylbenzidine 
(TMB, BD BioSciences, San Jose, CA, USA) was added to each well. The plate was incubated for 15 
minutes in the dark before the reaction was stopped by adding 50uL of 2M Sulphuric Acid (Sigma, 
St. Louis, MO, USA) to each well. Absorbance was measured using a microplate reader at 450nm 
within 30 minutes to obtain optical density (OD), a surrogate marker of antibody titre. 
As above, mean blank values (wells coated with antigen and secondary conjugated antibody but 
no serum) were subtracted from all OD readings and geometric mean used in analysis.  
 
2.5.7 Total IgG ELISA method development  
In order to find the dynamic range of IgG standards to use, a full titration curve was conducted 
using one GPC serum sample (sample number 910163), pooled UK serum control, and an IgG 
antibody standard (I4506; Sigma). The intention was to find approximately five concentrations of 
the IgG standard that would form a reproducible standard curve to be used on each plate with 
which to extrapolate total IgG concentration in test sera.  
A doubling dilution was used to obtain a titration from 1:100 to 1: 13,421,772,800 of IgG standard 
which, based on an initial concentration of 0.86mg/mL of IgG, equates to concentrations ranging 
from 8.6µg/mL to 16.8ng/mL (see Table 2-4).  
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Two concentrations of mouse anti-human IgG coating antibody (ab 200699; Abcam) were trialled 
(1.0 and 0.5µg/mL) and a concentration of 0.5µg/mL was determined to give similar OD 
measurements as the higher dilution but with minimal background. Duplicate samples of each 
dilution of standard and test sample were plated following an overnight incubation of 0.5µg/mL 
overnight at 4°C with 50µL sodium carbonate buffer containing mouse anti-human IgG at 
0.5ug/mL 
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Table 2-4 – IgG standard curve titration  
 Standard dilution  mg/mL ug/mL ng/mL 
100 0.0086 8.6 8600 
200 0.0043 4.3 4300 
400 0.00215 2.15 2150 
800 0.001075 1.075 1075 
1600 0.0005375 0.5375 537.5 
3200 0.00026875 0.26875 268.75 
6400 0.000134375 0.134375 134.375 
12800 6.71875E-05 0.0671875 67.1875 
25600 3.35938E-05 0.03359375 33.59375 
51200 1.67969E-05 0.016796875 16.79688 
102400 8.39844E-06 0.008398438 8.398438 
204800 4.19922E-06 0.004199219 4.199219 
409600 2.09961E-06 0.002099609 2.099609 
819200 1.0498E-06 0.001049805 1.049805 
1638400 5.24902E-07 0.000524902 0.524902 
3276800 2.62451E-07 0.000262451 0.262451 
6553600 1.31226E-07 0.000131226 0.131226 
13107200 6.56128E-08 6.56128E-05 0.065613 
26214400 3.28064E-08 3.28064E-05 0.032806 
52428800 1.64032E-08 1.64032E-05 0.016403 
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104857600 8.2016E-09 8.2016E-06 0.008202 
209715200 4.1008E-09 4.1008E-06 0.004101 
419430400 2.0504E-09 2.0504E-06 0.00205 
838860800 1.0252E-09 1.0252E-06 0.001025 
1677721600 5.126E-10 5.126E-07 0.000513 
3355443200 2.563E-10 2.563E-07 0.000256 
6710886400 1.2815E-10 1.2815E-07 0.000128 
13421772800 6.4075E-11 6.4075E-08 6.41E-05 
 
Figure 2-3 shows the dynamic range of standards and samples. For standards, dilutions of 1:6,400, 
1:12,800, 1:25,600, 1:51,200 and 1:102,400 (with respective concentrations of 134.4, 67.2, 33.6, 
16.8 and 8.4ng/mL of IgG – highlighted in grey in Table 2-4) were chosen as being on the linear 
portion of the curve – highlighted on the graph. For the test sera, a dilution of approximately 
1:819,200 gives an OD reading within the dynamic range of the spectrophotometer used to read 
plates (between 0.5 and 1.6 OD), therefore a dilution of 8x105 was chosen for all test sera.  
  
 87 
 
Figure 2-3- Standard curve for IgG and test sera titrations (UK pooled sera and one GPC sample) 
 
 
2.5.8 Total IgG ELISA 
All samples were tested for total IgG content at LSHTM, London, UK. Half volume ELISA plates 
(Fisher Scientific) were coated overnight at 4°C with 50µL sodium carbonate buffer containing 
mouse anti-human IgG at 0.5ug/mL (ab 200699; Abcam). IgG antibody standards (134.4-8.4 
ng/mL) were prepared by diluting purified human IgG (0.86 mg/mL; I4506; Sigma) in PSBT-5% milk 
and test sera were diluted 8x105 in PBST-5% milk. Plates and reagents were brought to room 
temperature and the plate washed 3 times with PBST. The plate was blocked for 1 hour at room 
temperature with 100µL blocking buffer (PBS, 5% milk (w/v)). Standards and diluted test samples 
were aliquotted in duplicate and the sealed plate was incubated for one hour at 37°C. The plate 
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was washed 5 times with PBST and 50ul of HRP-conjugated goat anti-human Fc (ab97225; Abcam) 
diluted 1/500 with PBST-5% milk was added for 1 hour at room temperature. As above, plates 
were developed using TMB, and sulphuric acid was used to stop the reaction. Plates were read at 
450nm and OD measurements converted into g/L by use of the standard curve on each plate 
(calculations detailed in APPENDIX 4). 
 
2.6 Luminex  
Luminex multiplex cytokine platform was used to determine the concentrations of IL-6, TNF-α, 
IFN-γ, IFN-α1, IL-1a, IP-10, IL-1b, IL-1Ra, IL-10, IL-12p40, IL-12p70. Cytokines were tested using 
Millipore kits (Merck Millipore, USA) according to the manufacturer's instructions. Standard curves 
were generated from the serial dilutions that were made from the assay controls supplied and 
matched against the cytokine concentration for quantification. The concentrations of all the 
analytes in the quality control reagents were found to be within the ranges expected. The Bio-Plex 
manager version 6.1 was used for bead acquisition and analysis of median fluorescence intensity 
(MFI). 
 
2.7 Sodium thiocyanate antibody avidity  
Antibody avidity was assessed by ELISA using the chaotropic agent sodium thiocyanate (NaSCN) to 
dissociate low-affinity IgG binding using a previously described method [6]. An avidity index (AI) 
was calculated as the molar concentration of NaSCN required to reduce antigen specific IgG 
binding by 50%. 
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An 8M stock solution of NaSCN (Acros Organics, Belgium) in water was prepared (19.45g NaSCN in 
30ml water). Further concentrations were prepared from the 8M stock to give eight 
concentrations between 0-7M NaSCN.  
All samples were tested for antibody avidity to PPD at LSHTM, London, UK. Half volume ELISA 
plates (Fisher Scientific) were coated overnight at 4°C with 50µL sodium carbonate buffer 
containing 1.5ug/mL PPD (Lot 051815KA, Aeras, USA).  
Plates and reagents were brought to room temperature and the plate washed 3 times with PBST. 
The plate was blocked for 1 hour at room temperature with 100µL blocking buffer (PBS, 5% milk 
(w/v)). Serum was diluted 1:100 with PBS, 5% milk (w/v) and 50µL of each sample in duplicate for 
each NaSCN concentration was added to the appropriate wells in the ELISA plate (Figure 2-4).  
The plate was sealed and incubated at room temperature for 2 hours. Without removing the 
sample, 50µL of NaSCN of the appropriate dilution was added. The plate was incubated at room 
temperature for 15 minutes before the plates were washed 5 times with PBST.  
50 µL of 1:500 dilution goat anti-human IgG-conjugated to HRP detection antibody (04-10-20; KPL, 
Gaithersburg, MD, USA) was then added to each well, the plate sealed again and incubated at 
room temperature for 1 hour. The detection antibody was removed and the plate washed 7 times 
with PBST and 50µL tetramethylbenzidine (TMB, BD BioSciences, San Jose, CA, USA) was added to 
each well. The plate was incubated for 15 minutes in the dark before the reaction was stopped by 
adding 50uL of 2M Sulphuric Acid (Sigma, St. Louis, MO, USA) to each well. Absorbance was 
measured using a microplate reader at 450nm within 30 minutes to obtain optical density (OD) 
which was then converted into AI using calculations detailed in APPENDIX 5.  
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Figure 2-4 – 96 well plate layout of sodium thiocyanate avidity assay. Duplicate samples are plated 
for each concentration of NaSCN (S1 – Sample 1) 
Conc 
of 
NaSCN 
1 2 3 4 5 6 7 8 9 10 11 12 
0 S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
1M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
2M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
3M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
4M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
5M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
6M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
7M S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
 
 
2.8 Peripheral Blood Mononuclear Cells (PBMC) isolation 
To isolate PBMC, 15mL Lymphoprep (Axis Shield) was added to Leucosep tubes (Greiner) and 
centrifuged at 1800rpm for 1 minute to pull the lymphoprep below the level of the porous disc. 
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Between 15-30mL of heparinised blood was added to each leucosep tube and tubes centrifuged at 
1000 x g for 13 minutes at room temperature. The centrifuge was left to stop on its own, without 
the use of a brake. The plasma fraction was removed and the PBMC at the interface were 
collected into a falcon tube (Fisher Scientific), with R0 (RPMI (Sigma), 1% Penicillin-Streptomycin 
(Gibco), 1% L-Glutamine (Gibco)) added, up to a volume of 45ml. Tubes were centrifuged at 
1800rpm at room temperature for 5 minutes, with braking. The supernatant was discarded and 
the pellet resuspended in 45ml R0 before centrifuging again at 1800 rpm at room temperature for 
5 minutes.  Cells were resuspended in 10mL R10 (RPMI (Sigma) 10% FCS (Biosera), 1% Penicillin-
Streptomycin (Gibco), 1% L-Glutamine (Gibco), 1% Sodium Pyruvate (Gibco) for counting.  
 
2.9 Ex-vivo IFN-γ Enzyme-Linked ImmunoSpot (ELISPOT)  
ELISPOT is used to detect and enumerate cytokine-secreting antigen-specific T-cells. Here, IFN-γ 
secretion was measured. ELISPOT plates (Millipore) were prepared by adding 50µL of 0.05M 
carbonate-bicarbonate buffer containing 15µg/mL anti-IFN- γ capture antibody (Mabtech) to each 
well and incubating overnight at 4°C. The plate was washed 5 times with 120µL per well of sterile 
PBS and 100µL of R10 blocking solution added to each well and incubated at 37°C for 2-5 hours. 
Following blocking, 0.3x106 PBMC in a volume of 80µL were added to duplicate wells. 20µL of each 
antigen was then added to the appropriate wells (each antigen was tested in duplicate). Antigens 
were prepared as follows: PPD (FDA) 100µg/mL to give a final concentration of 20µg/mL, 
phytohemagglutinin (PHA, Sigma) and phorbol 12-myristate 13-acetate (PMA, Sigma) which are 
potent positive controls, at 50µg/mL and 250 µg/mL respectively to give a final concentration of 
10µg/mL and 50 µg/mL respectively, Antigen85B (Ag85B, BEI resources) 50µg/mL to give a final 
concentration of 10µg/mL, lipoarabinomannan (LAM, BEI Resources) 100µg/mL to give a final 
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concentration of 20µg/mL and a mixture of ESAT6 and CFP10 (both BEI resources) at 50µg/mL 
(25µg/mL each antigen) to give a final concentration of 10µg/mL (5µg/mL each antigen).  
The plate negative control was 20µL of R10. The plate was then incubated for 18-20 hours at 37°C 
before washing 5 times with 1xPBS w/0.05% Tween20 (v/v). Biotin anti-IFN-γ antibody (Mabtech) 
was diluted 1:1000 with PBS and 50µL added to each well. The plate was incubated for 2 hours at 
room temperature before washing 5 times with PBS as above. Streptavidin-ALP (alkaline 
phosphatase) was diluted 1:1000 in PBS and 50µL was added to each well. The plate was 
incubated for 1 hour at room temperature, washed 5 times and 50µL BCIP/NBT (Europa 
Bioproducts) developer was then added to each well. Colour was left to develop for 5 minutes and 
the reaction was terminated by running the plate under tap water. The plate was allowed to dry 
on the bench overnight before reading the next day using a plate reader and ELISPOT 5.0 software 
(AID Diagnostika, Germany).  
 
2.10 Mycobacterial Growth Inhibition Assay (MGIA) 
MGIA was conducted by modifying the Zelmer et al protocol [7]. MGIA is used to assess effect of 
immune cells upon growth of BCG (used as a surrogate for M.tb) over a 4 day culture period. After 
culture, cells are lysed and bacteria transferred to a tube where bacterial growth is quantified 
based on a fluorescent quench curve. Normally the 4 day culture period uses Fetal Bovine Serum 
(FBS) as the source of serum. This experiment instead used human serum from GPC serum 
samples characterised with respect to their anti-mycobacterial or HCMV antibody content. Sera 
from 5 TB cases was also included (see sampling methods, above). Controls (in duplicate) included 
FBS (Biosera), heat inactivated pooled human serum (AB serum, Sigma) and IgG-depleted AB 
serum.  
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The BD MGIA system is based on fluorescence quenching by oxygen. During bacterial growth, 
oxygen levels are depleted, releasing fluorescence which is measured hourly by the BACTEC 
system. A standard curve is produced with known bacterial concentrations to convert a Time To 
Positivity (TTP) readout into a Colony Forming Unit (CFU) measurement. In these experiments, 
fresh human PBMC from one UK-born LSHTM volunteer who was not historically vaccinated with 
BCG was used for the MGIA experiments. Figure 2-5 illustrates the methodology.  
 
Following isolation (see methods above), PBMC were resuspended in RPMI-MGIT (RPMI-1640 
HEPES modification (Sigma), 2mM L-Glutamine (Gibco), containing no FCS) at a concentration of 
14.6 x106/mL to give a final concentration of 3.5 x106 human PBMC in 240µL. 60 µL of each test 
sera was added to the PBMC. 300 CFU/mL BCG was prepared in RPMI-MGIT to give a final input 
dose of 90 CFU in 300µL. Human PBMC, test sera and BCG were co-cultured for 4 days in a 37C, 
5% CO2 incubator in 48-well plates where the outer-most wells were filled with 1mL RPMI-MGIT 
to minimise evaporation from test wells.  BCG input CFU was verified by plating 100µL in duplicate 
onto 7H11 agar plates and counting colonies after approximately 2-3 weeks of incubation at 37C. 
After 4 days of incubation, 48-well plates were removed from the incubator and centrifuged at 
12,000rpm for 10 minutes. 500 µL of supernatant was removed, ensuring the pellet remained 
intact. 400 µL of sterile tissue grade water was added to lyse the cells, and liquid in the plates was 
mixed by pipetting. After standing at room temperature for 5 minutes, liquid in the wells was 
again mixed by pipetting. 800µL MGIT PANTA (BD) enrichment medium was added to each MGIT 
tube (BD) and then the total volume of one well (approximately 500 µL) was added to the MGIT 
tube. After inverting the tube to mix the contents, the tube was placed in the BACTEC MGIT 
machine to await a TTP readout. Two “direct-to-MGIT” tubes, containing BCG input only, were 
included as quality controls to ensure reproducibility across experiments. Based on the initial input 
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of BCG, the TTP readout was converted to CFU using a previously prepared standard curve in 
GraphPad Prism 7 software. 
 
Figure 2-5 – MGIA methodology. Adapted with permission from H. Painter. 
 
 
2.11 Statistical analysis 
Data were entered using Microsoft Excel and analysed using Stata version 14 (Stata Corporation, 
College Station, TX, USA). Some method development work and MGIA results were analysed using 
GraphPad Prism 7.  
Due to the large number of different exposures investigated in this project and the possibility of 
multiplicity, a p value of 0.01 was considered strong evidence against the null hypothesis of no 
difference between comparison groups, and 99% confidence intervals (CI) are reported. 
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A variety of statistical analyses were used and further details are given in corresponding results 
sections.  
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CHAPTER 3 -  RESEARCH PAPER 
 
Human cytomegalovirus epidemiology and relationship to tuberculosis in a rural Ugandan 
cohort 
 
3.1 Chapter background 
This chapter is a research paper published in PLOS One [1] with the title “Human 
cytomegalovirus epidemiology and relationship to cardiovascular and tuberculosis disease risk 
factors in a rural Ugandan cohort” (see Appendix 6). This chapter fulfills aim 1: to characterise 
HCMV serostatus in the cohort. This paper measures HCMV seropositivity in the GPC and 
explores magnitude of HCMV seropositivity (measured by IgG) and associations with age, sex, 
TB and HIV.  
The published research paper also utilizes the serendipitous availability of CVD risk factor data 
for adults within the cohort. This enabled investigation into associations between HCMV 
response and CVD, a relationship seen in high-income countries but not studied in low-income 
settings. For the purposes of this thesis, however, only those sections pertaining to the PhD 
project aims are included in this chapter.  
 
3.2 Abstract 
Human cytomegalovirus (HCMV) infection has been associated with increased morbidity and 
mortality in high-income countries (HICs). There is a paucity of data in low- and middle-income 
countries (LMICs) where HCMV seropositivity is higher. Serum samples from 2,174 Ugandan 
individuals were investigated for HCMV antibodies and data linked to demographic 
information and HIV and TB co-infections. HCMV seropositivity was 83% by one year of age, 
increasing to 95% by five years. Female sex, HIV positivity and active pulmonary tuberculosis 
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(TB) were associated with an increase in HCMV IgG levels in adjusted analyses. HCMV infection 
is ubiquitous in this rural Ugandan cohort from a young age. The association between TB 
disease and high HCMV IgG levels merits further research.  
 
 
3.3 Introduction 
Human Cytomegalovirus (HCMV), also known as human herpesvirus-5 (HHV-5), is a member of 
the β-herpesviridae subfamily which is widely distributed in human populations. HCMV 
transmission occurs through person-to-person contact. It can be transmitted transplacentally 
to neonates or through breast milk of an infected and shedding mother, by intimate contact 
and by transplantation from (or sharing syringes with) an infected individual [2]. It has been 
shown that young children shed HCMV virus in saliva and urine at high levels which may add to 
transmission between infants and adult caregivers [3].  
 
Congenital HCMV infection is the leading cause of permanent hearing and neurological 
impairment as well as vision loss in infants worldwide [4]. Maternal primary infection, re-
infection, or reactivation, especially during the first trimester, is particularly associated with 
adverse neonatal outcomes [5]. The incidence of congenital HCMV infection is estimated at 
between 0.7 and 5% of all births in low- and middle-income countries (LMICs) [6].  
In immunocompetent adults, HCMV infection rarely causes disease; however, once infected, 
the virus remains latent in a wide range of cell types, including lymphocytes and myeloid 
lineage cells, as well as smooth muscle cells and endothelial cells which line blood vessels [7]. 
HCMV/HIV co-infection is common and is an important cause of HCMV retinitis and severe 
non-AIDS events, including death, in HIV-infected individuals [8,9]. HCMV infection is 
associated with chronic immune activation [10] and recent evidence implicates immune 
activation with increased risk of tuberculosis (TB) disease [11].  
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In this study, we investigate HCMV seroprevalence in a large cross-sectional rural Ugandan 
cohort (n=2,174) and investigate associations with co-infections and demographic information.  
 
3.4 Material and Methods 
 
3.4.1 Study Area and design 
The General Population Cohort (GPC) is a population-based open cohort study, set up in 1990 
by the Medical Research Council (MRC) UK in collaboration with the Uganda Virus Research 
Institute (UVRI). Initially established to examine trends in HIV prevalence and incidence, the 
GPC is located in Kyamulibwa sub-county of Kalungu district, rural south-western Uganda [12].  
The cohort now comprises a cluster of 25 neighboring villages with approximately 20,000 
residents (52% aged ≥13 years) from three ethnic groups, the majority (75%) being from the 
Baganda tribe, the main tribal group in the region.  
Blood samples are transported to MRC/UVRI laboratories in Entebbe where a portion of the 
venous blood sample is analysed according to protocol guidelines. Remaining samples are 
stored at –80C in a biobank in Entebbe [12].  
The majority of samples tested for HCMV in this study were taken from 2011. Samples from TB 
cases were from a range of GPC rounds sampled between 1999 and 2014.  Active pulmonary 
TB was diagnosed through positive sputum smear microscopy after passive case detection. 
 
3.4.2 Sampling 
Individuals were selected at random, having been stratified by age and sex. Infants under 5 
years of age were oversampled in anticipation of high age-dependent HCMV seropositivity 
based on evidence from other sub-Saharan countries. A target sample size of approximately 
100 individuals per year of age from under 1 year to 5 years were sampled and 200 individuals 
 100 
per 5 or 10 year age groups thereafter. The sex ratio was approximately equal within each age 
group.  
The age structure of sampling for this study was determined based on Ugandan demographics: 
49% of Ugandans are under 14 years of age; 21% are between 15-24 years of age; 28% 
between 25 and 64 years of age and only 2% over 65. The sampling here was similar to the 
Ugandan demographic with 45% under 14 years, 18% 15-24, 32% 25-64 and 5% over 65 years 
of age. 
Being a cross-sectional study, each individual was only sampled once. Siblings and parent-child 
pairs were not excluded.  
 
Table 3-1. General Population Cohort characteristics of individuals included in this study 
 
Age, mean (range) 22.7 (0.08-100.75) 
HIV prevalence, percentage (number/total) 4.6% (100/2,134) 
Sex, percentage female (number/total) 50.2% (1,091/2,174) 
Active TB cases, percentage (number/total) 1.3% (27/2,134) 
Tribe, percentage (number/total)  
- Baganda 75% (1,524/2,035) 
- Rwandese Ugandan 16% (319/2,035) 
- Other § 9% (192/2,035) 
§ Other tribes include Bakiga, Batooro, Banyankole, Basoga, Bafumbira, Tanzanian, Barundi 
3.4.3 Ethics  
Written consent for the use of clinical records and biological samples for research purposes 
was obtained from all GPC participants following Uganda National Council of Science and 
Technology guidelines. 
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Ethical approval for the use of samples for this study was obtained from The UVRI Research 
and Ethics Committee and from the Uganda Council for Science and Technology, in addition to 
the London School of Hygiene & Tropical Medicine, London, UK.  
 
3.4.4 HCMV serology 
Serum samples were tested for antibodies against HCMV using standard, validated and 
commercially available enzyme-linked immunosorbent assay (ELISA) against HCMV IgG (IBL 
International GmbH). Testing was conducted at UVRI in Entebbe. Briefly, serum samples were 
thawed and diluted as per kit instructions to 1:100 in sample diluent. One hundred microliters 
of diluted serum and controls in duplicate were dispensed into a 96-well plate coated with 
HCMV antigen. Plates were covered and incubated for 1hr at 37°C and then washed before 
100μL of anti-IgG conjugate was added and the plate covered and incubated again for 30 
minutes at room temperature. After another washing step, 100μL of tetra-methyl-benzidine 
(TMB) substrate solution was added and the plate incubated for 15 minutes in the dark at 
room temperature before 100μL of 0.2M sulphuric acid solution was added to stop the 
reaction. Plates were read at 450/620nm within 30 minutes to obtain optical density (OD), a 
surrogate marker of antibody titer.  
Individuals were considered to be seropositive if the IgG OD measurement of plate controls fell 
within the kit specifications and the mean of duplicate measurements was above the 
calculated cut off.  
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3.4.5 Linking to GPC data 
Testing for HIV was carried out immediately after blood collection in Uganda as previously 
described by Asiki et al [12]. Data were linked to the samples retrieved via each participant’s 
unique GPC identifier. Total IgG was measured by ELISA utilizing a commercial standard curve. 
Degraded samples with negative total IgG were excluded from the study.  
Samples used in this study were linked to demographic and other clinical data corresponding 
to the same time period at which the sample was taken.  
 
3.4.6 Statistical analysis 
Participants were categorized as either HCMV seronegative or seropositive based upon OD 
results; seropositive samples were further categorized into tertiles of OD, to differentiate low, 
medium and high responders. The Student’s t test was used to compare continuous variables 
(such as HCMV IgG antibody OD measurement) between two independent groups (sex, tribe 
(Baganda or other), HIV and TB status). Associations of HCMV IgG OD with age, tribe, sex, HIV 
and TB were investigated. An analysis of variance (ANOVA) was used to compare continuous 
variable outcomes between HCMV tertiles. 
Linear regression was used to determine the relationship between HCMV IgG OD (as the 
dependent variable) and age, sex, HIV and TB status (as the independent variables – tribe was 
excluded in HCMV IgG OD regression analysis due to missing data – 10/27 active TB cases did 
not have information on tribe). HCMV OD data were slightly positively skewed, possibly 
resulting in artificially narrower confidence intervals (CI) around estimates.  
To account for evidence of non-linearity of HCMV OD with age (likelihood ratio test p=0.0025), 
a quadratic term for age was included in the regression analyses.  
To account for multiple comparisons, 99% CI are reported and a p value of 0.01 is considered 
to represent strong evidence to reject the null hypothesis. 
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Data were entered using Microsoft Excel and analysed using STATA version 14 (Stata 
Corporation, College Station, TX, USA).  
 
3.5 Results 
Of the 2,189 samples tested, 15 had negative total IgG levels and so were excluded due to 
probable degradation of sample, resulting in 2,174 samples being included in initial analyses. 
Following these exclusions, 40 individuals did not have a valid HIV result and so were excluded 
from regression analysis where HIV was included as a regression term.  
Overall 91% (1,988/2,174) of the population tested positive for HCMV antibodies. Among 
children less than 15 years of age, 1% (10/991) were HIV positive; among individuals over 15 
years of age, 8% (90/1,143) were HIV positive. The highest proportion infected with HIV (15%) 
was within the 41-50 year age group.  
 
The percentage of HCMV seropositive individuals in this population increases for both males 
and females equally from birth until the 6-10 year age group, after which seropositivity levels 
plateau at around 95% (Figure 1): 83% HCMV seropositivity was seen by age one year and this 
increased to 95% by age five. 
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Figure 3-1. Percent HCMV seropositive by age group (years). Red shows females and blue 
shows males. 
 
 
Because of the ubiquity of HCMV infection within this population it was decided to conduct 
further analyses on the HCMV seropositive population only. An analysis of the HCMV negative 
population (n=186, none of whom were TB cases and only 4 HIV positive) showed no 
significant associations for sex or HIV in regression analysis. The only significant association 
was with age in years (p<0.001).  
 
Of the HCMV seropositive individuals, IgG levels initially decrease from a peak in those <1 year 
until the 16-20 year age group, after which HCMV IgG levels increase for both males and 
females (Figure 3-2A). When HIV negative individuals are plotted separately, the increased 
HCMV IgG levels in the 31-50 year old groups coincide with the highest HIV positivity (Figure 3-
2B).  
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Figure 3-2A. Median HCMV IgG OD levels (among HCMV seropositive) in HIV negative 
individuals by age group (years) and sex. Figure 3-2B. Median HCMV IgG OD levels (among 
HCMV seropositive) in HIV negative individuals by age group (years) and sex. Figure 3-2C. 
Median HCMV IgG OD levels in HIV negative and HIV positive individuals combined, HCMV 
seropositive individuals by age group (years) and sex. 
 
 
Red lines show female median values, blue lines show male median values. Vertical lines show 
interquartile range. HCMV - human cytomegalovirus, HIV - human immunodeficiency virus. 
 
To investigate impact of age on HCMV IgG levels, ages were further split into < 9 months, 9 
months to 12 years, 13-20 years, 20-60 and 60 years and above. Age groups selected are based 
on presence of maternal antibodies (conservative estimate of 9months [13]), prior to sexual 
debut (9 months - 12 years [14]), post sexual debut (13-20 years [14]), 21-59 years and post 60 
years. It was found that infants under the age of 9 months have higher mean HCMV IgG (1.25 
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OD) than any other age group apart from the over 60 years olds (1.34 OD) in unadjusted 
analyses.  
A 0.07 OD increase in HCMV IgG (99% CI 0.02,0.12, p<0.001) is associated with being female in 
unadjusted analyses. This increase remained after adjusting for age, HIV and TB infection 
status (mean difference 0.07 OD 99% CI 0.03,0.11, p<0.001) (Table 3-2). The 0.49 OD increase 
in HCMV IgG associated with HIV infection also remained after adjustment for age, sex and TB 
infection status (mean difference 0.47 OD 99% CI 0.37,0.57, p<0.001) (Table 3-2).  
 
Table 3-2. Unadjusted and fully adjusted mean differences (values obtained using a 
multivariable model including age, quadratic age, sex, HIV and TB status) in HCMV IgG OD with 
p value (t test for unadjusted values, regression for adjusted values) and 99% confidence 
intervals.  
 
Factor (n) 
HCMV IgG     
  
  
Unadjusted 
mean 
difference  P value 99% CI 
Adjusted 
mean 
difference P value 99% CI 
Sex             
Male (978) baseline      baseline     
Female (978) 0.07 <0.001 0.02, 0.12 0.07  <0.001 0.03, 0.11 
HIV †             
Negative (1,860) baseline      baseline     
Positive (96) 0.49 <0.001 0.40, 0.60 0.47  <0.001 0.37, 0.57 
TB ‡             
Negative (1,929) baseline      baseline     
Positive (27) 0.34 <0.001 0.15, 0.53 0.19  0.006 0.01, 0.37 
 
CI - confidence interval, HCMV - human cytomegalovirus, †HIV - human immunodeficiency 
virus, ‡TB – Active pulmonary Tuberculosis. 
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Mean HCMV IgG OD levels among the 27 people with sputum-confirmed pulmonary TB was 
0.34 OD higher than individuals without active TB. After adjusting for age, sex and HIV 
infection status this difference is partly explained by those variables but there remains good 
evidence of that active TB disease is associated with an increased HCMV level of 0.19 OD (99% 
CI 0.01,0.37, p=0.006) (Table 3-2) which equates to a 7% increase based the range of HCMV OD 
values (min 0.31, max 2.84 OD). When HCMV seropositivity was divided into low, medium and 
high responders, the majority of active TB cases had high HCMV IgG levels (16/27, 59%). Thirty 
three percent were of medium HCMV IgG (9/27), 7% (2/27) had low HCMV, and none were 
HCMV seronegative (Figure 3-3).  
 
Figure 3-3. Number of active TB cases by HCMV IgG tertile. Numbers above or within bars 
show number of active TB cases over the total number of individuals within that HCMV tertile 
(n=27 total active TB cases). 
 
When HIV positive and negative individuals are analysed separately, the effect of active TB 
disease is shown to be greater in the HIV positive group, but the direction of effect is the same. 
Among HIV negative people (Table 3-3), having active TB disease is associated with an adjusted 
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increase of 0.11 OD of HCMV IgG (99% CI -0.10-0.33, p=0.170) whereas among the HIV positive 
individuals (Table 3-4), having active TB disease is associated with an increased HCMV IgG OD 
of 0.32 OD (99% CI -0.12,0.77, p=0.063). 
Being from a tribe other than the majority Baganda tribe was associated with a 0.14 OD 
increase in HCMV IgG (99% CI 0.09,0.19, p<0.001). Due to missing data (10/27 active TB cases 
did not have information on tribe), and the fact that inclusion of tribe into regression analyses 
did not alter mean difference coefficients, this variable was not included in regression 
analyses. Although not included, a sensitivity analysis including tribe resulted in a change in 
coefficient for sex from 0.068 to 0.070 OD, a change in coefficient for HIV from 0.466 to 0.454 
and a change in coefficient for TB from 0.193 to 0.184. The coefficient for tribe was 0.11 OD 
99% CI 0.06-0.16.  
Table 3-3. Unadjusted and fully adjusted mean differences (values obtained using a 
multivariable model including age, quadratic age, sex and TB status) in HCMV IgG OD with p 
value (t test for unadjusted values, regression for adjusted values) and 99% confidence 
intervals for HIV negative individuals only (n=1,860).  
Factor (n) 
HCMV IgG     
  
  
Unadjusted 
mean 
difference  P value 99% CI 
Adjusted 
mean 
difference P value 99% CI 
Sex             
Male (941) baseline      baseline     
Female (919) 0.06 <0.001 0.01,0.10 0.06 <0.001 0.02, 0.10 
TB ‡             
Negative 
(1,842) baseline      baseline     
Positive (18) 0.13 0.142 -0.09-0.35 0.11 0.170 -0.10, 0.33 
CI - confidence interval, HCMV - human cytomegalovirus, ‡TB – Active pulmonary Tuberculosis. 
 109 
Table 3-4.  Unadjusted and fully adjusted mean differences (values obtained using a 
multivariable model including age, quadratic age, sex and TB status) in HCMV IgG OD with p 
value (t test for unadjusted values, regression for adjusted values) and 99% confidence 
intervals for HIV positive individuals only (n=96).  
 
Factor (n) 
HCMV IgG     
  
  
Unadjusted 
mean 
difference  P value 99% CI 
Adjusted 
mean 
difference P value 99% CI 
Sex             
Male (37) baseline      baseline     
Female (59) 0.18 0.087 -0.09, 0.45 0.14 0.174 -0.13, 0.42 
TB ‡             
Negative (87) baseline      baseline     
Positive (9) 0.38 0.030 -0.07-0.83 0.32 0.063 -0.12, 0.77 
 
CI - confidence interval, HCMV - human cytomegalovirus, ‡TB – Active pulmonary Tuberculosis. 
 
3.6 Discussion 
HCMV is an important pathogen in congenital neurological conditions and in the context of 
immune suppression. Recent studies have suggested a link between HCMV seropositivity and 
excess overall mortality within HIC settings [15–19].  
 
Here, we find that 95% of this rural Ugandan population are seropositive for HCMV by age five 
years (Figure 3-1). This finding corroborates other findings in sub-Saharan African settings 
where high levels of HCMV seropositivity have been found; 96% in Egypt [20], 97% in Benin 
[21], 99% in the Gambia [22] and 86% in South Africa [23].  
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Among the HCMV seropositive population in this study we see high levels of HCMV IgG 
antibody in young infants under the age of nine months (Figure 3-2). While this may be a true 
reflection of congenital or primary infection of infants, IgG is the only antibody isotype that 
can be transferred through the placenta [24], and so these high levels may be driven by the 
inability of the assay to distinguish between maternal and ‘self’ IgG. Detection of virus as 
opposed to antibodies would allow elucidation during the first nine months of life while 
maternal antibodies persist.  
 
After initial high levels of HCMV IgG in infants under the age of one year, we see a rapid 
decline whereby maternal antibodies are lost, or primary infection is controlled (but 
individuals remain seropositive), followed by a gradual increase from the age of 16 years of 
age up to the highest OD levels seen after 40 years of age. The magnitude of antibody 
response to virus after maternal antibodies have waned is indicative of intensity of exposure. 
The finding that females have higher HCMV antibody levels compared to males after adjusting 
for age, HIV and TB (Table 3-2) was interesting. There is evidence that risk factors throughout 
life result in a higher risk of HCMV transmission in women compared to men; a study 
conducted in Uganda using data on breast feeding trends, showed that being a male baby 
increased the risk of early termination of breastfeeding compared to females [25]. Findings 
from another Ugandan longitudinal cohort found that age at sexual debut has been 
consistently lower for women than for men from the 1950’s to 1990’s [14]. In addition, the 
infant caregiving role of females results in disproportionate female interaction with infants 
during the peak shedding at 1-2 years of age [26]. 
 
Our results suggest that HIV infection and active TB disease are independently associated with 
increased levels of HCMV IgG antibodies (Table 3-2). HIV infection is correlated with 
hypergammaglobulinaemia by way of defective humoral immunity resulting in hyperactivated 
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naive B cells producing large quantities of IgG [27]. Here we see an association between HIV 
infection and elevated IgG specific to HCMV, however in the same cohort, we see increased 
total IgG as well as tetanus toxoid-specific IgG in HIV-infected individuals, an association which 
remained after adjusting for age and sex (Stockdale et al, submitted). Despite this potential 
confounding of HIV infection upon IgG levels, the increased levels of HCMV IgG in HIV infected 
individuals is corroborated by epidemiological evidence pointing towards high levels of HIV 
and HCMV co-infection due to similar routes of transmission [8].  
Both TB and HIV are known to increase general inflammation [28,29], an immune environment 
which is associated with the increased likelihood of HCMV reactivation [30]. Both reactivation 
and reinfection expose the immune system to HCMV antigens, thereby resulting in elevated 
levels of HCMV-specific IgG antibodies. 
The association of active pulmonary TB with raised HCMV IgG levels was in contrast to findings 
of a hospital-based study where HCMV-specific T-cell responses in a whole blood assay were 
found to be lower in TB patients who died when compared to TB patients who survived [31]. In 
this hospital-based study, HCMV responses were likely a general indicator of ‘immune fitness’ 
and therefore predictive of patient survival. By contrast, our study was community based and 
the severity of TB disease at the time of blood draw would have been low when compared to a 
hospital-based study.  
The association of active pulmonary TB with raised HCMV IgG in our study was consistent with 
the findings of a correlates of TB risk study in South African infants where risk of active TB 
disease was increased with an activated T-cell phenotype which was itself correlated with T-
cell interferon gamma (IFN-) production upon stimulation with HCMV antigens [11].  Neither 
active case finding, nor routine latent TB infection screening is conducted in the Ugandan GPC 
and therefore we cannot be certain that ‘non-TB’ individuals here have not been exposed to 
TB or indeed that they are not latently infected with Mycobacterium tuberculosis. Despite 
there only being 27 active TB cases within this cohort, there remains strong evidence of an 
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association between TB and elevated HCMV IgG after adjusting for age and sex; an association 
which appears to be intensified by co-infection with HIV (Table 3-3 and 3-4). 
In view of the 1.5 million deaths per year associated with TB [32], the association of increased 
HCMV IgG with active TB disease may be an important future research area, especially in areas 
with large numbers of people living with HIV.  
 
3.7 Limitations 
It is important to note that the data from this study give us no information on causality. 
Longitudinal studies measuring systemic viral loads along with antibody levels to HCMV (and 
other herpes viruses) in stored sera would be useful to understand progression of both herpes 
virus and TB disease in this cohort. 
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CHAPTER 4 – RESEARCH PAPER 
HIV, HCMV and mycobacterial antibody levels: a cross-sectional study in a rural Ugandan 
cohort 
4.1 Chapter Background 
This chapter is a research paper, published in Tropical Medicine and International Health. This 
chapter fulfills aim 2 of this thesis: to measure mycobacteria-specific antibody levels and link 
these to demographic information and co-infection with HIV and HCMV.  
Having characterised the samples for HCMV seropositivity (Chapter 3), this research paper 
measures mycobacterial antibody levels in the same Ugandan GPC serum samples and uses 
magnitude of HCMV IgG response as an exposure in regression analysis. The chapter 
investigates associations of mycobacterial antibody levels with age, sex, along with TB disease 
and infection with HIV.  In this published article, I use the generally accepted assumption 
that increased HCMV-specific IgG is a result of increased viral exposure however it is 
important to note that this assumption has not been proven. 
 
4.2     Abstract 
Background 
A growing evidence base implicates human cytomegalovirus (HCMV) as a risk factor for TB 
disease. We investigated total IgG and mycobacteria-specific antibodies in a cross-sectional 
study nested within a rural Ugandan General Population Cohort (GPC), in relation to the 
magnitude of HCMV IgG response.  
Methods 
Sera from 2,189 individuals (including 27 sputum positive TB cases) were analysed for 
antibodies against mycobacteria (Ag85A, PPD, LAM, ESAT6/CFP10) and HCMV, tetanus toxoid 
(TT) and total IgG.  
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Findings  
Anti-mycobacterial antibodies increased with age until approximately 20 years, when they 
plateaued. Higher HCMV exposure (measured by IgG) was associated with lower levels of anti-
mycobacterial antibodies, but no increase in total IgG. HIV infection was associated with a 
decrease in anti-mycobacterial antibodies and an increase in total IgG.  
Interpretation 
The increase in anti-mycobacterial antibodies with age suggests increasing exposure to non-
tuberculous mycobacteria (NTM), and to M.tb itself. Both HIV infection and high levels of 
HCMV IgG are associated with decreased levels of mycobacterial antibodies, pointing towards 
the importance of humoral immune responses in TB disease and highlighting a role of HCMV 
as a risk factor for TB disease.  
This work demonstrates, for the first time, an association between magnitude of HCMV IgG 
and reduced levels of mycobacterial antibodies.  
 
4.3    Introduction 
The role of antibody-mediated immunity in TB has not been fully elucidated (reviewed in [1]). 
Despite the importance of cell-mediated Th1 responses in TB disease [2,3], attempts to 
stimulate this arm of the human immune response by vaccine developers have not translated 
into protection from disease in human efficacy trials [4,5], and there may be useful humoral 
correlates of disease or protection yet to be identified. 
A growing evidence base for the importance of antibodies in protection against other 
intracellular pathogens such as Listeria monocytogenes [6] and Salmonella spp [7] has led to 
renewed interest in humoral responses to TB and the factors which may affect them. Recent 
work has suggested a potential protective role of antigen 85A (Ag85A)-specific antibodies in 
reduced TB disease risk in BCG vaccinated South African infants [8,9].  
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It is known that TB and HIV work synergistically to exacerbate morbidity and mortality in co-
infected individuals with respect to both diseases [10]. Epidemiologically, concomitant viral 
infections other than HIV are known to be associated with poor TB outcomes. In Taiwan 
Hepatitis C infection was associated with a higher risk of developing active TB disease [11], and 
in South Africa influenza/TB co-infection was associated with increased mortality [12].  A large 
TB vaccine trial in South Africa, which investigated correlates of TB disease risk or protection, 
found an association between CD8 T-cell activation and HCMV response [8] which was linked 
to increased risk of TB disease and shorter time to diagnosis [13]. The ubiquitous herpes virus 
HCMV is known to cause immune activation [14], immune senescence [15], and is a significant 
factor in immune variation [16]. Recently, our group has reported elevated levels of HCMV IgG 
among TB patients when compared to controls [17].  Despite this, and the findings of some 
early epidemiologic studies [18,19], data linking HCMV and TB is sparse.   
 
To investigate mycobacteria-specific antibody levels across ages, and to examine potential 
effects of HCMV co-infection on antibody levels, this study tested 2,187 stored serum samples 
(of which 27 were active TB cases) from a rural Ugandan cohort for IgG responses to Ag85A, 
purified protein derivative (PPD), lipoarabinomannan (LAM) and CFP10/ESAT6, along with IgM 
responses to Ag85A. These antigens were chosen based on availability, evidence of their 
potential importance in TB disease from the literature (Ag85A [9], LAM [20,21], PPD [22]), and 
specificity to M.tb (CFP10/ESAT6 [23]). Seropositivity to HCMV was measured and existing data 
on HIV, BCG vaccination status, as well as demographic information was matched and 
investigated for associations. Responses to tetanus toxoid (TT) and total IgG levels were also 
investigated as control antibodies.  
 
 
  120 
4.4     Methods 
4.4.1 Study area and design 
The General Population Cohort (GPC) is a population-based open cohort study in rural south-
western Uganda, administered by the Medical Research Council (MRC) UK in collaboration 
with the Uganda Virus Research Institute (UVRI) [24]. The cohort comprises approximately 
20,000 residents (52% aged ≥13 years). Data are collected through an annual census, 
questionnaire and serological survey. Blood specimens are obtained and tested for HIV-1, with 
the remainder stored at -80°C. The majority of samples used for this study were collected from 
adults and children in 2011.  
Active TB cases were diagnosed through positive sputum smear microscopy after passive case 
detection and were sampled from a range of GPC rounds between 1999 and 2014. Sera 
collected as close as possible to the time of TB diagnosis were used for this study.  
 
4.4.2 Sampling  
Individuals were selected for inclusion in this cross-sectional study at random after 
stratification by age and sex. Due to anticipated high levels of HCMV seropositivity, infants 
under the age of 5 were oversampled. Individuals were only sampled once and siblings and 
parent-child pairs were not excluded. The total planned sample size was 2,000, plus 10% 
oversampling.  A target of approximately 100 individuals per year of age up to 5 years, 200 
individuals aged 6-10, 11-15 and 16-20, 200 in subsequent ten year intervals up to 60 years 
and 200 people aged 61 years or over. The sex ratio was approximately equal within each age 
group.  
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4.4.3 Ethics  
Ethical approval for the study was obtained from London School of Hygiene & Tropical 
Medicine (LSHTM), the UVRI Research and Ethics Committee, and from the Uganda Council for 
Science and Technology.  
 
4.4.4 Serology: Ag85A, PPD, LAM, CFP10/ESAT6 and TT 
Antibody content was measured using ELISA. Experimenters were blind to exposure group for 
all samples. Testing was conducted at UVRI in Entebbe, Uganda (Ag85A IgG and PPD IgG) and 
LSHTM, London, UK (CFP10/ESAT6 IgG, Ag85A IgM, LAM IgG and TT IgG). Half volume ELISA 
plates (Fisher Scientific) were coated overnight at 4°C with sodium carbonate buffer containing 
1.5µg/mL recombinant Ag85A protein (Aeras, USA), 1.5µg/mL PPD (Lot 051815KA, Aeras, USA), 
0.5µg/mL TT (02/232, NIBSC, UK), 0.5µg/mL LAM (NR-14848, BEI Resources, VA, USA), 
0.25ug/mL each CFP10 (NR-49425, BEI Resources, VA, USA) and ESAT6 (NR-14868, BEI 
Resources, VA, USA). Plates and reagents were brought to room temperature and the plate 
washed 3 times with PBS, 5% Tween20 (v/v) (PBST). After blocking with PBS 5% milk (w/v) 
blocking buffer, duplicate 1:100 test serum, high and low PPD responder controls and plate 
blanks consisting of assay diluent alone with no serum were added in triplicate. Incubation for 
2 hours at room temperature, and washing with PBST was followed by a one hour incubation 
with an appropriately diluted peroxidase-conjugated secondary antibody in PBST-5% (IgG, 
1:500 dilution of goat anti-human IgG-HRP (04-10-20, KPL, USA); IgM, 1:10,000 dilution of goat 
anti-human IgM-HRP (Abcam ab97205, RRID: AB_10695942)). After washing with PBST, 50µL 
tetramethylbenzidine (TMB, BD BioSciences, USA) was added to each well. The plate was 
incubated for 15 minutes in the dark before the reaction was stopped by adding 50uL of 2M 
Sulphuric Acid (Sigma, USA) to each well. Absorbance was measured at 450nm within 30 
minutes to obtain optical density (OD), a surrogate marker of antibody titre. 
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Mean blank values were subtracted from all OD readings, and geometric means of duplicates 
were used to reduce the effect of skewed distribution. Median levels with interquartile ranges 
(IQR) are used for graphical representation of antibody levels in figures 4-1 and 4-2.  
 
4.4.5 Total IgG serology 
All samples were tested for total IgG content at LSHTM. As above, half volume ELISA plates 
were coated overnight with mouse anti-human IgG at 0.5ug/mL (Abcam). IgG antibody 
standards (134.4-8.4 ng/mL) were prepared by diluting purified human IgG (Sigma) in PSBT-5% 
milk and test sera were diluted 8x105 in PBST-5% Milk. Duplicate test samples, controls and 
blanks were incubated for one hour at 37°C, and, after washing, samples incubated with 
peroxidase-conjugated goat anti-human Fc (Abcam) diluted 1/500 with PBST-5% Milk for one 
hour at room temperature. Plates were developed with TMB, and sulphuric acid was added to 
stop the reaction. Plates were read at 450nm and OD measurements converted into g/L by use 
of the standard curve on each plate.  
 
4.4.6 Serology HCMV 
Samples were tested for IgG antibodies against HCMV using a commercial ELISA kit (Novatec 
Immunodiagnostica GmbH) according to kit instructions (described in [17]).  
 
4.4.7 Sample size estimation 
Based on data from a Phase 2b South African infants vaccine study [8], an increase of 
approximately 0.5 Optical Density units (OD) in Ag85A IgG was observed in the median 
response in the control vs case infants. These data indicate that a change of 0.5 OD may be 
biologically meaningful in terms of protection against TB disease. Using power calculations for 
a type 1 error (alpha) of 0.05, power of 0.80, with an effect size of 0.5 OD, we would require 64 
individuals per comparison group.  
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4.4.8 Statistical analysis 
Correlations between each pair of mycobacterial antibody OD levels were conducted using 
Spearman’s rho. Because of the ubiquity of HCMV infection within this population [17], 
analysis was conducted on the HCMV seropositive population only.  
Individuals seropositive for HCMV IgG were further categorized into 3 groups according to 
tertiles of HCMV antibody concentrations (measured by OD): low, medium and high. 
Linear regression was used to determine the association of each antibody response (as 
continuous dependent variables) with HCMV IgG tertile and HIV infection (as independent 
variables with HCMV as a categorical variable), adjusting for age and sex. BCG vaccination 
status and active TB disease were also included in the regression model, however as 89% 
(24/27) of active TB cases had unknown BCG status, it was not possible to include both 
variables in the same model. The model including TB was preferred, with the model including 
BCG run as a comparison to confirm the consistency of the results. BCG vaccination was 
included in a separate regression analysis using the same model.  
Individuals with unknown HIV were excluded from all regression analyses and individuals with 
unknown BCG vaccination status were excluded from regression analyses including BCG. To 
account for evidence of non-linearity of antibody OD with age (likelihood ratio test p<0.001 for 
all antibodies), a quadratic term for age was included in the regression analyses. Numbers 
included in each of the regression analyses are shown in tables 4-2 and 4-3. 
 
To account for multiple comparisons, 99% confidence intervals (CIs) are reported and a p value 
of 0.01 is considered to represent strong evidence to reject the null hypothesis. Due to 
different dynamic ranges of spectrophotometers used in Uganda and the UK, antibody OD 
measurements (for mycobacterial antibodies only) were rescaled for graphical representation. 
This was done by dividing each individual’s OD value by the maximum OD for that antibody; 
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hence figure 4-1 shows the percentage of the maximum OD. All analysis was performed using 
Stata version 14 (Stata Corporation, College Station, TX, USA).  
 
4.5 Results  
Sera were sampled from 2,189 individuals. Total IgG levels could not be determined in 15 
instances, likely due to protein degradation. Of the remaining 2,174 individuals, 8.6% 
(186/2,174) of individuals were HCMV seronegative and were excluded from analysis. The 
HCMV negative population contained no TB cases, 4 HIV positive individuals, 98 (53%) were 
female and the mean age was 14.6 years (range 3 months-95 years). 
The remaining 1,988 individuals were included in further analyses. The mean age was 23.4 
years (range 30 days-100 years) and 50% were female (Table 4-1). Ninety-eight percent 
(1,956/1,988) of individuals had a valid HIV result, and of those, 4.9% (96/1,956) were HIV 
positive, with the greatest proportion of HIV positive individuals in the 31-50 year age group.  
Twenty-seven sputum-confirmed TB cases were included in the study. Of these 27 individuals, 
63% (17/27) were female and the mean age was 36 years (range 12-59 years). Only three TB 
cases had BCG vaccination information and all of those were unvaccinated. All 27 were HCMV 
seropositive, with 59% (16/27) having HCMV IgG levels in the upper tertile.  
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Table 4-1: Study participant characteristics of evaluable individuals (N=1,988).  
Age, mean (range, years) 23.4 (0.08-100.75) 
Age of study participants (years): 
 <1 
 1 
 2 
 3 
 4 
 5 
 6-10 
 11-15 
 16-20 
 21-30 
 31-40 
 41-50 
 51-60 
 61 and over 
Total 
Number of individuals included in sample: 
 75 
 83 
 82 
 87 
 100 
 106 
 183 
 192 
 204 
 216 
 238 
 166 
 109 
 147 
1,988 
Sex, percent female (number/total) 50.0 (993/1,988) 
HIV prevalence, percentage (number/total) 4.9 (96/1,956) 
BCG vaccinated, percentage (number/total) 70.2 (1,225/1,744) 
Active TB cases, percentage (number/total) 1.4 (27/1,988) 
Tribe, percentage (number/total)  
Baganda 
Other * 
74.3 (1,400/1,883) 
25.7 (483/1,883) 
* Other tribes include Rwandese Ugandan, Bakiga, Batooro, Banyankole, Basoga, Bafumbira, 
Tanzanian, Barundi 
 
4.5.1 Mycobacterial antibody responses increase until late adolescence 
 
IgG against Ag85A, PPD, LAM, CFP10/ESAT6 and IgM against Ag85A all increased from birth to 
approximately 20 years of age, after which OD values reached a plateau. Figure 4-1 shows 
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median OD for each of the mycobacterial antibody levels by age group. Initial levels in infants 
under the age of one year range from a median of 4% of maximum OD (0.12 OD) for Ag85A 
IgM to 12% of maximum OD (0.35 OD) for LAM IgG. Responses to the M.tb-specific 
ESAT6/CFP10 antigens did not show the same rapid increase from birth as responses to other 
mycobacterial antibodies. Univariate analysis showed no differences in mean OD levels by sex. 
Analysis of correlation showed a high degree of co-linearity between all mycobacterial 
antibodies (0.33>rho<0.65, all p<0.001).  
 
 
Figure 4-1. Median adjusted mycobacterial antibody OD by age group.  Vertical lines show IQR 
for each median data point. Total n= 1,988. OD values adjusted by dividing OD by the 
maximum OD response for that antibody. IQR – interquartile range, OD – optical density. 
 
 
 
TT and total IgG levels were investigated as control antibodies (figure 4-2). TT vaccination 
induces high levels of TT IgG and is given at birth and to pregnant females as part of the 
Uganda immunization schedule [25]. TT IgG showed high levels of antibody from birth and a 
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clear sex difference with females having higher overall IgG levels (p<0.001, figure 4-2A). This 
difference is driven by females aged between 16 and 50 years (figure 4-2A). Total IgG levels 
increase with age from birth (median 46.2g/L in infants less than one year of age) to a plateau 
after 11 years of age (median 69.4g/L), figure 4-2B. Since a univariate analysis of total IgG by 
sex indicated no difference, data were not separated by sex for this plot. 
 
 
Figure 4-2A. Median OD levels for TT IgG by sex and age group. B. Median total IgG (g/L) by age 
group. Vertical lines show IQR for each median data point. Total n=1,988. Figure 4-2A red lines 
represent median values for females, blue lines for males. Figure 4-2B shows data for males 
and females combined. IQR – interquartile range, OD – optical density. 
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4.5.2 Decreased anti-mycobacterial antibodies with high HCMV IgG and in HIV positive 
individuals  
 
In a multivariable linear regression model including TB disease status, being HIV positive was 
associated with a decrease in all mycobacterial antibody levels studied (magnitude ranged 
from mean decrease of 0.240 OD (99% CI -0.361, -0.119) for IgG against Ag85A), to a mean 
decrease of 0.446 OD (99% CI -0.640, -0.251) for IgM against Ag85A, all p<0.001, table 4-2). 
Similarly, being in the upper tertile of HCMV IgG response was associated with a decrease in 
Ag85A, PPD and LAM IgG levels compared to being in the middle tertile: a mean decrease of 
0.067 OD (99% CI -0.122, 0.012) for Ag85A IgG, 0.057 OD (99% CI -0.105, -0.009) for PPD IgG 
and 0.107 (99% CI -0.194, 0.019) for LAM IgG (all p<0.001, table 4-2). While the direction of 
change was the same for CFP10/ESAT6 IgG and Ag85A IgM, the mean decrease associated with 
being in the upper tertile of HCMV IgG response was not sufficiently large to provide good 
evidence of a difference based upon our significance threshold (table 4-2). The association 
between mycobacterial antibody levels and magnitude of HCMV IgG response was not linear 
(Figure 4-3): in comparison to the middle tertile of HCMV IgG response, the lowest tertile was 
also associated with a decrease in mycobacterial antibody levels. A mean decrease of 0.100 OD 
(99% CI -0.156, -0.044) p<0.001 was seen for CFP10/ESAT6 IgG and a mean decrease of 0.104 
OD (99% CI -0.205, -0.004) p=0.01 for Ag85A IgM. The direction of change was the same for 
the remaining mycobacterial antibodies (table 4-2).  
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Figure 4-3. Adjusted mean OD change associated with HCMV tertile comparing to medium 
HCMV tertile as baseline. P values from multivariable linear regression model including age, 
quadratic age, sex, HIV and TB. Total n=1,956. Vertical lines show 99% CI for each mean OD 
change. OD – optical density, CI – confidence interval. (* model includes, age, quadratic age, 
sex, HIV and TB). 
 
 
 
 
 
 
 
 
  
  130 
 
Table 4-2. Fully adjusted mean differences in mycobacterial antibodies (values obtained using 
a multivariable regression model including age, quadratic age, sex, HIV and TB status, with p 
values and 99% CI (n=1,956). (CI – confidence interval, OD – optical density) 
 
    Ag85A IgG OD PPD IgG OD LAM IgG OD CFP10 ESAT 6 IgG Ag85A IgM 
Variable N (%) 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Sex 
 
    
  
    
  
    
Male 
978/1956 
(50.0%) baseline   baseline 
 
baseline   baseline 
 
baseline   
Female 
978/1956 
(50.0%) 
 -0.002  
(-0.045, 
0.041) 0.9 
 -0.002  
(-0.042,  
0.038) 0.91 
 -0.017  
(-0.099,  
0.064) 0.58 
 -0.025  
(-0.083,  
0.033) 0.27 
 -0.012  
(-0.103,  
0.079) 0.73 
HCMV Tertiles                     
HCMV 
low 
650/1956 
(33.2%) 
 -0.037  
(-0.090, 
0.016) 0.07 
 -0.009  
(-0.051,  
0.033) 0.57 
 -0.061  
(-0.151,  
0.030) 0.08 
 -0.100  
(-0.156,  
-0.044) <0.001 
 -0.104  
(-0.205,  
-0.004) 0.01 
HCMV 
medium 
650/1956 
(33.2%) baseline   baseline 
 
baseline   baseline 
 
baseline   
HCMV 
high 
656/1956 
(33.5%) 
 -0.067  
(-0.122,  
-0.012) <0.001 
 -0.057  
(-0.105,  
-0.009) <0.001 
 -0.107  
(-0.194,  
-0.019) <0.001 
 -0.015  
(-0.077,  
0.047) 0.54 
 -0.058  
(-0.152,  
0.035) 0.11 
HIV Status   
 
      
 
        
Negative 
1860/1956 
(95.1%) baseline 
 
baseline   baseline 
 
baseline   baseline   
Positive 
96/1956 
(4.9%) 
 -0.240  
(-0.361,  
-0.119) <0.001 
 -0.310  
(-0.422,  
-0.198) <0.001 
 -0.420  
(-0.586,  
-0.253) <0.001 
 -0.266  
(-0.409,  
-0.123) <0.001 
 -0.446  
(-0.640,  
-0.251) <0.001 
TB Status                     
Negative 
1929/1956 
(98.6%) baseline   baseline 
 
baseline   baseline 
 
baseline   
Positive 
27/1956 
(1.4%) 
 -0.101  
(-0.322, 
0.121) 0.24 
 -0.035  
(-0.217,  
0.147) 0.62 
 0.158  
(-0.107,  
0.424) 0.13 
0.175  
(-0.241,  
0.590) 0.28 
 -0.135  
(-0.609,  
0.340) 0.46 
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4.5.3 Active TB disease and BCG vaccination: associations with mycobacterial antibody levels 
 
Being a sputum confirmed active TB case was not associated with any differences in any 
mycobacterial antibody level after adjusting for age, sex, HIV and HCMV level, although given 
that there were only 27 cases, there was limited statistical power to detect associations (table 
4-2). Coefficients of the effect of HIV and HCMV for each outcome measurement were similar 
for a model including BCG instead of TB, and the magnitude of effect was not altered by 
adjusting for total IgG. Being BCG vaccinated was associated with a 0.115 OD increase in TT IgG 
(99% CI 0.004 - 0.227) p=0.01.  
 
 
Table 4-3 shows that HIV positivity was associated with an increase in total levels of IgG (9.110 
g/L (99% CI 3.735, 14.485), p<0.001). Being female was associated with an increase in TT of 
0.272 OD (99% CI 0.188, 0.356, p<0.001) but no difference in total IgG levels. While being an 
active TB case was not associated with any differences in TT IgG, being a TB case was 
associated with a 5.8 OD decrease (99% CI -13.298, 1.720) in total IgG however this was not 
significant (p=0.05). The magnitude of HCMV IgG response did not affect either total IgG levels 
or TT IgG response (table 4-3).  
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Table 4-3. Fully adjusted mean differences in total IgG and TT IgG OD (values obtained using a 
multivariable regression model including age, quadratic age, sex, HIV and TB status, with p 
value and 99% CI (n=1,956). (CI – confidence interval, OD – optical density) 
    Total IgG (g/L) TT IgG OD 
Variable N (%) 
Coeff  
(99% CI) 
P 
value 
Coeff  
(99% CI) P value 
Sex 
 
        
Male 
978/1956 
(50.0%) baseline   baseline   
Female 
978/1956 
(50.0%) 
 -0.326  
(-2.350,  
1.697) 0.68 
0.272  
(0.188,  
0.356) <0.001 
HCMV Tertiles         
HCMV low 
650/1956 
(33.2%) 
0.318  
(-2.240,  
2.877) 0.75 
 -0.090  
(-0.187,  
0.008) 0.02 
HCMV 
medium 
650/1956 
(33.2%) baseline   baseline   
HCMV high 
656/1956 
(33.5%) 
0.915  
(-1.508,  
3.338) 0.33 
0.065  
(-0.029,  
0.159) 0.08 
HIV Status         
Negative 
1860/1956 
(95.1%) baseline   baseline   
Positive 
96/1956 
(4.9%) 
9.110  
(3.735,  
14.485) <0.001 
 -0.172  
(-0.357,  
0.012) 0.02 
TB Status         
Negative 
1929/1956 
(98.6%) baseline   baseline   
Positive 
27/1956 
(1.4%) 
 -5.789  
(-13.298,  
1.720) 0.05 
 -0.081  
(-0.328,  
0.165) 0.4 
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4.6 Discussion 
Previously we have shown that TB patients have increased levels of HCMV IgG [17] and that 
HCMV positive infants (as measured by HCMV IFN- ELISPOT) were at higher risk of 
progressing to active TB disease [13].  
In this study, we found that individuals with the highest levels of HCMV IgG had decreased 
levels of mycobacterial antibodies, and had no corresponding change in total IgG levels. We 
found that HIV infected individuals had decreased levels of mycobacterial antibodies, with a 
concomitant increase in total IgG. These findings suggest that HCMV co-infection, like HIV, may 
be associated with increased risk of TB disease, and that they both act to specifically deplete 
mycobacterial antibodies which may be contributing to protective mechanisms against M.tb 
infection.  
 
As has been seen previously [26], humoral responses against RD1 antigens ESAT6 or CFP10 
(mycobacterial proteins associated specifically with M.tb and not NTM or BCG) did not show 
an association with active TB cases in this study. Due to a lack of active TB case-finding in the 
GPC, it is likely that some of the individuals classed as TB negative here were latently infected 
with M.tb based on epidemiologic data on exposure in Uganda [27,28]. The finding that IgG 
responses to these M.tb-specific antigens increase with age, following a similar pattern as 
other non-M.tb-specific mycobacterial antibodies, suggests that while NTM may be driving 
high responses of acute (IgM) and sustained (IgG) mycobacterial responses, exposure to M.tb 
itself cannot be ignored. 
BCG vaccine status allocation in this study was by presence of scar, inspection of immunization 
card or verbal confirmation by parent of guardian. Despite issues with these methods [29], 
classification was thought to be robust due to the evidence of association of TT IgG with BCG 
indicating that people vaccinated for one Extended Programme of Immunization (EPI) schedule 
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vaccine are more likely to have received other vaccinations upon accessing local health 
centers.  
 
The magnitude of difference in mycobacterial antibodies seen due to HIV infection was far 
greater than due to either active TB disease or BCG vaccination. The lower levels of 
mycobacterial antibodies seen in individuals infected with HIV is not associated with an 
accompanying decrease in TT IgG or total IgG. The effect seen here points towards HIV 
infection having a mycobacteria-specific effect as opposed to a more general depression of all 
antibody levels, thereby confirming evidence seen previously in Italy [30], in this rural Ugandan 
cohort. Here we see a similar association between the highest levels of HCMV IgG (indicative 
of highest exposure [31,32]), and decreased levels of some mycobacterial antibodies. Again, 
this decrease is not accompanied by a decrease in total IgG or TT IgG. 
As a human herpes virus, HCMV persists in a variety of cell types in a dormant state and is 
transmitted through body fluids [33]. Infection is not normally associated with symptomatic 
disease, however it poses a huge burden on the immune system, with maintenance of up to 
30% of both CD4 and CD8 circulating memory T cells being specific to HCMV [34]. The virus is a 
significant factor in immune variation [16], immunosenescence [15], and causes immune 
activation [14], including non-specific polyclonal B-cell activation and proliferation [35].  
In this study, we see decreased mycobacterial antibody levels at both HCMV IgG extremes 
among HCMV seropositive individuals. Evidence of HCMV effect on vaccine responses exists, 
showing both a detrimental impact of HCMV infection [36,37] and a positive, ‘adjuvanting’, 
effect of HCMV on vaccine-induced antibody responses in humans [38]. Given reports that 
cellular responses to heterologous virus challenge in mice may depend on the initial viral dose 
of HCMV [39,40] the lack of a linear response between HCMV IgG and mycobacterial antibody 
levels seen in this study may also be indicative of different effects at different HCMV exposure 
levels. PBMC samples were not available from this cohort for us to determine if magnitude of 
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HCMV IgG level had a similar impact on the mycobacteria-specific cellular immune response.  
However, it is likely that cellular immunity is also impacted by HCMV given that HCMV has 
been shown to affect both humoral and cell mediated immune responses to vaccine antigens 
[41,42].  
 
Before the widespread use of highly active anti-retrovirals (HAART), HCMV/HIV co-infection 
saw HCMV as an important cause of severe non-AIDS events, including death, in HIV-infected 
individuals [43]. High levels of HCMV IgG, caused by repeated reactivation or reinfection 
events, are associated with higher all-cause mortality [44] and lower CD4 cell count, with 
accompanying worse response to anti-retrovirals [45]. Despite literature describing HCMV-
induced B cell activation [35,46,47], in this study we saw no relationship between HCMV 
exposure and increased levels of total IgG. We do however see a consistent trend towards 
decreased mycobacterial antibody response in individuals with very high HCMV IgG responses 
after adjusting for HIV infection. Considering the risk of developing active TB disease increases 
over 20 times in individuals with HIV [48], and given the high degree of co-infection of HCMV 
and HIV due to similar transmission routes [43], it is likely that any added effect of HCMV 
would be masked. The mycobacterial antibody-specific decrease seen with both HIV infection 
and, independently, in the highest tertile of HCMV exposure, may be indicative of a functional, 
protective role of mycobacterial-specific antibodies which are independently decreased by HIV 
and high levels of exposure to HCMV.  
 
In summary, both HIV infection and high levels of HCMV IgG were both associated with 
decreases in mycobacterial antibody levels. Given this novel finding of effect of HCMV 
exposure on mycobacterial antibody levels, investigation of magnitude of HCMV may be 
important in future TB clinical trials to understand the immune environment, independently of 
HIV infection status. In addition to quantification of antibody levels, we believe that it will be 
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important to measure HCMV effect on mycobacteria-specific cellular responses. A more 
nuanced understanding of the quality, as well as the quantity, of the mycobacterial antibodies 
elicited, in terms of antibody class, subtype and avidity may help to shed light upon a potential 
mechanism by which they might confer protection to host cells.  
 
4.7 Limitations 
Due to insufficient volumes of sera, we were unable to investigate HCMV viral load in serum 
samples to ascertain whether active infection at point of blood draw was associated with any 
of the measurements taken for this study. Despite this, we believe that use of HCMV-specific 
IgG is a robust a measure of cumulative exposure. As previously mentioned, active TB case 
finding is not carried out within the GPC and therefore we cannot be sure that some 
individuals analysed as ‘non-TB’ are not latently infected.  PBMC samples were not available 
from this cohort for us to determine if HCMV had a similar impact on the mycobacterial 
cellular immune response.   
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CHAPTER 5 – RESEARCH PAPER 
Case control study of TB in rural Uganda:  HCMV infection, but not EBV or HSV, is associated 
with increased risk of TB disease up to 14 years before diagnosis. 
 
5.1 Chapter Background 
 
This chapter is a research paper written for submission to Lancet Infectious Diseases. This 
chapter fulfills aim 3 of this thesis: to identify associations between level of HCMV sero-
reactivity (and other herpes viruses) and markers of inflammation, and aim 4: to investigate 
links between HCMV infection, measures of antibody quality and TB disease risk.  
This research paper measures markers of inflammation in sera from a case control study 
nested within the cross-sectional cohort from the Ugandan GPC. Measures of chronic herpes 
virus IgG other than HCMV, as well as antibody avidity of PPD-specific IgG are investigated with 
respect to risk of TB disease diagnosis.  
5.2 Abstract 
 
Background 
Recent evidence highlights human cytomegalovirus (HCMV) and immune activation as risk 
factors for tuberculosis (TB) disease. This study investigates magnitude of HCMV IgG as a risk 
factor up to 14 years prior to TB diagnosis in a nested case-control study. 
Methods 
This case-control study used 52 stored serum samples from 26 TB cases stored up to 14 years 
prior to TB diagnosis from a rural Ugandan cohort. Controls who did not develop overt TB 
disease were matched on age, sex and HIV. Samples were investigated for herpes virus-specific 
IgG, serum markers of inflammation and PPD antibody avidity.  
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Findings 
HCMV IgG, but not Epstein Barr (EBV) or Herpes Simplex virus (HSV) IgG was associated with 
increased risk of active TB disease up to 14 years prior to TB diagnosis. In comparison to 
individuals with low HCMV IgG, the odds ratio (OR) of people with medium response was 2.2 
and for those with high levels was 3.3 (Ptrend= 0.0075). 
Increased PPD-specific IgG avidity associated with decreased risk of TB at early time points 
prior to TB diagnosis, but with increased risk at point of diagnosis. 
Interpretation 
These data provide evidence that magnitude of HCMV infection, but not EBV or HSV, is 
associated with risk of TB disease. In addition, mycobacterial antibody avidity may be a useful 
measure in the search for immune correlates of TB disease risk. 
 
5.3 Introduction 
 
Tuberculosis (TB) disease is responsible for 1·34 million deaths annually [1]. Epidemiological 
studies have identified important risk factors for TB: HIV [2], diabetes [3], IFN-γ deficiencies 
[4], anti-TNF-α therapies [5] and malnutrition [6].  Diagnostics to identify the approximately 
ten percent of infected individuals that will go on to develop active pulmonary TB disease [7], 
thereby perpetuating transmission, are still lacking. Recent efforts to discover correlates of risk 
to direct preventative therapy, or markers of protection to help guide drug and vaccine 
development have shown promise [8]. Investigation into immune correlates signatures has 
reconfirmed the importance of IFN-γ and identified a role for IFNαβ signalling [9], immune 
activation [10] and antibodies [11], however the mechanisms are not fully understood.  
 
Human cytomegalovirus (HCMV) is a common herpes virus which is transmitted through 
person-to-person contact. Once infected, HCMV establishes lifelong latency in a variety of cell 
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types. Infection rarely results in serious side effects in immune competent individuals, 
however it can cause permanent hearing and neurological damage in neonates and severe 
non-AIDS events in HIV-infected people [12]. HCMV infection is highly associated with immune 
variation [13], T cell activation [14], immune senescence, systemic inflammation [15], memory 
inflation, and increased numbers of B cells [16]. Evidence that accumulated exposure to HCMV 
correlates with high HCMV IgG titres exists [17,18], but is not proven [19]. Antibody levels are 
however linked to a range of chronic diseases [20] in addition to increased overall mortality 
[21]. Previous research from our group and others has observed increased IgG against HCMV 
in TB cases [22,23], and epidemiologic studies have found a link between HCMV and both TB 
and non-tuberculous mycobacterial (NTM) disease [23–25]. The mechanisms underlying this 
relationship have not been elucidated but likely involve sustained chronic inflammation and T 
cell activation, and may involve alterations in humoral responses.  
 
The objectives of this case control study were to investigate the relationship between extent 
of HCMV infection, inflammatory markers in serum, anti-mycobacterial antibody avidity as a 
measure of antibody function, and risk of TB disease in this Ugandan cohort. To determine if 
the association seen with HCMV is seen in other chronic herpes viruses, samples were also 
investigated for Epstein Barr (EBV) and herpes simplex viruses (HSV), the latter having good 
evidence to suggest that antibody levels are directly correlated with viral excretion [26].  
 
5.4 Methods 
5.4.1 Sampling 
 
The general population cohort (GPC) is a population-based open cohort based in rural Uganda. 
The GPC was established in 1989 to examine trends in prevalence and incidence of HIV 
infection and their determinants [27]. The cohort comprises approximately 20,000 people, half 
147 
 
of whom are aged below 13 years. Data are collected through an annual census and blood 
samples are stored in a biobank at -80°C, located in Entebbe, Uganda.  
TB is diagnosed through passive case identification of symptomatic individuals presenting for 
care at GPC clinics. Twenty-six individuals from this cohort who were diagnosed with sputum 
positive active TB disease between 1999 and 2014 were included in this study. From routine 
samples taken during GPC data collection, we retrieved all available stored serum samples 
from these 26 TB cases taken up to three months post diagnosis. Between one and four stored 
serum samples per TB case were identified and retrieved from the biobank of stored samples 
at time points before, and up to three months after TB diagnosis (total sample number – 52). 
We categorized the TB case samples into three time point groupings based on number of 
samples available and anticipated ability to detect differences prior to, and at point of TB 
diagnosis: between 14 and five years prior to TB diagnosis, between five and one year prior to 
TB diagnosis, and between one year prior and three months after TB diagnosis (considered 
point of diagnosis).  
 
For controls, we selected stored serum samples collected in 2011 from people within the GPC 
who had no record of TB disease. Samples were matched on age, sex and HIV status at time at 
which sample was taken. Control samples were designated the same time before TB diagnosis 
grouping as the TB case to which they were matched. Between four and six control individuals 
were matched per TB case sample (a maximum of one sample per control. Total number of 
control individuals – 300).  
 
Because of the ubiquity of HCMV infection within this population [22], HCMV seronegative 
samples were excluded (n=9, all nine were control individuals with a mean age of 37 years 
(26·9-50·8 years), two of these nine were HIV positive.) The resulting 343 HCMV positive 
samples, grouped into 52 matched sets, were included in analysis (Table 5-1). Individuals were 
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further categorized into three groups according to tertile of HCMV antibody concentrations 
(measured by optical density (OD)): low (n=116), medium (n=119), and high (n=108).  
 
Table 5-1 – Number of TB case samples and matched controls for time periods prior to, and at 
point of TB diagnosis. The table also shows age, sex and HIV status for the individuals included 
in this study (for TB case individuals, the mean age is age at sampling closest to diagnosis). 
 
Time before/after TB 
diagnosis 
Non-TB Control 
samples 
TB Case samples Total 
14-5 yrs before 96 17 113 
5-1 yr before 90 16 106 
1 yr before - 3 months after 105 19 124 
Total number of samples 291 52 343 
 
Number of individuals 291 26 317 
Mean age (range) yrs 34·45 (2·75-56·5) 36·31(13·08-56·5) 34·48 (2·75-56·5) 
Number female (%) 178 (61%) 16 (62%) 193 (61%) 
Number HIV positive (%) 87 (30%) 8 (31%) 95 (30%) 
 
 
The exposure of interest was TB disease as a binary measure. Serum samples were 
investigated for exposures: IgG against chronic herpes viruses HCMV, EBV and HSV1/2, non-
specific inflammatory markers: IFNα2, IFNγ, IL10, IL12p40, IL12p70, IL1Ra, IL1a, IL1b, IL6, IP10, 
TNFα, total IgG levels and, antibody avidity of PPD-specific IgG. Known confounders of HCMV 
IgG level; age, sex and HIV status, are adjusted for by matching controls on these variables. 
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Testing for HIV was carried out immediately after blood collection in Uganda as previously 
described by Asiki et al [27].  
 
5.4.2 Ethics 
 
Written consent for the use of clinical records and biological samples for research purposes 
was obtained from all GPC participants following Uganda National Council of Science and 
Technology guidelines. Ethical approval for this study was obtained from London School of 
Hygiene & Tropical Medicine (LSHTM), the UVRI Research and Ethics Committee, and from the 
Uganda Council for Science and Technology.  
 
5.4.3 Herpes virus-specific IgG 
 
Measurement of HCMV IgG and total IgG was conducted as has been previously described 
[22]. IgG against Epstein-Barr virus nuclear antigen 1 (EBNA-1) and HSV1 and HSV2 full 
antigens was measured using commercial kits (Euroimmun, Germany). Testing was conducted 
as per kit protocol. The resulting measurement (in relative units (RU)) was calculated based on 
a standard curve from the calibration sera and, based on kit cut-offs. 
 
5.4.4 Luminex 
 
Luminex multiplex cytokine platform was used to determine the concentrations of IFNα2, IFNγ, 
IL10, IL12p40, IL12p70, IL1Ra, IL1a, IL1b, IL6, IP10, TNFα in serum samples. Cytokines were 
tested using Millipore kits (Merck Millipore, USA) according to the manufacturer's instructions. 
Standard curves were generated from the serial dilutions that were made from the assay 
controls supplied and matched against the cytokine concentration for quantification. The 
concentrations of all the analytes in the quality control reagents were found to be within the 
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ranges as expected. The Bio-Plex manager version 6·1 was used for bead acquisition and 
analysis of median fluorescence intensity (MFI). MFI was converted to pg/mL. 
 
 
5.4.5 Total IgG 
 
Half volume ELISA plates (Fisher Scientific) were coated overnight at 4°C with 50µL sodium 
carbonate buffer containing mouse anti-human IgG at 0·5ug/mL (ab 200699; Abcam). IgG 
antibody standards (134·4-8·4 ng/mL) were prepared by diluting purified human IgG (0·86 
mg/mL; I4506; Sigma) in PSBT-5% Milk and test sera were diluted 8x105 in PBST-5% Milk. Plates 
and reagents were brought to room temperature and the plate washed 3 times with PBST. The 
plate was blocked for one hour at room temperature with 100µL blocking buffer (PBS, 5% Milk 
(w/v)). Standards and diluted test samples were tested in duplicate and the sealed plate was 
incubated for one hour at 37°C. The plate was washed five times with PBST and 50ul of 
peroxidase-conjugated goat anti-human Fc (ab97225; Abcam) diluted 1/500 with PBST-5% Milk 
was added for one hour at room temperature. Plates were developed using TMB, and 
sulphuric acid was used to stop the reaction, and read at 450nm. Optical density (OD) 
measurements converted into g/L by use of the standard curve on each plate.  
 
5.4.6 PPD antibody avidity 
 
Antibody avidity was assessed by ELISA using the chaotropic agent sodium thiocyanate 
(NaSCN) to dissociate low-affinity IgG binding using a previously described method [28]. An 
avidity index (AI) was calculated as the molar concentration of NaSCN required to reduce 
antigen specific IgG binding by 50%. 
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5.4.7 Statistical analyses 
 
Initial analyses were conducted on all 343 samples in order to investigate differences between 
individuals who went on to be diagnosed with active TB disease with those who remained TB-
free.  
 
Linear regression was used to investigate correlations between continuous serum marker 
levels, and between serum marker levels and sex, HIV infection status, HCMV tertile, PPD IgG 
avidity and age.  
To investigate associations between serum markers and TB disease, a conditional logistic 
regression model was used. The model was conditioned on the 52 matched case-control sets 
and included HCMV tertile as an a priori covariate. Due to different measurement ranges, all 
continuous exposure variable measurements were re-scaled on a 0-10 scale, where zero was 
the minimum and ten was the maximum observed response for that measurement. Hence 
reported odds ratios are for a ten percentage point increase in response. Conditional logistic 
regression analyses of risk of TB disease with increased levels of specific IgG against the other 
herpes viruses, EBV and HSV were limited by the number of positive individuals. Data on EBV 
tertile were missing for 19% (64/343) samples and HSV tertile information was missing for 1% 
(5/343) samples due to IgG levels being below the kit positive cut off. The remaining 
seropositive samples were divided into 3 groups to form tertiles and sample numbers included 
in conditional logistic regression analyses are stated in table 5-2. 
 
To determine if the effect of each exposure on TB risk is different in each of the three time 
periods in which samples were collected, a secondary analysis explored the interaction 
between the time before diagnosis, and risk of TB disease. For any exposure showing a 
directional trend in this secondary analysis, a sensitivity analysis was conducted whereby 
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HCMV tertile was not included in the conditional logistic regression analysis to determine the 
effect of HCMV.  
To account for multiple comparisons, 99% confidence intervals (CIs) are reported and a p value 
of 0·01 is considered to represent strong evidence to reject the null hypothesis. A robust 
standard error was employed in conditional regression analysis to account for the fact that 
some TB cases contributed more than one sample. All analyses were performed using Stata 
version 14 (Stata Corporation, College Station, TX, USA).  
 
5.5 Results 
 
Of the 317 HCMV seropositive individuals included in analyses, 30% of individuals were HIV 
positive (8/26 TB cases and 87/291 control samples, (table 5-2). Eighty one percent (279/343) 
of individuals were EBV IgG positive and 99% (338/343) were HSV IgG positive. HCMV IgG and 
HSV1/2 IgG were positively correlated (coefficient 0·231, 99% CI 0·082-0·381, p<0·0001). 
HCMV IgG levels were not associated with EBV IgG (coefficient -0·21, 99% CI -0·135-0·092, 
p=0·631).  
 
5.5.1 HCMV IgG positively correlates with the serum inflammatory marker CXCL10 (IP10) 
 
Of all the serum levels of inflammatory markers investigated, levels of interferon gamma-
induced protein 10 (IP-10) also known as CXCL10, and IFN-γ are positively correlated with 
HCMV IgG levels (IP10: coefficient 0·221, 99% CI 0·150 – 0·292, p<0·0001, IFN-γ: coefficient 
0·065, 99% CI 0·006-0·122, p=0·004). Neither of these are correlated with EBV or HSV1/2 
(Figure 5-1).   
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Figure 5-1 Correlations of IP10 with A) HCMV, B) HSV and C) EBV IgG. Correlations of IFNγ with 
D) HCMV, E) HSV and F) EBV IgG. Coefficients and P values reported are from an unadjusted 
linear regression analysis of 343 individuals. Blue hollow markers show HIV negative, and red 
show HIV positive results. 
 
 
 
After adjustment for matching criteria (age, sex, HIV) and TB disease, the regression coefficient 
between IP10 and HCMV was reduced from 0·221 to 0·185 (99% CI 0·036-0·335, p=0·001) but 
there remained good evidence of an association. The coefficient for the relationship between 
IFN-γ and HCMV is largely unchanged (coefficient after adjustment:  0·072, 99% CI -0·063-
0·208, p=0·167).  
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5.5.2 HCMV IgG not associated with increased total IgG  
 
Unadjusted linear regression analysis indicated that increased HCMV IgG was associated with 
increased total IgG (coefficient 10·80 (99% CI 5·85-15·76) p<0·0001) however, once matching 
criteria and TB disease were included in the linear regression model, this association was much 
reduced (coefficient 5·59 (99% CI -0·43-11·61), p=0·017). Neither EBV or HSV1/2 IgG were 
associated with changes in total IgG.  
 
5.5.3 High HCMV IgG, but not HSV or EBV, is associated with increased risk of TB 
 
Initial analyses of association of herpes virus exposure with TB disease risk showed that, 
irrespective of when the sample was taken prior to TB disease diagnosis, a conditional logistic 
regression (adjusted for age, sex, HIV status as per study matching) found the odds associated 
with active TB diagnosis were increased 2·2 times among individuals with an intermediate 
HCMV IgG compared to low IgG (99% CI 0·764-6·355, p=0·055) (Table 5-2 and Figure 5-2). 
Having HCMV IgG in the upper tertile of the range was associated with a 3·3 times greater 
odds of having active TB disease (99% CI 1·052-10·175, p=0·007). The same trend of increased 
risk with higher IgG was not seen with either EBV or HSV1/2 (Table 5-2).  
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Table 5-2 – Odds of TB disease by chronic herpes virus IgG level. Medium and high tertiles are 
compared to the lowest tertile of IgG level for each virus in a conditional logistic regression 
model including age, sex and HIV status. Odds ratios and 99% confidence intervals are given. 
The P value is from a likelihood ratio test for trend.  
 
 Herpes virus level (n) Odds Ratio (99% CI) Ptrend value 
HCMV 
Low (n=116) 
Medium (n=119) 
High (n=108) 
  
1.0 
2·204 (0·764-6·355) 
3·272 (1·052-10·175)  
  
0.0075 
HSV 
Low (n=109) 
Medium (n=107) 
High (n=110) 
  
1.0  
0·964 (0·387-2·401) 
0·581 (0·181-1·862) 
  
0.3363 
EBV 
Low (n= 84) 
Medium (n=88) 
High (n=85) 
  
1.0 
1·171 (0·423-3·245) 
0·652 (0·228-1·864) 
  
0.2271 
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Figure 5-2 - Odds of TB disease by HCMV IgG. Results shown are from a conditional logistic 
regression model which includes age, sex and HIV status. HCMV low is used as the baseline 
measurement. HCMV low n=116, HCMV medium n=119 and HCMV high n=108. Lines 
represent 99% CI 
  
 
 
5.5.4 Inflammatory markers IL1a and IP10 are associated with increased odds of TB 
 
Again, irrespective of when the sample was taken prior to TB disease, a conditional logistic 
regression analysis (adjusted for age, sex, HIV status and HCMV tertile) showed that each ten 
percentage point increase in IL1a within the range seen among this population was associated 
with a 27% increased odds of being diagnosed with TB up to 14 years prior to diagnosis (OR 
1·2695, 99% CI 1·0148,-1·5880, p=0·006, table 5-3). Each ten percentage point increase in IP10 
was associated with a 233% increased odds of being diagnosed with active TB disease (OR 3·3 
99% CI 1·2-9·1, p=0·002, table 5-3). Each ten percentage point increase in total IgG was 
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associated with 29% reduced odds of being diagnosed with active TB disease (OR 0·71, 99% CI 
0·51-0·98 p=0·007, table 5-3). 
 
Table 5-3 - Odds of TB disease in a univariate conditional logistic regression model including 
age, sex, HIV status and HCMV tertile. The Odds ratio reported here is per 10 percentage point 
increase in that marker. OD – optical density. 
 
 Mean (range) Odds Ratio (OR) 99% CI P value 
Inflammatory markers (unit of measurement) 
IFNα2 (pg/mL) 16·98 (0-502·9) 1·299 0·823, 2·050 0·140 
IFNγ (pg/mL) 3·80 (0-134·8) 1·340 0·936, 1·918 0·036 
IL10 (pg/mL) 19·50 (0-2711·4) 2·710 0·547, 13·427 0·109 
IL12p40 (pg/mL) 4·79 (0-440·8) 1·020 0·617, 1·685 0·919 
IL12p70 (pg/mL) 0·87 (0-34·2) 0·979 0·696, 1·376 0·869 
IL1Rα (pg/mL) 11·70 (0-904·3) 1·296 0·840, 1·999 0·124 
IL1α (pg/mL) 51·67 (0-805·7) 1·270 1·015, 1·588 0·006 
IL1β (pg/mL) 49·2 (0-746·6) 1·020 0·749, 1·388 0·870 
IL6 (pg/mL) 109·61 (0-4700) 1·126 0·871, 1·457 0·234 
IP10 (pg/mL) 298·9 (0-5533·6) 3·327 1·211, 9·140 0·002 
TNFα (pg/mL) 81·5 (0-768·7) 1·018 0·8130, 1·274 0·834 
Other serum markers 
Total IgG (g/L) 68·7 (19·52-117·3) 0·711 0·514, 0·983 0·007 
PPD IgG avidity index (OD) 3·0 (1·86-5·0) 1·004 0·817, 1·234 0·962 
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5.5.5 PPD antibody avidity is associated with changing risk of TB disease over time 
 
A likelihood ratio test (LRT) provided good evidence of an interaction between time before 
diagnosis and odds of TB disease risk for serum IFNα2 level and PPD IgG avidity (Table 5-4). 
There was no evidence of an interaction with time for any other exposure variable.  
 
Table 5-4. Investigating changes in serum IFNα2 levels and PPD IgG avidity at different time 
points prior to TB disease.  The p value reported is from the LRT. The OR and 99% CI reported 
are from a conditional logistic regression model (conditioned on matching criteria (age, sex, 
HIV status) including HCMV tertile and an interaction with the time point at which the sample 
was taken. The odds ratio reported is per ten percentage point increase in either IFNα2 or PPD 
IgG avidity at the time point tested. 
 
Variable Odds Ratio 99% CI P value (from LRT) 
IFNα2 
14-5 yrs before diagnosis 3·920 1·305,11·77  
0·0018 5-1 yr before diagnosis 0·831 0·425,1·626 
1 yr before-3 mo after diagnosis 1·407 0·763,2·597 
PPD avidity index 
14-5 yrs before diagnosis 0·778 0·561, 1·078  
0·0033 5-1 yr before diagnosis 0·872 0·569, 1·335 
1 yr before-3 mo after diagnosis 1·399 1·006, 1·947 
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Figure 5-3 – Graphical representation of odds ratios associated with univariate conditional 
logistic regression (model including matching criteria (age, sex, HIV status) and HCMV tertile) 
for IFNα2 and PPD IgG avidity index according to the time before TB diagnosis that serum 
samples were taken. The odds ratios and 99% CIs are representative of a ten percentage point 
increase in the respective exposure. 
 
 
 
For IFNα2, there was no directional trend in the run up to TB diagnosis: between 14 and five 
years before diagnosis, a ten percent increase in serum levels of IFNα2 is associated with 
increased risk of TB disease; between five and one year before diagnosis, the same increase 
was associated with decreased risk; and at point of diagnosis, with increased risk (figure 5-3 
and table 5-4).  
 
For PPD IgG avidity, between 14 and five years prior to TB diagnosis, a ten percent increase in 
avidity of PPD-specific antibodies is associated with a 22% decreased risk of TB diagnosis (OR 
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0·778, 99% CI 0·561, 1·078). Closer to point of diagnosis, the same increase in avidity is 
associated with a 12·8% decrease in risk (OR 0·872, 99% CI 0·569, 1·335). At point of TB 
diagnosis, each ten percentage point increase in PPD IgG avidity is associated with a 40% 
increased risk of TB diagnosis (OR 1·399, 99% CI 1·006, 1·947). These results are not affected 
by the adjustment for HCMV IgG tertile. In a sensitivity analysis where HCMV tertile was not 
included in the conditional logistic regression analysis, the overall P value from the LRT 
investigating the interaction of time with PPD IgG avidity changed from 0·0033 to 0·0074. The 
ORs for each time point are altered by less than four percent. 
 
5.6 Discussion 
 
It is estimated that approximately one quarter of the world’s population is infected with TB 
[29]. Identification of the 55.5 million people who are at high risk of TB disease [29] will be 
crucial to halt the epidemic. There remain many gaps in our knowledge as to the reasons for 
some individuals’ ability to control infection with M.tb while others develop active disease. 
Immunological risk factors include IFN-y deficiencies and decreases in T cell count: HIV 
infection being one of most important associations. Recent evidence implicates both immune 
activation, inflammation, and the human herpes virus HCMV as risk factors for TB disease.  
 
In this study, we used a case control design containing longitudinal samples taken before, and 
at point of TB diagnosis to investigate the relationship between HCMV, inflammatory markers, 
and risk of TB disease. We found that magnitude of HCMV infection, as measured by IgG, was 
associated, in a dose-dependent manner, with risk of TB disease up to 14 years prior to 
diagnosis. Well established confounders of HCMV and TB including age, sex and HIV were 
accounted for in the study design. The same association with TB risk is not seen with EBV or 
HSV despite evidence of co-linearity between HCMV and HSV seen here and elsewhere [30], 
and evidence of co-prevalence of these three chronic herpes viruses [31].  
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Our findings are consistent with a study in infants where a HCMV-specific T-cell response 
(measured by IFN-γ enzyme-linked immunospot (ELISpot)) was associated with increased risk 
of, and decreased time to, infection with TB [32]. HCMV infection is normally evaluated by 
serology, and high HCMV IgG titres are linked to accumulated HCMV burden [20,21]. It is not 
known whether the association between increased HCMV IgG, increased overall mortality [21], 
and chronic diseases [20] is also observed with HCMV-specific T cell responses. One study 
showed general concordance between antibody and cellular immune responses against HCMV, 
however the group found no association between HCMV IgG titre and quantitative HCMV-
specific ELISpot responses, and over a third of HCMV IgG seronegatives demonstrated a 
positive HCMV ELISpot response [33].  
 
Here, we see that being among the highest HCMV IgG group, risk of TB disease is increased 3·3 
times. HCMV seropositivity is ubiquitous in this population [22], and the assay used to quantify 
HCMV is semi-quantitative. The grouping into tertiles of HCMV-specific IgG is based upon the 
ranges seen in this population and may not be generalizable. It will be important to 
understand if the range seen here is similar to other populations and what specific cut-offs of 
HCMV IgG are associated with increased risk of TB.  
 
Circulating levels of most cytokines measured were below the threshold of assay sensitivity, 
however IP10 serum levels were generally high in this population and were further elevated in 
individuals with high HCMV IgG. This positive correlation between IP10 and HCMV was not 
seen with EBV or HSV. Along with other systemic immune activation markers such as serum C-
reactive protein and IFN-γ, elevated levels of IP10 have been associated with post-
transplantation morbidity in HCMV discordant recipients [15].  It is known that an interferon-
inducible gene profile, including IP10, is associated with active TB disease [9] however it is not 
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understood if it is TB itself, latent TB infection, or an underlying cause, such as viral co-
infection, which is driving this profile [34]. IP10 is positively correlated with HCMV IgG levels 
however IL1 α is not. Interestingly here we see that IP10 and IL1α are themselves associated 
with increased odds of TB disease after adjustment for HCMV IgG tertile, indicating that while 
risk of TB due to HCMV may be due to HCMV-mediated effects, a HCMV-independent 
inflammatory profile may also be linked to risk of disease. 
 
The only exposure that showed evidence of an interaction between time before TB diagnosis 
and clear directionality of response was PPD antibody avidity. Investigation of PPD IgG avidity 
at different time points prior to TB disease diagnosis showed a trend suggestive of highly avid 
antibodies specific to mycobacterial antigens having a positive, protective effect up to 14 years 
prior to TB diagnosis.  Measures of mycobacteria-specific antibody avidity prior to TB diagnosis 
have, to our knowledge, not been studied before. Work conducted by Perley et al found that 
active TB disease in humans was associated with a decrease in avidity of antibodies able to 
bind directly to the surface of live bacteria [35]. This finding, and our work, point towards the 
importance of qualitative analysis of antibodies; antibody avidity being one measure of quality 
that has been shown to be critical for protection induced by the meningococcal B vaccine [36]. 
 
In summary, this work shows, in this rural Ugandan population, that odds of TB disease are 
increased to 2·2 times among individuals with intermediate HCMV IgG, and 3·3 times among 
individuals with high levels of HCMV IgG. This finding is independent of HIV infection, age and 
sex.  
An inflammatory environment, here characterized by high IP10 and IL1α, is associated with 
increased risk of TB disease in this rural Ugandan cohort. Further work is needed to 
understand if the results found here are generalizable to other populations. Identification of 
robust correlates of TB disease risk up to 14 years prior to diagnosis would be transformative 
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to the TB field.  We believe that the data presented here warrant further research into the 
effect of magnitude of HCMV IgG levels, the possible protective effect of mycobacterial 
antibodies, and investigation of the immune environment in future TB clinical trials.  
 
The implications of this work for TB control efforts are that, given the excess TB disease risk 
associated with HCMV, HCMV infection should be given the same importance as other known 
TB risk factors such as HIV and diabetes. Development of an HCMV vaccine is already 
underway [37], however target groups mainly consist of women of child bearing age to protect 
neonates from HCMV-associated neurological disorders. The data presented here show that 
the need for HCMV control measures may be greater than initially predicted.  
 
5.7 Limitations 
 
Although the capacity exists within the GPC to collect PBMC, cells were not available for the 
current study.  The normal study design of a case-control cohort dictates that controls be 
matched to cases at point of diagnosis. Using stored serum samples, and only having one 
serum sample per non-TB control, we were unable to match in this way retrospectively. This 
may introduce a potential source of bias for this study.  Control samples were matched to case 
samples on age, sex and HIV status when the sample was taken. In order to mitigate this bias, 
one individual who was diagnosed with active TB disease changed HIV status during the 
sampling time and so was excluded. The passive case-finding within the GPC likely 
underestimates the true burden of disease. The control individuals included in this study were 
not investigated for TB infection. More stringent inclusion criteria for controls may have 
resulted in larger differences between groups.   
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Chapter 6 – UNPUBLISHED RESULTS 
Use of Mycobacterial growth inhibition assay (MGIA) to investigate ability of serum to inhibit 
mycobacterial growth 
 
6.1 Chapter Background 
 
Results chapters 3 and 4 have characterised HCMV IgG and mycobacterial antibodies 
respectively. Chapter 4 described associations between mycobacterial antibody levels and 
HCMV, HIV, BCG vaccination status and TB disease. Chapter 5 investigated inflammatory 
markers and PPD-specific antibody avidity and linked those with HCMV, EBV and HSV, and risk 
of TB disease at different time points before TB diagnosis.  
Based on the findings that HCMV IgG levels were higher in TB cases than in individuals who 
were not diagnosed with active TB disease (chapter 3); that high levels of HCMV IgG were 
associated with decreased levels of the mycobacterial antibodies Ag85a, PPD and LAM 
(chapter 4); and that highly avid PPD-specific antibodies were associated with a directional 
trend to decreased odds of TB many years prior to TB diagnosis, the functional activity of 
serum to inhibit mycobacterial growth is investigated in this final results chapter. This chapter 
is not prepared for publication.  
 
6.2 Introduction 
 
The ex-vivo mycobacterial growth inhibition assay (MGIA) is a functional assay that aims to 
provide a summative assessment of immune mechanisms and their interactions within a 
biological sample [1]. Initially supported by the WHO, the MGIA was developed to overcome 
the lack of defined immune correlates of vaccine efficacy in human studies. Use of a 
standardized, validated stock of BCG specifically prepared for use in the MGIA, instead of 
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variable quality stocks of M.tb helped to increase assay reproducibility, and avoid the use of 
biosafety level 3 facilities. A good correlation was seen between BCG and M.tb in comparative 
studies [2]. 
MGIA, using quantification based on the BACTEC mycobacteria growth indicator tube (MGIT) 
automated system, has been shown to discriminate between individuals by their functional 
ability to control bacillary growth following vaccination [3]. As opposed to a single measure of 
host immune response such as the IGRA, this assay provides an unbiased assessment of 
mycobacterial control as a measure of anti-mycobacterial immunity. Normally the MGIA is 
used to measure cell-mediated immunity induced by developmental vaccines in animal models 
[4] and humans [1] using serum of bovine origin to provide growth factors in cell culture.  
To determine if serum from TB cases or individuals with particularly high or low levels of anti-
mycobacterial, and HCMV, antibodies was having any effect on the ability of human peripheral 
blood mononucleocytes (PBMC) to inhibit mycobacterial growth, the MGIA was utilised here.  
 
6.3 Methods 
 
PBMC were isolated from one UK-born, BCG-unvaccinated volunteer from LSHTM (see Chapter 
2.8 for methodology). These cells were tested for IFN- by ELISPOT (see Chapter 2.9 for 
details), and used in a BCG MGIA where cells were combined with heat inactivated sera from 
individuals within the GPC (see Chapter 2.10 for full methods of MGIA). Briefly, 3.5 x 106 PBMC 
were combined with 20% serum from one of 37 individuals from the GPC chosen based on 
either being a confirmed TB case or levels of Ag85A, LAM or HCMV IgG within the highest or 
lowest 20% of the range seen in the samples included in the nested case control (see Chapter 
2.2.4 for sampling). All serum donors were randomly selected from HIV negative individuals 
over the age of 15 years. BCG vaccination status was not specified in the sample selection.  
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Controls consisting of commercial FBS and human AB serum and IgG-depleted AB serum were 
included in duplicate. Positive controls consisting of a mixture of PHA and PMA were included 
in duplicate.  
A final input of BCG of 90 CFU in 300L was added to the PBMC and serum and left to incubate 
for 4 days. After this, cells were washed, lysed and added to a BACTEC MGIT tube. The system 
is based on fluorescence quenching by oxygen. As oxygen levels within the tube are depleted 
by bacterial growth, fluorescence is released and measured hourly by the BACTEC machine 
which gives a ‘time to positivity’ (TTP) readout. This readout is compared to a ‘direct-to-MGIT’ 
where BCG is inoculated directly into the tube. The readout of TTP was converted to log CFU of 
BCG in the sample based on a standard curve. A total of 37 test samples were included in 
singlicate, and controls in duplicate.  
 
6.3.1 Statistics 
 
Data were analysed using GraphPad Prism 7 and Stata version 14 (Stata Corporation, College 
Station, TX, USA). An age and sex adjusted linear regression model was used to investigate 
associations between log CFU and BCG vaccination and log CFU and sex. Associations between 
log CFU and levels of mycobacterial antibodies, herpes virus IgG, inflammatory markers as well 
as total IgG and PPD-specific IgG avidity were investigated using linear regression model 
adjusting for age and sex. 
The non-parametric Mann-Whitney test was used to compare median log CFU between two 
groups (for example TB cases vs controls, BCG vaccinated vs BCG unvaccinated, and males vs 
females).  
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6.4 Results 
6.4.1 ELISPOT results 
 
The UK-born LSHTM-based volunteer who was used as the source of PBMC was tested for IFN-
 release following T-cell stimulation with various mycobacterial antigens. The positive control 
of PMA and PHA was unreadable due to blackout (too many spots to count), confirming that 
the cells could produce IFN- upon stimulation by a mitogen. Unstimulated cells provided a 
background reading of 1.75 SFU. After background subtraction, the individual was negative for 
reactivity to ESAT6/CFP10 and LAM antigens (2.75 and 0.75 SFU respectively). The individual 
had positive responses to PPD and Ag85B antigens with mean SFU measurements of 51.75 and 
12.5 respectively.  
 
6.4.2 MGIA Results 
 
Associations between log CFU and BCG vaccination were investigated in an age and sex 
adjusted linear regression model. Of the 37 individuals selected for inclusion in the MGIA 
experiment, 51% (19/37) were historically BCG vaccinated, 35% (13/37) were not vaccinated 
and 14% (5/37) had missing data on BCG vaccination status. No association was found 
between BCG vaccination status and ability to control BCG growth in the MGIA (coefficient= 
0.03, 99% CI -0.47- 0.53, p=0.879) (Figure 6-1). 
Similarly, no associations were seen between males and females in an age-adjusted model 
(coefficient= -0.046, 99% CI -0.55- 0.45, p=0.805).  
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Figure 6-1: Log CFU of serum from BCG vaccinated (n=19) and unvaccinated (n=13) individuals.  
Dashed line represents input dose of 90 CFU BCG. 
 
 
TB cases were compared to non-TB in Figure 6-2 below. The spread of data is large for both 
groups and there was no evidence of a difference between the 2 groups (coefficient=0.20, 99% 
CI -0.48 - 0.88, p=0.428).  
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Figure 6-2: Log CFU of serum from TB cases (n=5) and serum from individuals without active TB 
disease (n=32). Dashed line represents input dose of 90 CFU BCG. 
 
 
 
 
Results from a minimally adjusted linear regression model (including age and sex) of log CFU 
growth and deciles of exposures including mycobacterial antibody levels, herpes virus IgG, 
inflammatory markers as well as total IgG and PPD-specific IgG avidity are shown in Table 6-1 
below.  None of the exposures show any significant association with the ability of the serum to 
inhibit growth at the 0.01 significance level.  
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Table 6-1. Associations between mycobacterial growth inhibition and levels of exposures using a linear regression model adjusted for age and sex.  The coefficients 
reported here are per 10 percentage point increase in that marker. OD – optical density. 
 
 
Variable mean (range) coefficient 99% CI P value 
Mycobacterial Antibody levels 
Ag85A IgG (OD) 0.91 (0.23, 1.69) 0.0121 -0.0623, 0.0866 0.6585 
PPD IgG (OD) 1.18 (0.50, 1.70) -0.0058 -0.1097, 0.0982 0.8802 
LAM IgG (OD) 1.94 (0.35, 2.73) 0.0233 -0.0656, 0.1123 0.4776 
CFP10/ESAT6 IgG (OD) 0.69 (0.07, 1.98) -0.0386 -0.1361, 0.0589 0.2853 
Ag85A IgM (OD) 1.46 (0.27, 2.78) -0.0123 -0.0879, 0.0632 0.6569 
Herpes virus IgG levels 
HCMV IgG (OD) 1.07 (0.20, 1.75) -0.0419 -0.1526, 0.0688 0.3077 
EBV IgG (OD) 76.27 (0, 197.34) 0.0197 -0.0706, 0.1100 0.5553 
HSV IgG (OD) 145.52 (32.92, 245.11) -0.0526 -0.1570, 0.0518 0.1772 
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Inflammatory markers 
IFNa2 (pg/mL) 12.20 (0, 149.48) -0.0375 -0.1568, 0.0819 0.3963 
IFNg (pg/mL) 3.69 (0, 30.83) 0.0437 -0.0531, 0.1405 0.2254 
IL10 (pg/mL) 7.78 (0, 47.81) 0.0146 -0.0643, 0.0934 0.6167 
IL12p40 (pg/mL) 3.87 (0, 62.12) -0.0092 -0.1155, 0.0972 0.8152 
IL12p70 (pg/mL) 0.42 (0, 6.31) -0.0194 -0.1225, 0.0837 0.6092 
IL1Ra (pg/mL) 4.88 (0, 75.87) -0.0136 -0.1316, 0.1043 0.7536 
IL1a (pg/mL) 38.33 (0, 267.51) 0.0388 -0.0494, 0.1269 0.2372 
IL1b (pg/mL) 5.89 (0, 140.71) 0.0115 -0.1333, 0.1563 0.8286 
IL6 (pg/mL) 95.21 (0, 1846.34) 0.0076 -0.1059, 0.1211 0.8551 
IP10 (pg/mL) 165.97 (0, 1951.46) 0.0956 -0.0274, 0.2187 0.0411 
TNFa (pg/mL) 12.99 (0, 183.27) 0.0404 -0.0845, 0.1653 0.3822 
Other serum markers 
Total IgG (g/L) 69.57 (46.84, 104.68) -0.0089 -0.1082, 0.0903 0.8067 
PPD avidity index (OD) 3.02 (2.07, 4.68) 0.0436 -0.0435, 0.1307 0.1799 
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Figure 6-3 shows all groups plotted by the antibody levels for which the samples were chosen. 
Sample selection ensured that sera selected for inclusion were within the upper or lower 20% 
of measurements from samples included in the larger nested case-control study. Of the 32 
samples chosen for inclusion, 16 of those had Ag85A IgG levels within the top 20%, and 16 had 
Ag85A IgG levels within the lower 20%. Similarly, 16 were LAM IgG high, 16 LAM IgG low, 16 
were HCMV IgG high and 16 were HCMV IgG low. Figure 6-2 shows that there were no 
differences between ability to inhibit BCG growth based on the Ag85A IgG, LAM IgG or HCMV 
IgG level within the serum.  
 
Figure 6-3: Log CFU for all antibody level groups. Dashed line represents input dose of 90 CFU 
BCG. 
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Control samples consisting of FBS, AB serum and IgG-depleted AB serum were measured in 
duplicate. A high degree of variability was seen between these duplicates, with a coefficient of 
variation of 24%, 22%, and 14% respectively (Figure 6-3). 
  
6.5 Discussion 
 
Serum samples chosen for this assay were selected based upon their Ag85A, LAM or HCMV IgG 
content. Due to time constraints of this project, sample selection was carried out prior to the 
analysis of data for Chapter 5. In retrospect, given the link between PPD antibody avidity and 
risk of TB disease (Chapter 5), it may have been better to select samples based on that 
parameter instead.  
In order to minimise variation, PBMC from only one donor was used in this experiment. Only 
50mL of blood can be taken at any one time from a volunteer and so the number of cells 
available for use in this assay was limited. This therefore limited the number of comparison 
groups in addition to the number of replicates and controls included.  
 
The MGIA has been optimised over several years to determine the best mycobacterial input 
(BCG vs M.tb), the multiplicity of infection (how many bacteria per host cell), as well as 
parameters such as use of whole blood compared to PBMC, and antibiotic content in the 
culture medium [5].  
Prior to optimisation, the MGIA suffered from high intra-assay variability and could not detect 
vaccine-induced differences [6]. However, more recent studies have shown much lower levels 
of variability and higher consistency. In a study which investigated mycobacterial growth 
inhibition in the presence of pre- and post- primary or secondary BCG vaccination with THP-1 
cells, it was found that lower BCG growth was seen in post-vaccination sera compared to pre-
vaccination [7]. It was also found that both enhanced growth inhibition and enhanced 
phagocytosis was associated with IgG against arabinomannan [8].  
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The ELISPOT results showed that the PBMC, despite originating from a non-BCG vaccinated 
individual, may have some reactivity to environmental mycobacteria sharing PPD and Ag85B 
antigens. While it would have been ideal to test several donors, and use PBMC from someone 
with no T-cell responses to any mycobacterial antigens, that was not possible given the time 
and resource limitations of this project. The PPD and Ag85B positivity seen here is indicative of 
exposure to NTM which may be interacting with the mycobacteria in the MGIA and masking 
any effect due to serum levels.  
 
Here, we saw no associations between historic BCG vaccination and ability to control BCG 
growth ex-vivo, nor a link between active TB disease and growth. We also did not see any 
associations between serum antibody levels and growth. However, It is likely that the assay 
system used here was not sufficiently optimised for the assessment of a heterologous serum 
response on donor PBMC.  The use of donor PBMC limited the number of input cells per well 
which likely increased variability in the assay and restricted the number of individuals available 
for each group which meant the study was underpowered to observe differences between 
groups.  Also, the pre-existing immune response to mycobacterial antigens discussed above 
could have interfered with our ability to observe differences.  
 
The lack of difference between groups could also be due to other constituents of serum. The 
sera used here were only characterised for levels of 3 antibodies (Ag85A, LAM and HCMV IgG) 
but many others could be having an effect. Despite the samples having been heat inactivated 
to remove any effect of complement, there are likely to be other differences such as serum 
cytokine and chemokine levels not measured in the luminex assay.   
 
  179 
In conclusion, the MGIA assay was not able to show that sera from individuals with differing 
levels of certain antibodies was associated with any difference in ability to inhibit 
mycobacterial growth in this situation. It is likely that the assay was not sufficiently optimised 
and underpowered to see such difference due to the reason discussed above. In addition, 
serum samples used in this experiment were not sufficiently characterised and likely had high 
intrinsic heterogeneity, therefore masking any effect on mycobacterial growth. Evidence 
discussed previously in this thesis suggests that serum constituents can affect the ability of 
bacteria to enter cells and replicate within them. Therefore, given more time and resource, 
including development of more robust procedures with more stringent criteria for reactivity of 
donor PBMC, (and the use of a cell line to ensure large numbers of cells) the MGIA may well be 
able to differentiate between sera, if any real difference actually exists.  
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CHAPTER 7: OVERALL DISCUSSION AND CONCLUSIONS 
 
7.1 Summary and significance of findings 
Taken together, the data presented in this thesis add to the growing evidence that HCMV infection 
and TB disease are linked. In Chapter 3, I show that in this Ugandan cohort, HCMV seropositivity is 
ubiquitous. Higher HCMV IgG levels are linked to female sex, HIV infection, and active TB disease. 
In Chapter 4, I show that mycobacterial antibody levels increase with age, a finding indicative of 
cumulative exposure to NTM and M.tb over a lifetime. HIV infection, one of the most important 
risk factors in TB disease, is associated with dramatic decreases in all mycobacterial antibody levels 
investigated. The same pattern is seen with decreased mycobacterial antibodies in the highest 
tertile of HCMV IgG. Both HIV and HCMV show a much greater magnitude of effect on 
mycobacterial antibody levels compared to either active TB disease, or historic BCG vaccination.  
Having elucidated that increased HCMV IgG is linked to active TB disease in this cohort, and that 
high levels of HCMV are associated with decreased mycobacterial antibodies, I then wanted to 
investigate a link between HCMV and risk of TB disease in a nested case control study. In Chapter 
5, I show that up to 14 years prior to TB disease diagnosis, higher levels of HCMV IgG are 
associated with increased risk of TB disease in a dose-dependent manner. The same associations 
are not seen with other chronic herpes viruses EBV or HSV.  
Also in Chapter 5, I showed that PPD antibody avidity was associated with a directional trend to 
increased odds of TB disease as time to TB diagnosis decreased. Having highly avid PPD antibodies 
associated with a more protective phenotype at time points distal to diagnosis, which switched to 
being associated with risk at point of TB diagnosis. To test the hypothesis that HCMV may be 
affecting the quality of the antibody response, I investigated the interaction between HCMV IgG 
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level and PPD antibody avidity. The data did not support the hypothesis that HCMV IgG level was 
affecting PPD antibody avidity.  
While more work needs to be done to tease apart the mechanism by which HCMV may be 
affecting risk of TB disease, the work in this thesis clearly shows that HCMV is associated with risk 
of TB in this cohort. Spatial and temporal similarities between the two pathogens underscore the 
logic of a hypothetical interaction. Both TB and HCMV infect the same cell types in the same 
organ; both infect macrophages and can establish chronic latency in these cells in the lung [1–3], 
and NK cells play a critical role in the innate immune response against both pathogens [4,5]. As we 
saw in Chapter 3, HCMV infection is almost ubiquitous by age 5 in this Ugandan cohort [6] and this 
is representative of other LMICs [7]. The early exposure of the immune system to HCMV, a 
pathogen associated with immune activation and inflammation [8], may predispose HCMV-
infected individuals to infection with TB and ultimately, to increased susceptibility to development 
of active TB disease. Data is scarce on prevalence of LTBI however one study of 290 participants in 
Kampala, Uganda (75 % of whom were aged between 15–34 years) showed that overall 
prevalence of LTBI was 49% with older age being a significant risk factor [9]. While we cannot infer 
causality by the age at which infection occurs, in Uganda it seems as though infection with HCMV 
occurs earlier than infection with TB.  
 
In chapter 1 showed that extent of HCMV IgG, but not EBV or HSV, was positively correlated with 
the inflammatory marker IP10 (CXCL-10), and risk of TB disease also increased with increasing 
levels of IP-10, independently of HCMV IgG levels. IP10 is a potent inflammatory chemokine 
induced by IFN-γ. Specifically interacting with CXCR3 receptor, a surface molecule expressed on 
activated T and B and NK cells, IP10 induces chemotaxis of those activated cells to the site of 
secretion [10]. Latent HCMV infection has been shown to induce host cells to secrete pro-
inflammatory cytokines, including IP-10, into the extracellular environment [11,12]. In the absence 
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of viral exposure (indicative of latent HCMV infection [13]), taken here to be driving HCMV 
antibody responses [14], HCMV induces IP10 production by host cells, thereby insinuating 
additional risk associated with HCMV infection. Abnormal levels of IP10 have been observed in a 
variety of diseases including infectious diseases and cancer [15]. Therefore, while the potential risk 
of TB disease attributable to HCMV infection could well be a combined effect of both HCMV 
exposure (measured by IgG) in addition to HCMV-induced IP10 secretion, this hypothesis requires 
further research.  
 
It is important to highlight that the assumption used throughout this thesis is that HCMV IgG 
accurately reflects HMCV viral exposure. There remains conflicting evidence for this assumption 
[14,16]. There may be alternative mechanisms by which certain groups of individuals mount 
stronger humoral responses to HCMV infection. Unfortunately, we were unable to study possible 
genetic associations as only serum was available for the individuals analysed in this PhD. It is 
known that genetic variation in the human NKG2 receptor which determines ability of host cells to 
lyse HCMV-infected target cells [17] impacts susceptibility, but in addition, sex hormones have a 
large effect on immunity, and specifically inflammation [18]. Further work is needed to understand 
if there exists a genetic predisposition to high CMV titres, however females generally have higher 
antibody levels and B cell numbers than men [19].  
 
If, as is inferred from temporality of infection with the two pathogens, HCMV is acting to increase 
risk of TB disease, mechanisms by which HCMV may be doing this could be either TB-specific or 
more general. Results from the nested case-control do not show any evidence of a HCMV-specific 
alteration to mycobacterial antibody avidity (Chapter 5). The lack of PBMC in this project meant 
we were not able to investigate any effect of HCMV on mycobacteria-specific T-cells. Given the 
association between HCMV and T-cell activation [20], it is possible that increased HCMV exposure, 
 184 
could be or driving an apoptotic T cell phenotype [21], or, like HIV infection, could be specifically 
depleting TB-specific T cells [22].  Given the importance of NK cells in both pathogens [4,5], 
another possible mechanism by which HCMV might increase risk of TB could be the preferential 
trafficking of NK cells with anti-viral potential as opposed to anti-mycobacterial. Again, further 
work would be needed to test this hypothesis. Alternative mechanisms by which HCMV infection 
could be causing increased risk of TB disease might not be TB-specific. HCMV encodes many viral 
proteins including UL111A; a homologue to the Th2 cytokine IL-10 [23]. IL-10 is well known for 
regulating effector T cell immune responses, including inhibiting production of the protective pro-
inflammatory cytokine, IFN- [24]. Mouse models have highlighted the importance of IL-10 in TB 
infection and progression [25,26]. In humans, this has been linked to IL-10-dependent blocking of 
phagosome maturation [27]; an essential mechanism by which the phagosome and lysosome fuse, 
creating the phagolysosome capable of microbial degradation [28]. Innate lymphoid cell (ILC) 
subsets participate in early immune responses against foreign antigens by production of various 
cytokines [29,30]. Like Th1 cells, ILC1 cells produce IFN- upon interaction with pathogens [31]. 
Lung-resident ILCs (including natural killer (NK) cells) are among the first cell subsets to be exposed 
to inhaled M.tb bacilli and are thought to be crucial to the outcome of infection [32]. ILCs in the 
gut are regulated by ILC regulatory cells (ILCregs) which act via IL10 to control inflammation [33]. 
Because HCMV infection occurs very early in this population [6], it is possible that virally-encoded 
IL-10 could be interfering with innate immune control of initial TB infection, leading to a more TB-
permissive phenotype at a young age.  
 
Much as HIV infection status would always be taken into consideration when conducting a TB 
clinical trial, the data presented in this thesis support the idea that not only HCMV infection status, 
but extent of HCMV infection, should also be taken into consideration. This finding may well 
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extend to other pathogens other than TB which are affected by an inflammatory environment. 
These data may also add urgency to the HCMV vaccine effort.  
The role of antibodies in TB is still unclear, however the finding here that co-infections associated 
with increased risk (HIV and HCMV) act to decrease mycobacterial antibody levels, and that 
mycobacterial antibody avidity changes in the run up to TB disease may help to direct further 
mechanistic investigation of their importance.  
 
Both HCMV and TB have been associated with lower socio-economic status.  Large studies from 
the USA [34] and the UK [35] found HMCV seropositivity of 50% in age-adjusted analysis, and of 
70% in individuals over 65 years of age respectively. Both studies found a clear association 
between risk of HCMV infection and lower socio-economic status. To our knowledge, no work has 
investigated correlation between socio-economic status and HCMV as a continuous variable in 
areas of high HCMV seropositivity. An association between risk of TB and low socio-economic 
status in India was largely attributable to lower education level and poverty [36,37]. Among 
foreign-born individuals in the USA,  evidence showed that TB risk and socio-economic status were 
only weakly associated [38]. In this rural Ugandan cohort, not only is HCMV infection ubiquitous, 
but differences in socio-economic status are much less pronounced than in the USA and UK. Since 
all GPC participants are provided with access to healthcare, socio-economic status is calculated 
based on variables such as ownership of household items, wall type and roof quality [39]. 
Approximately 13% of the residents attain education beyond primary level, and the majority of 
people are employed in subsistence farming [40]. There are no tarmacked roads within the GPC 
and buildings are mostly semi-permanent structures made from locally available materials [41]. 
Despite the smaller scale differences in socio-economic status within the GPC in comparison to 
some high income countries, early studies of the HIV epidemic in Uganda showed that the heads 
of the poorest households were more likely to be HIV positive [42].  
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Socio-economic status was not investigated as a covariate in this project, and it, along with 
maternal education, may be a useful potential confounder to include in future analyses. In 
addition, determination of viral load and shedding by PCR of urine and or saliva would be very 
informative to understand what exactly high HCMV IgG levels are actually measuring. Longitudinal 
urine, saliva and blood samples would allow a greater understanding of whether reinfection and 
reactivation events are driving HCMV IgG. One interesting point to be kept in mind however, is 
that, given the long-term presence of the MRC research base providing healthcare, treatment and 
general health education, measurement of socio-economic status within the GOC may not be 
generalizable to other areas of Uganda.  
 
As previously discussed, research into HCMV vaccine development [43] mainly focusses on women 
of child bearing age to protect neonates from HCMV-associated neurological disorders. The data 
presented in this thesis show that the need for HCMV control measures may be greater than 
initially predicted given the excess TB disease risk associated with HCMV.  
 
 
7.2 Study strengths and limitations 
TB research usually relies on small sample sizes due to the paucity of funding and the high cost of 
clinical trials. The large sample sizes used here allowed greater granularity in the investigation of 
mycobacterial antibody levels by age. The investigation of vaccines in the 2011 GPC round allowed 
the inclusion of BCG vaccine status in analysis.  
Using an established cohort such as the GPC, while a phenomenal source of data and biological 
material, does also have its limitations. Individuals are not routinely investigated for TB or LTBI. 
Therefore, some ‘non-TB individuals’ are likely to have LTBI that has not been identified. With 
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more stringent diagnosis, I may have been able to see differences in mycobacterial antibody levels, 
or data from the MGIA would have been clearer. In a similar vein, BCG vaccination status, although 
corroborated by TT IgG levels indicative of access of healthcare and EPI schedule vaccines, is not 
entirely robust.  
The GPC has recently started collecting PBMC however these were not available for the years 
studied for this PhD. With stored PBMC, we would be able to test for LTBI, as well as investigate 
mycobacteria-specific cellular changes associated with extent of HCMV infection.   
As mentioned previously, TB is not actively diagnosed and so I was limited by the total number of 
individuals diagnosed with active TB disease with accessible samples.  Because of this, I was under-
powered to look at trends in antibody and cytokine levels at various points leading up to TB 
diagnosis in the nested case control study.  
Despite meticulous planning and scheduling of experiments to minimise amounts of serum used, 
limitations of financial resource as well as physical band width resulted in prioritisation of assays 
and depletion of some samples.  
 
7.3 Opportunities for future work 
The points raised through this research beg the question as to whether the same associations 
would be evident in geographic areas where HCMV infection is not as ubiquitous but where TB 
disease is an important cause of mortality and morbidity. Examples being homeless people in high 
income countries or among incarcerated populations.  
 
Despite not having access to matched samples from an area with lower HCMV prevalence, in this 
study we do see that overall total IgG levels are much higher than reference values. Among the 
2,174 individuals included in the cross-sectional analyses, the mean total IgG levels are normally 
 188 
distributed around a mean of 6650 mg/dL with a range of 162 – 13118 mg/dL. The reference 
values for total IgG levels range between 500-1330mg/dL (mean 886.5 mg/dL) for Iranian 
adolescents [44] and 407–2170 mg/dL (mean 1118 mg/dL) for adults from Spain [45], and 251-
1349 mg/dL (mean for adults 994mg/dL) for US individuals [46,47]. As highlighted in work 
conducted for the first manuscript of this PhD thesis [6], there seems to be a paucity of 
information on reference values of widely-used measurements used for clinical diagnosis in sub-
Saharan African settings [48]. Although different techniques were used to study total IgG levels in 
the studies referenced above, the values found here in this study are over ten-fold higher than 
those of higher income countries. This work suggests that fundamental immune parameters 
should have reference values which are specific to the population of interest. The cross-sectional 
cohort used here would be well suited to investigate ranges of commonly-used reference values.  
 
Further work to continue the investigation into the importance of antibodies in TB may be fruitful. 
IgG subclasses exhibit functional differences in Fc receptor binding and complement activation; 
IgG1 and IgG3 are the most effective subclasses at complement activation whereas IgG2 can only 
weakly, and IgG4 cannot activate complement at all. IgG1 is the subclass most effective at 
complement-dependent cell lysis. In the example of HIV, elite controllers of viremia were linked to 
a higher IgG1/IgG3:IgG2/IgG4 profile which was independent of overall magnitude of antibody 
levels and individual effector functions [49]. Following recent work which identified differential 
glycosylation of the Fc portion of mycobacterial antibodies as being linked to active TB disease 
compared to LTBI, the samples from the nested case control study would be well placed to 
investigate qualitative changes such as this. 
 
Additionally, further investigation into the individuals seronegative for HCMV may be interesting. 
In an area with almost ubiquitous infection, it seems strange that some individuals are either not 
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exposed, or do not mount detectable antibody responses to HCMV antigens. This phenomenon is 
not unique to this cohort, seronegative individuals have been seen in studies across Africa [7]. It 
would be interesting to understand if these results are due to inadequate diagnostic tests or if 
these individuals really are seronegative. If the results are real over serial samples, are there any 
genetic associations or clinical advantages associated with protection from HCMV infection?  
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ELISA PLATE WORKSHEET – ELISAs MRC UGANDA JULY-AUGUST 2015 
ANALYST:  
DATE:  
ANTIGEN:  
PLATE NUMBERS:  
DILUTION FACTOR:  
SAMPLE INFO  
 
Stock concentrations: PPD – 0.5mg/mL, 85A – 0.82mg/mL, Goat anti-human – 0.1mg/mL (after 
reconstitution) 
REAGENTS 
Reagent Final 
concentration 
Stock 
concentration 
Batch number Volume 
Required 
(Solution and 
Stock) 
Capture Antigen     
Positive control     
Detection Antibody     
Coating buffer N/A N/A  N/A 
Blocking buffer N/A N/A  N/A 
Other reagents     
 
PLATE INCUBATION TIMES 
INCUBATION STEP START DATE/TIME STOP DATE/TIME 
Plate Coating (O/N) 
  
Blocking (1hr) 
  
Sample and Controls 
(2hrs) 
  
Detection Antibody (1hr) 
  
Substrate Development 
(15-25mins) 
  
Stop Reaction 
 
N/A 
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Plate Reading 
 
N/A 
 
ELISA PLATE MAP 
42 samples per plate (1 dilution in duplicate) 
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
Sample 
1 
1:100 
Sample 
2 
1:100 
Sample 
3 
1:100 
Sample 
4 
1:100 
Sample 
5 
1:100 
Sample 
6 
1:100 
Sample 
7 
1:100 
Sample 
8 
1:100 
Sample 
9 
1:100 
Sample 
10 
1:100 
Sample 
11 
1:100 
Sample 
12 
1:100 
B 
Sample 
1 
1:100 
Sample 
2 
1:100 
Sample 
3 
1:100 
Sample 
4 
1:100 
Sample 
5 
1:100 
Sample 
6 
1:100 
Sample 
7 
1:100 
Sample 
8 
1:100 
Sample 
9 
1:100 
Sample 
10 
1:100 
Sample 
11 
1:100 
Sample 
12 
1:100 
C 
Sample 
13 
1:100 
Sample 
14 
1:100 
Sample 
15 
1:100 
Sample 
16 
1:100 
Sample 
17 
1:100 
Sample 
18 
1:100 
Sample 
19 
1:100 
Sample 
20 
1:100 
Sample 
21 
1:100 
Sample 
22 
1:100 
Sample 
23 
1:100 
Sample 
24 
1:100 
D 
Sample 
13 
1:100 
Sample 
14 
1:100 
Sample 
15 
1:100 
Sample 
16 
1:100 
Sample 
17 
1:100 
Sample 
18 
1:100 
Sample 
19 
1:100 
Sample 
20 
1:100 
Sample 
21 
1:100 
Sample 
22 
1:100 
Sample 
23 
1:100 
Sample 
24 
1:100 
E 
Sample 
25 
1:100 
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REAGENT WORKSHEET – ELISAs MRC UGANDA JULY-AUGUST 2015 
ANALYST:  
DATE:  
 
10X PBS  
 
 
TO A 1L BEAKER, ADD: 
REAGENT AMOUNT LOT NUMBER TICK WHEN 
ADDED 
NaCl 80g   
KCl 2g   
Na2HPO4 14.4g   
KH2PO4 2.4g   
DEIONIZED WATER 800mL   
ADD STIR BAR AND LEAVE SPINNING UNTIL DISSOLVED 
CHECK pH – should be 7.4 If pH is higher than desired, use Hydrochloric acid, if lower, use 
sodium hydroxide 
Raise volume to 1L with deionized water 
 
COATING BUFFER 
BATCH NUMBER:   
DATE MADE:   
EXP:  
 
REAGENT AMOUNT LOT NUMBER TICK WHEN 
ADDED 
NaHCO3 8.4g   
Na2CO3 3.56g   
DEIONIZED WATER 1L   
ADD STIR BAR AND LEAVE SPINNING UNTIL DISSOLVED 
CHECK pH – should be 9.5 If pH is higher than desired, use Hydrochloric acid, if lower, use 
sodium hydroxide 
Raise volume to 1L with deionized water 
 
WASH BUFFER – MAKE 5L FOR 20 PLATES 
1XPBS w/0.05% T20 (v/v) 
BATCH NUMBER:   
DATE MADE:   
EXP: N/A 
 
BATCH NUMBER:   
DATE MADE:   
EXP: N/A 
   Appendix 200 
REAGENT AMOUNT LOT NUMBER TICK WHEN 
ADDED 
10XPBS 100mL   
DEIONIZED WATER 900mL   
Tween 20 0.5mL   
 
BLOCKING BUFFER/ASSAY DILUENT 
1xPBS w/5% MILK 
BATCH NUMBER:   
DATE MADE:   
EXP: 1 WEEK AFTER MADE: 
 
REAGENT AMOUNT LOT NUMBER TICK WHEN 
ADDED 
10XPBS 100mL   
DEIONIZED WATER 900mL   
MILK POWDER 50g   
 
TMB SUBSTRATE SOLUTION 
Prepare 6mL per plate working solution 15 minutes before it is needed. Mix equal volumes of 
Reagent A and B together and keep in the dark until needed.  
REAGENT AMOUNT LOT NUMBER TICK WHEN 
ADDED 
REAGENT A 3mL per plate   
REAGENT B 3mL per plate   
 
STOP SOLUTION 
2N H2SO4 or H3PO4 
REAGENT LOT NUMBER 
H2SO4  
 
COATING (PPD/85A): 
Both needed at 1.5ug/mL. Coat with 50uL per well 
PPD FDA   
LOT:  051815KA 
STOCK 
CONCENTRATION:  
0.5mg/mL 
Coating Buffer per 
plate:  
6mL 
PPD per plate: 18uL 
Aliquots made 7/7/15: 50uL per vial (enough 
for 4 plates) 
85A   
LOT:   
STOCK 
CONCENTRATION:  
0.82mg/mL 
Coating Buffer per 
plate:  
6mL 
85A per plate: 10.87uL 
Aliquots made 7/7/15: 80uL per vial (enough 
for 4 plates) 
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SECONDARY ANTIBODIES 
Reconstitute antibodies with 1mL filtered, deionized water. Aeras recon 0.1mg of antibody in 
1ml dioinised water giving conc of 0.1mg/mL. Need 6mL per plate. GOAT ANTI HUMAN 
SECONDARY – 1:500 (6ml per plate + 12uL of the Goat anti-human) 
TITRATIONS 
In separate non-treated 96-well V-bottom plate add 110uL of neat sample to wells (A-H row 1) 
according to plate map. Add 55ul sample diluent to dilution wells. Do a serial 1:2 dilution from 
row 1 to 12, taking 55uL of neat sample from row 1 into row 2, making sure to pipette up and 
down 4 times to thoroughly mix.  
Transfer 50uL into ELISA plate when ready.  
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APPENDIX 4 - Total IgG calculations 
 
TABLE 1 – 96-well plate layout with example duplicate data in rows A-G columns 1-12 (duplicate 
sample locations highlighted with boxes for columns 1-4 and row H). Total IgG standard curve 
dilutions and blanks are in row H, column 12 with concentrations detailed below row H. Data 
shown is OD reading at 450nm.  
 
 
TABLE 2 – Mean values of duplicate samples 
 
 
TABLE 3 – Mean OD for standard curve concentrations 
 
  
 
1 2 3 4 5 6 7 8 9 10 11 12
A 1.328 1.745 1.233 1.384 1.464 1.248 1.484 1.265 1.350 1.470 0.998 1.100
B 1.300 1.667 1.217 1.384 1.494 1.194 1.466 1.272 1.407 1.346 0.954 0.950
C 1.242 0.770 1.089 1.197 1.197 1.638 1.246 1.321 1.210 1.318 0.734 1.080
D 1.261 0.748 1.011 1.183 1.220 1.591 1.120 1.207 1.143 1.318 0.707 1.130
E 1.193 1.276 1.223 1.506 1.530 1.288 1.120 1.100 0.931 1.418 1.379 1.290
F 1.129 1.317 1.159 1.460 1.413 1.186 1.062 1.025 0.916 1.461 1.358 1.350
G 1.453 1.381 1.504 1.469 1.029 1.011 1.445 1.393 1.492 1.565 1.130 1.110
H 1.326 1.278 0.916 0.920 0.638 0.567 0.319 0.384 0.249 0.231 0.086 0.070
134.38ng/mL 67.19ng/mL 33.59ng/mL 16.8ng/mL 8.4ng/mL 0ng/mL
1 2 3 4 5 6 7 8 9 10 11 12
A 1.314 1.706 1.225 1.384 1.479 1.221 1.475 1.268 1.378 1.407 0.976 1.022
B
C 1.251 0.759 1.049 1.190 1.208 1.614 1.181 1.263 1.176 1.318 0.720 1.105
D
E 1.161 1.296 1.191 1.483 1.470 1.236 1.091 1.062 0.923 1.439 1.368 1.320
F
G 1.417 1.486 1.020 1.419 1.528 1.120
H
134.38 1.302
67.19 0.918
33.59 0.603
16.80 0.352
8.40 0.240
0 0.078
Mean 
Absorbance 
(OD)
Standards 
concentration 
(ng/mL)
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Figure 1 – Standard curve fit  
 
 
TABLE 4 – Total IgG ng/mL conversion using standard curve for duplicate measurements 
 
 
TABLE 5 – After linking sample locations to sample ID numbers, mean total IgG concentrations for 
test samples were multiplied by the dilution factor of 8x105 and converted into g/L by dividing by 
1x106. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0.00 20.00 40.00 60.00 80.00 100.00 120.00 140.00 160.00
M
ea
n
 A
b
so
rb
an
ce
Concentration (ng/mL)
Concentration vs Absorbance
1 2 3 4 5 6 7 8 9 10 11 12
A 121.913 163.928 112.371 129.431 139.614 111.912 139.191 117.040 128.809 131.859 85.634 90.622
B
C 115.212 62.372 93.522 108.616 110.597 154.141 107.687 116.419 107.119 122.350 58.237 99.469
D
E 105.460 120.027 108.680 140.033 138.693 113.548 97.956 94.869 80.025 135.368 127.764 122.528
F
G 132.922 140.416 90.377 133.160 144.886 101.104
Sample 
ID
Total IgG 
ng/mL Dilution 
CONCxDIL 
(ng/mL)
Total IgG 
(g/L)
843209 121.913 800000 97530674.432 97.5307
843227 163.928 131142015.250 131.142
843237 112.371 89896453.164 89.8965
843249 129.431 103544790.444 103.545
843254 139.614 111691589.431 111.692
843265 111.912 89529773.179 89.5298
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APPENDIX 5 – Sodium thiocyanate antibody avidity calculations  
 
TABLE 1 – 96-well plate layout of example data in rows A-H and columns 1-12 (duplicate samples 
are highlighted with boxes in columns 1-4). Column 1 and 2 contain the same sample diluted at 
1:100. Row A contains 0M NaSCN, row B, 1M NaSCN and so on. Data shown is OD reading at 
450nm. 
 
 
TABLE 2 – Mean OD values for duplicate samples. Boxed cells A2, A4, A6, A8, A10 and A12 show 
the value which is half the maximum OD (eg A1/2).  
 
 
TABLE 3 – After linking sample locations to sample ID numbers, avidity Index (AI) was calculated as 
the molar concentration of NaSCN required to reduce the measured OD to half of the maximum. 
 
NaSCN 
concentrations 1 2 3 4 5 6 7 8 9 10 11 12
0M A 1.073 1.086 1.289 1.277 1.068 1.138 1.803 1.776 0.403 0.393 1.955 1.860
1M B 0.270 0.282 1.063 1.077 0.415 0.433 1.626 1.599 0.387 0.381 1.270 1.230
2M C 0.148 0.154 0.929 0.899 0.326 0.323 1.515 1.503 0.325 0.305 0.979 0.980
3M D 0.108 0.115 0.588 0.615 0.212 0.228 1.265 1.279 0.263 0.265 0.653 0.650
4M E 0.071 0.080 0.209 0.205 0.115 0.115 0.843 0.823 0.157 0.155 0.305 0.300
5M F 0.054 0.051 0.091 0.088 0.068 0.071 0.239 0.259 0.043 0.038 0.105 0.110
6M G 0.052 0.046 0.047 0.040 0.059 0.061 0.082 0.077 0.025 0.019 0.063 0.080
7M H 0.052 0.049 0.036 0.035 0.049 0.046 0.059 0.062 0.020 0.017 0.073 0.070
NaSCN 
concentrations 1 2 3 4 5 6 7 8 9 10 11 12
0M 1.080 0.53975 1.283 0.6415 1.103 0.5515 1.790 0.89475 0.398 0.199 1.908 0.95375
1M 0.276 1.070 0.424 1.613 0.384 1.250
2M 0.151 0.914 0.325 1.509 0.315 0.980
3M 0.112 0.602 0.220 1.272 0.264 0.652
4M 0.076 0.207 0.115 0.833 0.156 0.303
5M 0.053 0.090 0.070 0.249 0.041 0.108
6M 0.049 0.044 0.060 0.080 0.022 0.072
7M 0.051 0.036 0.048 0.061 0.019 0.072
Sample 
ID
Avidity 
Index 
(AI)
901362 1.950
900378 2.981
906591 2.027
904643 3.603
902932 3.511
906595 2.509
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Abstract
Human cytomegalovirus (HCMV) infection has been associated with increased mortality,
specifically cardiovascular disease (CVD), in high-income countries (HICs). There is a pau-
city of data in low- and middle-income countries (LMICs) where HCMV seropositivity is
higher. Serum samples from 2,174 Ugandan individuals were investigated for HCMV anti-
bodies and data linked to demographic information, co-infections and a variety of CVD mea-
surements. HCMV seropositivity was 83% by one year of age, increasing to 95% by five
years. Female sex, HIV positivity and active pulmonary tuberculosis (TB) were associated
with an increase in HCMV IgG levels in adjusted analyses. There was no evidence of any
associations with risk factors for CVD after adjusting for age and sex. HCMV infection is
ubiquitous in this rural Ugandan cohort from a young age. The association between TB dis-
ease and high HCMV IgG levels merits further research. Known CVD risk factors do not
appear to be associated with higher HCMV antibody levels in this Ugandan cohort.
Introduction
Human Cytomegalovirus (HCMV), also known as human herpesvirus-5 (HHV-5), is a mem-
ber of the β-herpes virus family which is widely distributed in human populations. HCMV
transmission occurs through person-to-person contact. It can be transmitted transplacentally
to neonates or through breast milk of an infected and shedding mother, by intimate contact
and by transplantation from (or sharing syringes with) an infected individual [1]. It has been
shown that young children shed HCMV virus in saliva and urine at high levels which may add
to transmission between infants and adult caregivers [2].
Congenital HCMV infection is the leading cause of permanent hearing and neurological
impairment as well as vision loss in infants worldwide [3]. Maternal primary infection or
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reactivation, especially during the first trimester, is particularly associated with adverse neona-
tal outcomes [4]. The incidence of congenital HCMV infection is estimated at between 0.7 and
5% of all births in low- and middle-income countries (LMICs) [5].
In immunocompetent adults, HCMV infection rarely causes disease; however, once
infected, the virus remains latent in a wide range of cell types, including lymphocytes and mye-
loid lineage cells, as well as smooth muscle cells and endothelial cells which line blood vessels
[6]. HCMV/HIV co-infection is common and is an important cause of HCMV retinitis and
severe non-AIDS events, including death, in HIV-infected individuals [7,8]. HCMV infection
is associated with chronic immune activation [9] and recent evidence implicates immune acti-
vation with increased risk of tuberculosis (TB) disease [10].
Epidemiological studies in high-income countries (HICs) have found associations between
HCMV infection and increased risk of mortality in older people [11,12]. Further studies have
implicated chronic HCMV infection as a risk factor for cardiovascular disease (CVD); a recent
meta-analysis of studies conducted in HICs, estimated a 22% increased relative risk of CVD
with exposure to HCMV [13]. In a UK setting, HCMV infection was associated with the devel-
opment of arteriosclerosis [14] and a 3mmHg increase in systolic blood pressure among older
individuals [15]. As Africa undergoes what has been described as an ‘epidemiological shift’
from infectious to non-communicable disease [16], an estimated 1.2 million deaths in Africa
were attributed to CVD in 2004 [17].
Associations of HCMV and CVD have not been fully investigated in LMICs where HCMV
infection rates are much higher than in HICs [18–20]. Studies from other herpes viruses asso-
ciated with non-communicable disease (NCD) in areas where infection is ubiquitous (such as
EBV in relation to African Burkitt lymphoma and KSHV in relation to African Kaposi Sar-
coma), show that risk of NCD increases with increasing viral antibody titre [21–24].
In this study, we investigate HCMV seroprevalence in a large cross-sectional rural Ugandan
cohort (n = 2,174) and investigate associations with co-infections, clinical measurements and
demographic information. As a secondary analysis, we link cardiovascular risk factors to
HCMV antibody levels.
Material and methods
Study area and design
The General Population Cohort (GPC) is a population-based open cohort study, set up in
1990 by the Medical Research Council (MRC) UK in collaboration with the Uganda Virus
Research Institute (UVRI). Initially to examine trends in HIV prevalence and incidence, the
GPC is located in Kyamulibwa sub-county of Kalungu district, rural south-western Uganda
[25]. The cohort now comprises a cluster of 25 neighboring villages with approximately 20,000
residents (52% aged13 years) from three ethnic groups, the majority (75%) being from the
Baganda tribe, the main tribal group in the region.
Blood samples are transported to MRC/UVRI laboratories in Entebbe where a portion of
the venous blood sample is analysed according to protocol guidelines. Remaining samples are
stored at –80˚C in a biobank in Entebbe [25].
The majority of samples tested for HCMV in this study were taken from 2011. Samples from
TB cases were from a range of GPC rounds sampled between 1999 and 2014. Active pulmonary
TB was diagnosed through positive sputum smear microscopy after passive case detection.
Sampling
Individuals were selected at random, having been stratified by age and sex. Infants under 5
years of age were oversampled in anticipation of high age-dependent HCMV seropositivity
HCMV, TB and CVD
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based on evidence from other sub-Saharan countries. A target sample size of approximately
100 individuals per year of age from under 1 year to 5 year were sampled and 200 individuals
in 5 to 10 year age groups thereafter. The sex ratio was approximately equal within each age
group (Table 1).
The age structure of sampling for this study was determined based on Ugandan demo-
graphics; 49% of Ugandans are under 14 years of age, 21% are between 15–24 years of age,
28% between 25 and 64 years of age and only 2% over 65. The sampling here was similar to the
Ugandan demographic with 45% under 14 years, 18% 15–24, 32% 25–64 and 5% over 65 years
of age.
Being a cross-sectional study, each individual was only sampled once. Siblings and parent-
child pairs were not excluded.
Ethics
Written consent for the use of clinical records and biological samples for research purposes
was obtained from all GPC participants following Uganda National Council of Science and
Technology guidelines.
Ethical approval for the use of samples for this study was obtained from The UVRI Research
and Ethics Committee and from the Uganda Council for Science and Technology, in addition
to the London School of Hygiene & Tropical Medicine, London, UK.
HCMV serology
Serum samples were tested for antibodies against HCMV using standard, validated and com-
mercially available enzyme-linked immunosorbent assay (ELISA) against HCMV IgG (IBL
Table 1. General population cohort characteristics of individuals included in this study.
Age, mean (range) 22.7 (0.08–100.75)
Sex, percentage female (number/total) 50.2% (1,091/2,174)
HIV prevalence, percentage (number/total) 4.6% (100/2,134)
Body mass index, percentage (number/total)
- Underweight 21% (237/1,150)
- Normal 69% (797/1,150)
- Overweight 8% (97/1,150)
- Obese 2% (19/1,150)
Hypertension, percentage (number/total)
- Normal 46% (552/1,187)
- Pre-hypertension 39% (460/1,187)
- Hypertension 15% (175/1,187)
Tribe, percentage (number/total)
- Baganda 75% (1,524/2,035)
- Rwandese Ugandan 16% (319/2,035)
- Other § 9% (192/2,035)
body mass index 18.4 and below is underweight, 18.5–24.9 is normal, 25.0–29.9 is overweight, and 30 and above is
obese.
 Pre-hypertension is systolic blood pressure (SBP) between 120mmHg and 140 mmHg, and a diastolic blood
pressure (DBP) between 80 mmHg and 90 mmHg. Hypertension is defined as SBP140mmHg and DBP
90mmHg.
§ Other tribes include Bakiga, Batooro, Banyankole, Basoga, Bafumbira, Tanzanian, Barundi
https://doi.org/10.1371/journal.pone.0192086.t001
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International GmbH). Testing was conducted at UVRI in Entebbe. Briefly, serum samples
were thawed and diluted as per kit instructions to 1:100 in sample diluent. One hundred
microliters of diluted serum and controls in duplicate were dispensed into a 96-well plate
coated with HCMV antigen. Plates were covered and incubated for 1hr at 37˚C and then
washed before 100μL of anti-IgG conjugate was added and the plate covered and incubated
again for 30 minutes at room temperature. After another washing step, 100μL of tetra-methyl-
benzidine (TMB) substrate solution was added and the plate incubated for 15 minutes in the
dark at room temperature before 100μL of 0.2M sulphuric acid solution was added to stop the
reaction. Plates were read at 450/620nm within 30 minutes to obtain optical density (OD), a
surrogate marker of antibody titer.
Individuals were considered to be seropositive if the IgG OD measurement of plate controls
fell within the kit specifications and the mean of duplicate measurements was above the calcu-
lated cut off.
Linking to GPC data
Testing for HIV was carried out immediately after blood collection in Uganda as previously
described by Asiki et al [25]. Data were linked to the samples retrieved via each participant’s
unique GPC identifier.
Anthropometric measurements and blood sampling were performed by trained interview-
ers/nurses using calibrated instruments following standard protocol guidelines. Body mass
index (BMI) was calculated as weight (kg) divided by height (m)2. Pre-hypertension was
defined as having a systolic blood pressure (SBP) between 120mmHg and 140 mmHg, and a
diastolic blood pressure (DBP) between 80 mmHg and 90 mmHg. Hypertension was defined
as having a SBP140mmHg and DBP90mmHg. Proportion hypertensive was calculated by
dividing the number of hypertensive individuals by the combined number of normal and pre-
hypertensive individuals. Classification of BMI into four categories and definition of hyperten-
sion were derived from current World Health Organization (WHO) and National Institute of
Health guidelines, respectively [26,27]. Biochemical analyses were performed using the Cobas
Integra 400 plus analyser to determine lipid profiles for total cholesterol, high and low density
lipoproteins (HDL and LDL respectively) from serum samples, and HbA1c from whole blood
samples. Abnormal lipids were defined as raised total cholesterol being> 5.2mmol/L, low
HDL as< 1.0mmol/L for men, and< 1.3mmol/L for women [28].
Total IgG was measured by ELISA utilizing a commercial standard curve. Degraded sam-
ples with negative total IgG were excluded from the study.
Samples used in this study were linked to demographic and other clinical data correspond-
ing to the same time period at which the sample was taken.
Statistical analysis
Participants were categorized as either HCMV seronegative or seropositive based upon OD
results; seropositive samples were further categorized into tertiles of OD, to differentiate low,
medium and high responders. The Student’s t test was used to compare continuous variables
(such as HCMV IgG antibody OD measurement) between two independent groups (sex, tribe
(Baganda or other), HIV and TB status). Associations of HCMV IgG OD with age, tribe, sex,
HIV and TB were investigated. An analysis of variance (ANOVA) was used to compare con-
tinuous variable outcome between HCMV tertiles.
Linear regression was used to determine the relationship between HCMV IgG OD (as the
dependent variable) and sex, HIV and TB status (as the independent variables–tribe was
excluded in HCMV IgG OD regression analysis due to missing data– 10/27 active TB cases did
HCMV, TB and CVD
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not have information on tribe), and also between CVD risk factors with a continuous measure-
ment (dependent variables: HbA1c, cholesterol, HDL, LDL and BMI) and the independent
variables HCMV tertile, age and sex. Logistic regression was used for the binary outcome vari-
ables HCMV seropositive/seronegative and proportion hypertensive. Due to the approximate
two-fold increase in relative risk of coronary heart disease or acute myocardial infarction in
HIV-infected patients [29–31], associations between HCMV and CVD variables are limited to
HIV negative individuals in this analysis.
HCMV OD data were slightly positively skewed, possibly resulting in artificially narrower
confidence intervals (CI) around estimates. Cardiovascular disease (CVD) risk measurements
were available for individuals over the age of 12 years.
To account for evidence of non-linearity of HCMV OD with age (likelihood ratio test
p = 0.0025), a quadratic term for age was included in the regression analyses.
To account for multiple comparisons, 99% CI are reported and a p value of 0.01 is consid-
ered to represent strong evidence to reject the null hypothesis.
Data were entered using Microsoft Excel and analysed using STATA version 14 (Stata Cor-
poration, College Station, TX, USA).
Results
Of the 2,189 samples tested, 15 had negative total IgG levels and so were excluded due to prob-
able degradation of sample, resulting in 2,174 samples being included in initial analyses. Fol-
lowing these exclusions, 40 individuals did not have a valid HIV result and so were excluded
from regression analysis where HIV was included as a regression term.
Overall 91% (1,988/2,174) of the population tested positive for HCMV antibodies. Among
children less than 15 years of age, 1% (10/991) were HIV positive; among individuals over 15
years of age, 8% (90/1,143) were HIV positive. The highest proportion infected with HIV
(15%) was within the 41–50 year age group.
Factors affecting HCMV IgG antibody levels
The percentage of HCMV seropositive individuals in this population increases for both males
and females equally from birth until the 6–10 year age group, after which seropositivity levels
plateau at around 95% (Fig 1): 83% HCMV seropositivity was seen by age one year and this
increased to 95% by age five.
Because of the ubiquity of HCMV infection within this population it was decided to con-
duct further analyses on the HCMV seropositive population only. An analysis of the HCMV
negative population (n = 186, none of whom were TB cases and only 4 HIV positive) showed
no significant associations for sex or HIV in regression analysis. The only significant associa-
tion was with age in years (p<0.001).
Of the HCMV seropositive individuals, IgG levels initially decrease from a peak in those<1
year until the 16–20 year age group, after which HCMV IgG levels increase for both males and
females (Fig 2A). When HIV negative individuals are plotted separately, the increased HCMV
IgG levels in the 31–50 year old groups coincide with the highest HIV positivity (Fig 2B).
To investigate impact of age on HCMV IgG levels, ages were further split into < 9 months,
9 months to 12 years, 13–20 years, 20–60 and 60 years and above. Age groups selected are
based on presence of maternal antibodies (conservative estimate of 9months [32]), prior to
sexual debut (9 months—12 years [33]), post sexual debut (13–20 years [33]), 21–59 years and
post 60 years. It was found that infants under the age of 9 months have higher mean HCMV
IgG (1.25 OD) than any other age group apart from the over 60 years olds (1.34 OD) in unad-
justed analyses.
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A 0.07 OD increase in HCMV IgG (99% CI 0.02,0.12, p<0.001) is associated with being
female in unadjusted analyses. This increase remained after adjusting for age, HIV and TB
infection status (mean difference 0.07 OD 99% CI 0.03,0.11, p<0.001) (Table 2). The 0.49 OD
increase in HCMV IgG associated with HIV infection also remained after adjustment for age,
sex and TB infection status (mean difference 0.47 OD 99% CI 0.37,0.57, p<0.001) (Table 2).
Mean HCMV IgG OD levels among the 27 people with sputum-confirmed pulmonary TB
was 0.34 OD higher than individuals without active TB. After adjusting for age, sex and HIV
infection status this difference is partly explained by those variables but there remains good
evidence of that active TB disease is associated with an increased HCMV level of 0.19 OD
(99% CI 0.01,0.37, p = 0.006) (Table 2) which equates to a 7% increase based the range of
HCMV OD values (min 0.31, max 2.84 OD). When HCMV seropositivity was divided into
low, medium and high responders, the majority of active TB cases had high HCMV IgG levels
(16/27, 59%). Thirty three percent were of medium HCMV IgG (9/27), 7% (2/27) had low
HCMV, and none were HCMV seronegative (Fig 3).
When HIV positive and negative individuals are analysed separately, the effect of active TB
disease is shown to be greater in the HIV positive group, but the direction of effect is the same.
Among HIV negative people (S1 Table), having active TB disease is associated with an adjusted
increase of 0.11 OD of HCMV IgG (99% CI -0.10–0.33, p = 0.170) whereas among the HIV
positive individuals (S2 Table), having active TB disease is associated with an increased
HCMV IgG OD of 0.32 OD (99% CI -0.12,0.77, p = 0.063).
Fig 1. Percent HCMV seropositive by age group (years). Vertical lines show 99% CI for each mean data point. CI—confidence interval, HCMV—human
cytomegalovirus.
https://doi.org/10.1371/journal.pone.0192086.g001
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Being from a tribe other than the majority Baganda tribe was associated with a 0.14 OD
increase in HCMV IgG (99% CI 0.09,0.19, p<0.001). Due to missing data (10/27 active TB
cases did not have information on tribe), and the fact that inclusion of tribe into regression
analyses did not alter mean difference coefficients, this variable was not included in regression
analyses. Although not included, a sensitivity analysis resulted in a change in coefficient
for sex from 0.068 to 0.070 OD, a change in coefficient for hiv from 0.466 to 0.454 and a
change in coefficient for TB from 0.193 to 0.184. The coefficient for tribe was 0.11 OD 99% CI
0.06–0.16.
Association of HCMV IgG levels with cardiovascular disease risk factors
Cardiovascular risk factors were assessed in individuals over 12 years of age (mean age of indi-
viduals included in CVD risk factors analysis: 36.5 years, range 12–100 years) due to availabil-
ity of data.
Fig 2. Fig 2A. Mean HCMV IgG OD levels in HIV negative, HCMV seropositive individuals by age group (years) and sex. Fig 2B. Mean HCMV IgG OD levels in
HIV negative and HIV positive individuals combined by age group (years) and sex. Red lines show female mean values, blue shows male mean values. Vertical lines
show 99% CI for each mean data point. CI—confidence interval, HCMV—human cytomegalovirus, HIV—human immunodeficiency virus.
https://doi.org/10.1371/journal.pone.0192086.g002
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Because of the known increased risk of CVD in HIV-infected individuals, associations
between HCMV and CVD predictors is limited to HIV negative individuals in this analysis,
who represented 94% (2,034/2,174) of the total sample.
Of the 2,034 HIV negative individuals included in this analysis, data for cholesterol, HDL,
LDL, and mean SBP and DBP were available for 58% (1,186) of individuals, HbA1c levels for
58% (1,176) and BMI measurements were available for 57% (1,150) of individuals, all of whom
were over the age of 12 years.
Among the individuals for whom BMI data was available in this cohort, 21% (237/1,150)
were underweight, 69% (797) normal weight, 8% (97) overweight and 2% (19) obese. Of the
1,0186 individuals with measured blood pressure, 15% (175) were hypertensive, 39% (460)
were pre-hypertensive, and 46% (552) were not hypertensive (Table 1).
Initial regression analyses showed no evidence of a difference between CVD risk factors
between HCMV seropositive and HCMV seronegative individuals in a model adjusting for
age and sex. When HCMV seropositive individuals were further divided into low, medium
and high responders, the only CVD risk factor that showed an association with HCMV IgG
levels in univariate analysis was hypertension, which is more prevalent in people with medium
or high HCMV IgG levels (Fig 4). After adjusting for age and sex however, this association is
explained by these variables (Table 3). Addition of tribe as an explanatory variable in regres-
sion analyses did not alter coefficients.
Discussion
HCMV is an important pathogen in congenital neurological conditions and in the context of
immune suppression. Recent studies have suggested a link between HCMV seropositivity and
excess overall mortality, specifically from CVD, within HIC settings [12–15,34]. Relatively little
attention has been paid to determining HCMV prevalence and associations with non-commu-
nicable disease in LMICs.
Here, we find that 95% of this rural Ugandan population are seropositive for HCMV by age
five years (Fig 1). This finding corroborates other findings in sub-Saharan African settings
where high levels of HCMV seropositivity have been found; 96% in Egypt [35], 97% in Benin
[36], 99% in the Gambia [37] and 86% in South Africa [38].
Table 2. Unadjusted and fully adjusted mean differences (values obtained using a multivariable model including age, quadratic age, sex, HIV and TB status) in
HCMV IgG OD with p value (t test for unadjusted values, regression for adjusted values) and 99% confidence intervals.
Factor (n) HCMV IgG
Unadjusted mean difference P value 99% CI Adjusted mean difference P value 99% CI
Sex
Male (978) baseline baseline
Female (978) 0.07 <0.001 0.02, 0.12 0.07 § <0.001 0.03, 0.11
HIV †
Negative (1,860) baseline baseline
Positive (96) 0.49 <0.001 0.40, 0.60 0.47 <0.001 0.37, 0.57
TB ‡
Negative (1,929) baseline baseline
Positive (27) 0.34 <0.001 0.15, 0.53 0.19 0.006 0.01, 0.37
CI—confidence interval, HCMV—human cytomegalovirus
†HIV—human immunodeficiency virus
‡TB–Active pulmonary Tuberculosis.
https://doi.org/10.1371/journal.pone.0192086.t002
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Among the HCMV seropositive population in this study we see high levels of HCMV IgG
antibody in young infants under the age of nine months (Fig 2). While this may be a true
reflection of congenital or primary infection of infants, IgG is the only antibody isotype that
can be transferred through the placenta [39], and so these high levels may be driven by the
inability of the assay to distinguish between maternal and ‘self’ IgG. Detection of virus as
opposed to antibodies would allow elucidation during the first nine months of life while mater-
nal antibodies persist.
After initial high levels of HCMV IgG in infants under the age of one year, we see a rapid
decline whereby maternal antibodies are lost, or primary infection is controlled (but individu-
als remain seropositive), followed by a gradual increase from the age of 16 years of age up to
the highest OD levels seen after 40 years of age.
The magnitude of antibody response to virus after maternal antibodies have waned is indic-
ative of intensity of exposure. The finding that females have higher HCMV antibody levels
compared to males after adjusting for age, HIV and TB (Table 2) was surprising. There is evi-
dence that risk factors throughout life result in a higher risk of HCMV transmission in women
compared to men; a study conducted in Uganda using data on breast feeding trends, showed
Fig 3. Number of active TB cases by HCMV IgG tertile. Numbers above bars show number of active TB cases (n = 27 total active TB cases).
https://doi.org/10.1371/journal.pone.0192086.g003
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Fig 4. Bar graphs showing unadjusted mean CVD risk factors by HCMV IgG OD level. HIV positive individuals were excluded from this analysis. Mean and 99%
CI with p value from linear regression or logistic regression (for hypertension). p values shown are from age- and sex-adjusted likelihood ratio tests. CI—
confidence interval, CVD—cardiovascular disease, HCMV—human cytomegalovirus, HIV—human immunodeficiency virus.
https://doi.org/10.1371/journal.pone.0192086.g004
Table 3. Age and sex-adjusted regression for CVD risk factors cholesterol, HbA1c, HDL, LDL and BMI and hypertension showing mean difference (or Odds Ratio),
p value from likelihood ratio test and 99% CI.
HbA1c (%) Cholesterol (mmol/L) HDL (mmol/L) LDL (mmol/L) Hypertension
(proportion)
BMI (mg/kg2)
HCMV
level
Mean
difference
p value 99% CI Mean
difference
p
value
99%
CI
Mean
difference
p
value
99%
CI
Mean
difference
p
value
99%
CI
Odds
ratio
p
value
99%
CI
Mean
difference
p
value
99%
CI
Negative baseline baseline baseline baseline baseline baseline
Low -0.032 0.803 -0.26,
0.20
-0.113 0.076 -0.43,
0.20
0.007 0.450 -0.14,
0.15
-0.080 0.023 -0.34,
0.18
1.073 0.878 0.34,
3.35
-0.485 0.175 -1.69,
0.72
Medium -0.072 -0.30,
0.16
-0.172 -0.49,
0.14
0.025 -0.12,
0.17
-0.159 -0.41,
0.10
1.095 0.36,
3.34
-0.736 -1.93,
0.46
High -0.046 -0.28,
0.19
-0.266 -0.58,
0.05
-0.028 -0.17,
0.12
-0.234 -0.49,
0.02
1.256 0.42,
3.78
-0.910 -2.12,
0.30
CI—confidence interval, CVD—cardiovascular disease, HDL—high density lipoproteins, LDL—low density lipoproteins, BMI—body mass index
https://doi.org/10.1371/journal.pone.0192086.t003
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that being a male baby increased the risk of early termination of breastfeeding compared to
females [40]. Findings from another Ugandan longitudinal cohort found that age at sexual
debut has been consistently lower for women than for men from the 1950’s to 1990’s [33]. In
addition, the infant caregiving role of females results in disproportionate female interaction
with infants during the peak shedding at 1–2 years of age [41].
Our results suggest that HIV infection and active TB disease are independently associated
with increased levels of HCMV IgG antibodies (Table 2). HIV infection is correlated with
hypergammaglobulinaemia by way of defective humoral immunity resulting in hyperactivated
naive B cells producing large quantities of IgG [42]. Here we see an association between HIV
infection and elevated IgG specific to HCMV, however in the same cohort, we see increased
total IgG as well as tetanus toxoid-specific IgG in HIV-infected individuals, an association
which remained after adjusting for age and sex (Stockdale et al, manuscript in preparation).
Despite this potential confounding of HIV infection upon IgG levels, the increased levels of
HCMV IgG in HIV infected individuals is corroborated by epidemiological evidence pointing
towards high levels of HIV and HCMV co-infection due to similar routes of transmission [7].
Both TB and HIV are known to increase general inflammation [43,44], an immune envi-
ronment which is associated with the increased likelihood of HCMV reactivation [45]. Both
reactivation and reinfection expose the immune system to HCMV antigens, thereby resulting
in elevated levels of HCMV-specific IgG antibodies.
The association of active pulmonary TB with raised HCMV IgG levels was in contrast to
findings of a hospital-based study where HCMV-specific T-cell responses in a whole blood
assay were found to be lower in TB patients who died when compared to TB patients who sur-
vived [46]. In this hospital-based study, HCMV responses were likely a general indictor of
‘immune fitness’ and therefore predictive of patient survival. By contrast, our study was com-
munity based and the severity of TB disease at the time of blood draw would have been low
when compared to a hospital-based study.
The association of active pulmonary TB with raised HCMV IgG in our study was consistent
with the findings of a correlates of TB risk study in South African infants where risk of active
TB disease was increased with an activated T-cell phenotype which was itself correlated with
T-cell interferon gamma production upon stimulation with HCMV antigens [10]. Neither
active case finding, nor routine latent TB infection screening is conducted in the Ugandan
GPC and therefore we cannot be certain that ‘non-TB’ individuals here have not been exposed
to TB or indeed that they are not latently infected with Mycobacterium tuberculosis. Despite
there only being 27 active TB cases within this cohort, there remains strong evidence of an
association between TB and elevated HCMV IgG after adjusting for age and sex; an association
which appears to be intensified by co-infection with HIV (S1 and S2 Tables).
In view of the 1.5 million deaths per year associated with TB [47], the association of
increased HCMV IgG with active TB disease may be an important future research area, espe-
cially in areas with large numbers of people living with HIV.
It is important to note that the data from this study gives us no information on causality.
Longitudinal studies measuring systemic viral loads along with antibody levels to HCMV (and
other herpes viruses) in stored sera would be useful to understand progression of both herpes
virus and TB disease in this cohort.
Association of HCMV with CVD risk factors
Rates of CVD are increasing in sub-Saharan Africa [48]. In 2014, the WHO estimated that
27% of all deaths in Uganda were attributable to non-communicable diseases; specifically 9%
of all deaths to CVD [49]. In HICs it has been postulated that the increased overall mortality
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associated with HCMV infections is associated with vascular morbidity [34]. HCMV infection
has been implicated in increased arterial stiffness in chronic kidney patients [14] and in older
individuals in the UK [15], and there is growing evidence of an important role for HCMV-
induced inflammation in vessel walls [50] through persistent replication of HCMV in endothe-
lial cells [6].
The current literature reports conflicting evidence for an association of HCMV infection
with increased risk for CVD mortality. Of the ten studies included in a recent meta-analysis
which found an excess risk of ischemic heart disease, stroke, and cardiovascular death with
HCMV exposure [34], none were carried out in sub-Saharan Africa or other LMICs (studies
were from United States (4 studies), United Kingdom (3 studies), Canada (1 study), Sweden (1
study), and Italy (1 study)). Another large meta-analysis comprising three studies and 9,657
patients found an overall significant association between HCMV positivity and hypertension
(79% of the hypertension patients were HCMV positive compared with 64% of the controls–
(Odds Ratio (OR) 1.39, 95% CI 0.95,2.05, p = 0.017) [13]. Of the three studies included, one
was carried out in the USA, one in Iran and one in China. The overall OR masks large hetero-
geneity in the data, with the Iranian study showing high levels of HCMV seropositivity (93%
overall seropositivity) and no association, while the US study reported 55% HCMV seroposi-
tivity and association between HCMV and hypertension among males only [13]. In one US
population, association of HCMV seropositivity with all-cause mortality remained after
adjusted analysis, however specific association with CVD mortality disappeared after adjusting
for confounders [51] and in another, an association with hypertension was largely explained
away by age [52].
The aforementioned studies investigated HCMV seropositivity in relation to CVD risk
factors. In our study we investigate magnitude of antibody response to HCMV in a near-
ubiquitously infected population. We do not see an association between the burden of
HCMV infection, as measured by IgG, and CVD risk factors. It may be that the association
between HCMV and CVD is masked due to burden of other chronic and acute infections in
these communities. However more studies are needed to determine any association with
excess mortality in populations with ubiquitous HCMV infection, and to assess if risk fac-
tors found to be important in one population are useful indicators of risk in other popula-
tions. Indeed, many studies have found reference standards developed in Europe and North
America unhelpful when studying other populations [53,54]. It is essential that measure-
ments are clinically relevant to the population in question, and that clinical research institu-
tions ensure that standardized methods are used if data are to be comparable across
countries and continents.
Despite the young age of individuals in this cohort (mean age 36.5 years, range 12–100
years), we do know that CVD outcomes (such as stroke) are not uncommon [55] and so these
analyses could be expected to show association with HCMV antibodies if any exist. Evidence
from a large cohort study in the US found that CVD risk factors linked to myocardial infarc-
tion and coronary heart disease death in later life are measurable in individuals as young as 20
years of age [56].
Despite an established link between HCMV serum antibody levels and blood viremia (and
viral shedding in urine and saliva) among children [57], and the link between high systemic
viral copy number and increased risk of mortality in HIV positive adults [58], it may be of
interest in future studies to link viral load and risk factors to active HCMV disease in this pop-
ulation. Due to limited sample volume here, we were unable to measure viral DNA copy num-
ber in this study.
Considering the paucity of studies linking HCMV and all-cause mortality in LMIC settings
and the association seen here between HCMV and TB, we believe it will be important to
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conduct longitudinal studies to elucidate these associations further in areas with almost uni-
versal prevalence of HCMV infection, specifically in sub-Saharan Africa.
Limitations
The GPC has no official vital registration system and so we do not have CVD outcomes to link
to CVD risk factors. Future studies which specifically investigate CVD related deaths within
the GPC would be helpful to link HCMV antibody levels in longitudinal retrospective analyses
using stored sera. The GPC is perfectly placed to collect CVD outcome data in future rounds
of data collection and so these outcome measures can be linked back to clinical measurements
and stored biological samples.
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Abstract objectives A growing evidence base implicates human cytomegalovirus (HCMV) as a risk factor
for TB disease. We investigated total IgG and mycobacteria-specific antibodies in a cross-sectional
study nested within a rural Ugandan General Population Cohort (GPC), in relation to HIV infection
and the magnitude of HCMV IgG response.
methods Sera from 2189 individuals (including 27 sputum-positive TB cases) were analysed for
antibodies against mycobacteria (Ag85A, PPD, LAM, ESAT6/CFP10) and HCMV, tetanus toxoid
(TT) and total IgG.
results Anti-mycobacterial antibodies increased with age until approximately 20 years, when they
plateaued. Higher HCMV exposure (measured by IgG) was associated with lower levels of some anti-
mycobacterial antibodies, but no increase in total IgG. HIV infection was associated with a decrease
in all anti-mycobacterial antibodies measured and with an increase in total IgG.
conclusions The increase in anti-mycobacterial antibodies with age suggests increasing exposure to
non-tuberculous mycobacteria (NTM), and to M.tb itself. HIV infection is associated with decreased
levels of all mycobacterial antibodies studied here, and high levels of HCMV IgG are associated with
decreased levels of some mycobacterial antibodies. These findings point towards the importance of
humoral immune responses in HIV/TB co-infection and highlight a possible role of HCMV as a risk
factor for TB disease.
keywords TB, HIV, HCMV, Mycobacterium
Introduction
The role of antibody-mediated immunity in TB has not
been fully elucidated (reviewed in [1]). Despite the impor-
tance of cell-mediated Th1 responses in TB disease [2, 3],
attempts to stimulate this arm of the human immune
response by vaccine developers have not translated into
protection from disease in human efficacy trials [4, 5],
and there may be useful humoral correlates of disease or
protection yet to be identified.
A growing evidence base for the importance of anti-
bodies in protection against other intracellular pathogens
such as Listeria monocytogenes [6] and Salmonella spp.
[7] has led to renewed interest in humoral responses to
TB and the factors which may affect them. Recent work
has suggested a potential protective role of antigen 85A
(Ag85A)-specific antibodies in reduced TB disease risk in
BCG-vaccinated South African infants [8, 9].
It is known that TB and HIV work synergistically to
exacerbate morbidity and mortality in co-infected individ-
uals with respect to both diseases [10]. Epidemiologically,
concomitant viral infections other than HIV are known
to be associated with poor TB outcomes. In Taiwan
Hepatitis C infection was associated with a higher risk of
developing active TB disease [11], and in South Africa
influenza/TB co-infection was associated with increased
mortality [12]. A large TB vaccine trial in South Africa,
which investigated correlates of TB disease risk or protec-
tion, found an association between CD8 T-cell activation
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and HCMV response [8] that was linked to an increased
risk of TB disease and shorter time to diagnosis [13].
The ubiquitous herpes virus HCMV is known to cause
immune activation [14], immune senescence [15], and is
a significant factor in immune variation [16]. Recently,
our group has reported elevated levels of HCMV IgG
among TB patients compared to controls [17]. Despite
this, and the findings of some early epidemiologic studies
[18, 19], data linking HCMV and TB are sparse.
To investigate mycobacteria-specific antibody levels
across ages, and to examine potential effects of HCMV
co-infection on antibody levels, this study tested 2187
stored serum samples (of which 27 were active TB cases)
from a rural Ugandan cohort for IgG responses to
Ag85A, purified protein derivative (PPD), lipoarabino-
mannan (LAM) and CFP10/ESAT6, along with IgM
responses to Ag85A. These antigens were chosen based
on availability, evidence of their potential importance in
TB disease from the literature (Ag85A [9], LAM [20, 21],
PPD [22]), and specificity to M.tb (CFP10/ESAT6 [23]).
Seropositivity to HCMV was measured and existing data
on HIV, BCG vaccination status, as well as demographic
information was matched and investigated for associa-
tions. Responses to tetanus toxoid (TT) and total IgG
levels were also investigated as control antibodies.
Materials and methods
Study area and design
The General Population Cohort (GPC) is a population-
based open cohort study in rural south-western Uganda,
administered by the Medical Research Council (MRC)
UK in collaboration with the Uganda Virus Research
Institute (UVRI) [24]. The cohort comprises a cluster of
25 neighbouring villages with approximately 20 000 resi-
dents (52% aged <13 years) from three ethnic groups,
the majority (75%) being from the Baganda tribe, the
main tribal group in the region. Data are collected
through an annual census, questionnaire and serological
survey (further details on questions included in the census
can be found in a publication by Asiki et al. [24]).
Demographic information was collected at the same time
as the blood samples. Blood specimens were obtained
and immediately tested for HIV-1. Samples with incon-
clusive results were retested. Remaining sera were stored
at 80 °C. All samples used for this study, except active
TB cases, were collected from adults and children in GPC
round 22, conducted in 2011. Active TB cases were diag-
nosed through positive sputum smear microscopy after
passive case detection and were sampled from a range of
GPC rounds between 1999 and 2014. Sera collected as
close as possible to the time of TB diagnosis were used
for this study (between 5 years prior to, and 0.8 years
after diagnosis of active TB diagnosis).
Sampling
Individuals were selected for inclusion in this cross-sec-
tional study at random after stratification by age and sex.
Due to anticipated high levels of HCMV seropositivity,
infants under the age of 5 were oversampled. Individuals
were only sampled once and siblings and parent-child
pairs were not excluded. The total planned sample size
was 2000, plus 10% oversampling. A target of approxi-
mately 100 individuals per year of age up to 5 years, 200
individuals aged 6–10, 11–15 and 16–20, 200 in subse-
quent 10-year intervals up to 60 years and 200 people
aged 61 years or over. The sex ratio was approximately
equal within each age group (Table 1).
Ethics
Written consent or assent in conjunction with parental/
guardian consent for those younger than 18 years were
obtained following Uganda National Council of Science
and Technology (UNCST) guidelines before all survey
procedures [24]. Written consent/assent was also
obtained from participants on the use of their clinical
records and stored biological samples for research
purposes.
Ethical approval for the use of GPC samples for this
study was obtained from the UVRI Research and Ethics
Committee and from the UNCST, in addition to the Lon-
don School of Hygiene & Tropical Medicine (LSHTM),
London, UK.
Serology: Ag85A, PPD, LAM, CFP10/ESAT6 and TT
Antibody content was measured using ELISA. Experi-
menters were blind to exposure group for all samples.
Testing was conducted at UVRI in Entebbe, Uganda
(Ag85A IgG and PPD IgG) and LSHTM, London, UK
(CFP10/ESAT6 IgG, Ag85A IgM, LAM IgG and TT
IgG). Half volume ELISA plates (Fisher Scientific) were
coated overnight at 4 °C with sodium carbonate buffer
containing 1.5 lg/ml recombinant Ag85A protein (Aeras,
USA), 1.5 lg/ml PPD (Lot 051815KA, Aeras, USA),
0.5 lg/ml TT (02/232, NIBSC, UK), 0.5 lg/ml LAM
(NR-14848, BEI Resources, VA, USA), 0.25 lg/ml each
CFP10 (NR-49425, BEI Resources, VA, USA) and ESAT6
(NR-14868, BEI Resources, VA, USA). Plates and
reagents were brought to room temperature and the plate
was washed three times with PBS, 5% Tween20 (v/v)
(PBST). After blocking with PBS 5% milk (w/v) blocking
2 © 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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buffer, duplicate 1:100 test serum, high and low PPD
responder controls and plate blanks consisting of assay
diluent alone with no serum were added in triplicate.
Incubation for 2 h at room temperature and washing
with PBST was followed by a one hour incubation with
an appropriately diluted peroxidase-conjugated secondary
antibody in PBST-5% (IgG, 1:500 dilution of goat anti-
human IgG-HRP (04-10-20, KPL, USA); IgM, 1:10 000
dilution of goat anti-human IgM-HRP (Abcam ab97205,
RRID: AB_10695942)). After washing with PBST, 50 ll
tetramethylbenzidine (TMB, BD BioSciences, USA) was
added to each well. The plate was incubated for 15 min
in the dark before the reaction was stopped by adding
50 ll of 2M Sulphuric Acid (Sigma, USA) to each well.
Absorbance was measured at 450 nm within 30 min to
obtain optical density (OD), a surrogate marker of anti-
body titre.
Mean blank values were subtracted from all OD read-
ings, and geometric means of duplicates were used to
reduce the effect of skewed distribution. Median levels
with interquartile ranges (IQR) are used for graphical
representation of antibody levels in Figures 1 and 2.
Total IgG serology
All samples were tested for total IgG content at LSHTM.
As above, half volume ELISA plates were coated over-
night with mouse anti-human IgG at 0.5 lg/ml (Abcam
ab200699). IgG antibody standards (134.4–8.4 ng/ml)
were prepared by diluting purified human IgG (Sigma
I4506, RRID:AB_1163606) in PSBT-5% milk and test
sera were diluted 8 9 105 in PBST-5% Milk. Duplicate
test samples, controls and blanks were incubated for one
hour at 37 °C, and, after washing, samples incubated
with peroxidase-conjugated goat anti-human Fc (Abcam
ab97225, RRID: AB_10680850) diluted 1/500 with
PBST-5% Milk for one hour at room temperature. Plates
were developed with TMB, and sulphuric acid was added
to stop the reaction. Plates were read at 450 nm and OD
measurements converted into g/l by use of the standard
curve on each plate.
Serology HCMV
Samples were tested for IgG antibodies against HCMV
using a commercial ELISA kit (Novatec Immunodiagnos-
tica GmbH) according to kit instructions (described in
[17]).
Statistical analysis
Correlations between each pair of mycobacterial antibody
OD levels were conducted using Spearman’s rho. Because
of the ubiquity of HCMV infection within this popula-
tion [17], analysis was conducted on the HCMV-seropo-
sitive population only.
Individuals seropositive for HCMV IgG were further
categorised into three groups according to the tertiles of
HCMV antibody concentrations (measured by OD): low,
medium and high.
Linear regression was used to determine the association
of each antibody response (as continuous dependent
Table 1 Characteristics of study partici-
pants (HCMV seropositive individuals by
age group (n = 1988)). Sex, HIV infec-
tion, BCG vaccination and TB case preva-
lence is shown for each age group
Age
group
(year) n
Sex (percentage
female
(number/total))
HIV prevalence,
percentage
(number/total)
BCG vaccinated,
percentage
(number/total)
Active TB
cases,
percentage
(number/total)
<1 75 47% (35/75) 4% (3/73) 76% (54/71) 0% (0/75)
1 83 51% (42/83) 1% (1/80) 96% (73/76) 0% (0/83)
2 82 52% (43/82) 1% (1/78) 90% (63/70) 0% (0/82)
3 87 47% (41/87) 1% (1/85) 93% (70/75) 0% (0/87)
4 100 52% (52/100) 0% (0/97) 94% (82/87) 0% (0/100)
5 106 54% (57/106) 1% (1/101) 8% (80/90) 0% (0/106)
6–10 183 47% (86/183) 1% (2/175) 90% (135/150) 0% (0/183)
11–15 192 49% (94/192) 0% (0/187) 81% (125/155) 1% (1/192)
16–20 204 51% (105/204) 1% (3/204) 69% (132/190) 0.5% (1/204)
21–30 216 56% (120/216) 9% (19/216) 70% (128/184) 2% (5/216)
31–40 238 52% (123/238) 13% (31/238) 57% (119/209) 4% (10/238)
41–50 166 45% (74/166) 15% (25/166) 52% (75/145) 4% (6/166)
51–60 109 49% (53/109) 6% (7/109) 53% (52/98) 4% (4/109)
61+ 147 46% (68/147) 1% (2/147) 26% (37/144) 0% (0/147)
Total 1988 50% (993/1988) 5% (96/1956) 70% (1225/1744) 1.4% (27/1988)
© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 3
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variables) with HCMV IgG tertile and HIV infection (as
independent variables with HCMV as a categorical vari-
able), adjusting for age and sex. BCG vaccination status
and active TB disease were also included in the regression
model, however as 89% (24/27) of active TB cases had
unknown BCG status, it was not possible to include both
variables in the same model. The model including TB
was preferred, with the model including BCG run as a
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comparison to confirm the consistency of the results.
BCG vaccination was included in a separate regression
analysis using the same model.
Individuals with unknown HIV status were excluded
from all regression analyses and individuals with
unknown BCG vaccination status were excluded from
regression analyses including BCG. To account for evi-
dence of non-linearity of antibody OD with age (likeli-
hood ratio test P < 0.001 for all antibodies), a quadratic
term for age was included in the regression analyses.
Numbers included in each of the regression analyses are
shown in Tables 2 and 3.
To account for multiple comparisons, 99% confidence
intervals (CIs) are reported and a P value of 0.01 was
considered to represent strong evidence to reject the null
hypothesis. Due to different dynamic ranges of spec-
trophotometers used in Uganda and the UK, antibody
OD measurements (for mycobacterial antibodies only)
were rescaled for graphical representation. This was
done by subtracting the minimum value within the range
from each value, dividing by the range for that antibody
and multiplying by 100; hence Figure 1 shows the per-
centage of the maximum OD. All analyses were per-
formed on raw data using Stata version 14 (Stata
Corporation, College Station, TX, USA). Anonymised
participant data are available.
Results
Sera were sampled from 2189 individuals. Total IgG
levels could not be determined in 15 instances, likely due
to protein degradation. Of the remaining 2174 individu-
als, 8.6% (186/2174) were HCMV-seronegative and were
excluded from analysis. The HCMV-negative population
contained no TB cases and 4 HIV-positive individuals.
Ninety-eight (53%) were female and the mean age was
14.6 years (range 3 months–95 years).
The remaining 1988 individuals were included in fur-
ther analyses. The mean age was 23.4 years (range
30 days–100 years) and 50% were female (Table 1).
Ninety-eight per cent (1956/1988) of individuals had a
conclusive HIV result, and of those, 4.9% (96/1956)
were HIV-positive, with the greatest proportion in the
31–50 year age group.
Twenty-seven sputum-confirmed TB cases were
included in the study, of whom 63% (17/27) were female
and whose mean age was 36 years (range 12–59 years).
Only three TB cases had BCG vaccination information
and all of those were unvaccinated. All 27 were HCMV-
seropositive, with 59% (16/27) having HCMV IgG levels
in the upper tertile.
Antibody responses
IgG against Ag85A, PPD, LAM, CFP10/ESAT6 and IgM
against Ag85A all increased from birth to approximately
20 years of age, after which OD values reached a pla-
teau. Figure 1 shows median OD for each of the
mycobacterial antibody levels by age group. Initial levels
in infants under the age of one year range from a median
of 4% of maximum OD (0.12 OD) for Ag85A IgM to
12% of maximum OD (0.35 OD) for LAM IgG.
Responses to the M.tb-specific ESAT6/CFP10 antigens
did not show the same rapid increase from birth as
responses to other mycobacterial antibodies. The highest
10% of responders in terms of CFP10/ESAT6, being
M.tb specific antigens, were investigated further and there
was no evidence of a difference in proportion of TB cases or
HIV positive individuals compared with the lowest 10%.
Univariate analysis showed no differences in mean OD
levels by sex. Analysis of correlation showed a high
degree of co-linearity between all mycobacterial antibod-
ies (0.33> rho <0.65, all P < 0.001). OD ranged from
0.002 to 1.793 OD for Ag85A IgG, 0.000 to 1.930 OD
for PPD IgG, 0.004 to 2.961 OD for LAM IgG, 0.005 to
2.927 OD for CFP10/ESAT6 IgG and 0.001 to 2.926
OD for Ag85A IgM.
Tetanus toxoid and total IgG levels were investigated
as control antibodies (Figure 2). TT vaccination induces
high levels of TT IgG and is given at birth and to preg-
nant females as part of the Uganda immunisation sched-
ule [25]. TT IgG showed high levels of antibody from
birth and a clear sex difference with females having
higher overall IgG levels (P < 0.001, Figure 2a). This
difference is driven by females aged between 16 and
50 years (Figure 2a). Total IgG levels increase with age
from birth (median 46.2 g/l in infants less than one year
of age) to a plateau after 11 years of age (median
69.4 g/l), Figure 2b. Since a univariate analysis of total
IgG by sex indicated no difference, data were not sepa-
rated by sex for this plot.
In a multivariable linear regression model including TB
disease status, being HIV-positive was associated with a
decrease in all mycobacterial antibody levels studied
(magnitude ranged from mean decrease in 0.240 OD
(99% CI 0.361, 0.119) for IgG against Ag85A), to a
mean decrease in 0.446 OD (99% CI 0.640, 0.251)
for IgM against Ag85A, all P < 0.001, Table 2). Simi-
larly, being in the upper tertile of HCMV IgG response
was associated with a decrease in Ag85A, PPD and LAM
IgG levels compared to being in the middle tertile: a
mean decrease in 0.067 OD (99% CI 0.122, 0.012) for
Ag85A IgG, 0.057 OD (99% CI 0.105, 0.009) for
PPD IgG and 0.107 (99% CI 0.194, 0.019) for LAM
© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 5
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IgG (all P < 0.001, Table 2). While the direction of
change was the same for CFP10/ESAT6 IgG and Ag85A
IgM, the mean decrease associated with being in the
upper tertile of HCMV IgG response was not sufficiently
large to provide good evidence of a difference based upon
our significance threshold (Table 2). The association
between mycobacterial antibody levels and magnitude of
HCMV IgG response was not linear (Figure 3): in com-
parison to the middle tertile of HCMV IgG response, the
lowest tertile was also associated with a decrease in
mycobacterial antibody levels. A mean decrease of 0.100
OD (99% CI 0.156, 0.044) P < 0.001 was seen for
CFP10/ESAT6 IgG and a mean decrease of 0.104 OD
(99% CI 0.205, 0.004) P = 0.01 for Ag85A IgM. The
direction of change was the same for the remaining
mycobacterial antibodies (Table 2).
Being a sputum-confirmed active TB case was not asso-
ciated with any differences in any mycobacterial antibody
level after adjusting for age, sex, HIV and HCMV level,
although given that there were only 27 cases, there was
limited statistical power to detect associations (Table 2).
Coefficients of the effect of HIV and HCMV for each
outcome measurement were similar for a model including
BCG instead of TB, and the magnitude of effect was not
altered by adjusting for total IgG. Being BCG vaccinated
was associated with a 0.115 OD increase in TT IgG
(99% CI 0.004–0.227) P = 0.01.
Table 3 shows that HIV positivity was associated with
an increase in total levels of IgG (9.110 g/l (99% CI
3.735, 14.485), P < 0.001). Being female was associated
with an increase in TT of 0.272 OD (99% CI 0.188,
0.356, P < 0.001) but no difference in total IgG levels.
While being an active TB case was not associated with
any differences in TT IgG, being a TB case was associ-
ated with a 5.8 g/l decrease (99% CI 13.298, 1.720) in
total IgG however this was not significant (P = 0.05).
The magnitude of HCMV IgG response did not affect
either total IgG levels or TT IgG response (Table 3).
Discussion
In this study, we found that HIV infected individuals had
decreased levels of all mycobacterial antibodies studied,
with a concomitant increase in total IgG. We also found
that individuals with the highest levels of HCMV IgG
(indicative of highest exposure [26, 27]), had decreased
levels of IgG specific for Ag85A, PPD and LAM, but had
no corresponding change in total IgG levels. Previously
our group has shown that TB patients have increased
levels of HCMV IgG [17] and that HCMV positive
infants (as measured by HCMV IFN-c ELISPOT) were at
higher risk of progressing to active TB disease [13].
HCMV infection, being linked to poor long-term health
outcomes [28, 29] and large immune system subversion
[16, 30], may be acting to manipulate mycobacterial anti-
bodies which may be contributing to protective mecha-
nisms against M.tb infection.
As has been seen previously [31], humoral responses
against RD1 antigens ESAT6 or CFP10 (mycobacterial
proteins associated specifically with M.tb and not NTM
or BCG) did not show an association with active TB
cases in this study. Due to a lack of active TB case-find-
ing in the GPC, it is likely that some of the individuals
classed as TB negative here were latently infected with
Table 3 Multivariable linear regression of variables with a potential influence on total IgG and TT-specific IgG levels. Values obtained
using a multivariable regression model including age, quadratic age, sex, HIV and TB status, with P value and 99% CI (n = 1956)
Variable n (%)
Total IgG (g/l) TT IgG OD
Coeff (99% CI) P value Coeff (99% CI) P value
Sex
Male 978/1956 (50.0%) Baseline Baseline
Female 978/1956 (50.0%) 0.326 (2.350, 1.697) 0.68 0.272 (0.188, 0.356) <0.001
HCMV tertiles
HCMV low 650/1956 (33.2%) 0.318 (2.240, 2.877) 0.75 0.090 (0.187, 0.008) 0.02
HCMV medium 650/1956 (33.2%) Baseline Baseline
HCMV high 656/1956 (33.5%) 0.915 (1.508, 3.338) 0.33 0.065 (0.029, 0.159) 0.08
HIV status
Negative 1860/1956 (95.1%) Baseline Baseline
Positive 96/1956 (4.9%) 9.110 (3.735, 14.485) <0.001 0.172 (0.357, 0.012) 0.02
TB status
Negative 1929/1956 (98.6%) Baseline Baseline
Positive 27/1956 (1.4%) 5.789 (13.298, 1.720) 0.05 0.081 (0.328, 0.165) 0.4
CI, confidence interval; OD, optical density.
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M.tb based on epidemiologic data on exposure in Uganda
[32, 33]. The finding that IgG responses to these M.tb-
specific antigens increase with age, following a similar
pattern as other non-M.tb-specific mycobacterial antibod-
ies, suggests that while NTM may be driving high
responses of acute (IgM) and sustained (IgG) mycobacte-
rial responses, exposure to M.tb itself cannot be ignored.
BCG vaccine status allocation in this study was by the
presence of scar, inspection of immunisation card or ver-
bal confirmation by parent of guardian. Despite issues
with these methods [34], classification was thought to be
robust due to the evidence of association of TT IgG with
BCG indicating that people vaccinated for one Extended
Programme of Immunization (EPI) schedule vaccine are
more likely to have received other vaccinations upon
accessing local health centres.
The magnitude of difference in mycobacterial antibod-
ies seen due to HIV infection was far greater than due to
either active TB disease or BCG vaccination. The lower
levels of mycobacterial antibodies seen in individuals
infected with HIV is accompanied by an increase in total
IgG. The effect seen here points towards HIV infection
having a mycobacteria-specific effect as opposed to a
more general depression of all antibody levels, thereby
confirming evidence seen previously in a much smaller
number of patients in Italy [35]. It is known that HIV
preferentially depletes TB-specific CD4 T cells [36].
Through their absence, TB-specific T cells would not pro-
vide signals to B cells in order for them to proliferate and
differentiate into immunoglobulin-secreting plasma cells.
As far as we are aware, the possible downstream humoral
mechanism of HIV-associated TB-specific T-cell depletion
has not been investigated.
Here we see a similar association between the highest
levels of HCMV IgG, and decreased levels of some
mycobacterial antibodies. This is not accompanied by a
decrease in total IgG or TT IgG. As a human herpes
virus, HCMV persists in a variety of cell types in a dor-
mant state and is transmitted through body fluids [37].
Infection is not normally associated with symptomatic
Ag85A lgG OD
Baseline Baseline
Baseline
Lo
w
Me
diu
m
Hig
h
Lo
w
Me
diu
m
Hig
h
Lo
w
Me
diu
m
Hig
h
Lo
w
Me
diu
m
Hig
h
Lo
w
Me
diu
m
Hig
h
Baseline
Baseline
HCMV tertile HCMV tertile
HCMV tertile HCMV tertile
HCMV tertile
CFP10 ESAT6 lgG OD Ag85A lgM OD
Mean
99% CI
P = 0.1000.0
5
0
–
0.0
5
–
0.1
0
–
0.1
5
–
0.2
0
0.0
5
0
–
0.0
5
–
0.1
0
–
0.1
5
–
0.2
0
0.0
5
0
–
0.0
5
–
0.1
0
–
0.1
5
–
0.2
0
0.0
5
0
–
0.0
5
–
0.1
0
–
0.1
5
–
0.2
0
0.0
5
0
–
0.0
5
–
0.1
0
–
0.1
5
–
0.2
0
Es
tim
at
ed
 c
ha
ng
e 
in
 O
D 
*
Es
tim
at
ed
 c
ha
ng
e 
in
 O
D 
*
Es
tim
at
ed
 c
ha
ng
e 
in
 O
D 
*
Es
tim
at
ed
 c
ha
ng
e 
in
 O
D 
*
Es
tim
at
ed
 c
ha
ng
e 
in
 O
D 
*P ≤ 0.001
P = 0.710P ≤ 0.001
P = 0.690 P = 0.010 P = 0.120 P = 0.010
P = 0.010 P = 0.200
PPD lgG OD LAM lgG OD
Figure 3 Adjusted mean OD change associated with HCMV tertile comparing to medium HCMV tertile as baseline. P values from
multivariable linear regression model including age, quadratic age, sex, HIV and TB. Total n = 1956. Vertical lines show 99% CI for
each mean OD change. CI, confidence interval, OD, optical density (*model includes, age, quadratic age, sex, HIV and TB).
8 © 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
Tropical Medicine and International Health volume 00 no 00
L. Stockdale et al. HIV, HCMV and mycobacterial antibody levels
228
disease; however, it poses a huge burden on the immune
system, with maintenance of up to 30% of both CD4
and CD8 circulating memory T cells being specific to
HCMV [38]. The virus is a significant factor in immune
variation [16], immunosenescence [15] and causes
immune activation [39], including non-specific polyclonal
B-cell activation and proliferation [40].
In this study, we see decreased mycobacterial antibody
levels at both HCMV IgG extremes among HCMV
seropositive individuals. Evidence of HCMV effect on
vaccine responses exists, showing both a detrimental
impact of HCMV infection [41, 42] and a positive, ‘adju-
vanting’, effect of HCMV on vaccine-induced antibody
responses in humans [43]. Given reports that cellular
responses to heterologous virus challenge in mice may
depend on the initial viral dose of HCMV [44, 45] the
lack of a linear response between HCMV IgG and
mycobacterial antibody levels seen in this study may also
be indicative of different effects at different HCMV expo-
sure levels. PBMC samples were not available from this
cohort for us to determine if the magnitude of HCMV
IgG level had a similar impact on the mycobacteria-speci-
fic cellular immune response. However, it is likely that
cellular immunity is also impacted by HCMV given that
HCMV has been shown to affect both humoral and cell-
mediated immune responses to vaccine antigens [46, 47].
Before the widespread use of highly active anti-retrovir-
als (HAART), HCMV/HIV co-infection saw HCMV as
an important cause of severe non-AIDS events, including
death, in HIV-infected individuals [48]. High levels of
HCMV IgG, caused by repeated reactivation or reinfec-
tion events, are associated with higher all-cause mortality
[49] and lower CD4 cell count, with accompanying
worse response to anti-retrovirals [50]. Despite literature
describing HCMV-induced B-cell activation [40, 51, 52],
in this study we saw no relationship between HCMV
exposure and increased levels of total IgG. We do how-
ever see a trend towards decreased mycobacterial anti-
body response in individuals with very high HCMV IgG
responses after adjusting for HIV infection. Considering
the risk of developing active TB disease increases over 20
times in individuals with HIV [53], it is likely that any
added effect of HCMV would be masked. The mycobac-
terial antibody-specific decrease seen with both HIV
infection and, independently, in the highest tertile of
HCMV exposure, may be indicative of a functional, pro-
tective role of mycobacterial-specific antibodies which are
independently decreased by HIV and high levels of expo-
sure to HCMV.
In summary, both HIV infection and high levels of
HCMV IgG were both associated with decreases in
mycobacterial antibody levels. Given this novel finding of
effect of HCMV exposure on mycobacterial antibody
levels, investigation of magnitude of HCMV may be
important in future TB clinical trials to understand the
immune environment, independently of HIV infection sta-
tus. In addition to quantification of antibody levels, we
believe that it will be important to measure HCMV effect
on mycobacteria-specific cellular responses. A more
nuanced understanding of the quality, as well as the
quantity, of the mycobacterial antibodies elicited, in
terms of antibody class, subtype and avidity may help to
shed light upon a potential mechanism by which they
might confer protection to host cells.
Due to insufficient volumes of sera, we were unable to
investigate HCMV viral load in serum samples to ascer-
tain whether active infection at point of blood draw was
associated with any of the measurements taken for this
study. Despite this, we believe that the use of HCMV-spe-
cific IgG is a robust a measure of cumulative exposure. As
previously mentioned, active TB case finding is not carried
out within the GPC and therefore we cannot be sure that
some individuals analysed as ‘non-TB’ are not latently
infected. PBMC samples were not available from this
cohort for us to determine if HCMV had a similar impact
on the mycobacterial cellular immune response.
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